Close

Form 6-K ICON PLC For: Mar 31

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 4/25/2024

1. TSLA
2. META
3. ENPH
4. TXN
5. BA
6. SPOT
7. IBM
8. V
9. HCP
10. CMG


May 4, 2016 4:00 PM EDT
 

 FORM 6-K
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 under
the Securities Exchange Act of 1934
 
For
the month ended May, 2016

ICON plc
(Registrant's name)


333-08704
(Commission file number)


South County Business Park, Leopardstown, Dublin 18, Ireland
(Address of principal executive offices)


Brendan Brennan, CFO
South County Business Park, Leopardstown, Dublin 18, Ireland.
011-353-1-291-2000
 (Name, telephone number, email and/or facsimile number and address of Company contact person)



Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
 
Yes__X__
No_______
 
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
 
Yes______
No___X___
 
Indicate by check mark whether the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
 
Yes______
No___X___
 
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule12g3-2(b) under the Securities Exchange Act of 1934.
 
Yes______
No___X___
 
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):82 N/A
 
1
 
ICON plc

Rider A

This report on Form 6-K is hereby incorporated by reference in the registration statement on Form F-3 (Registration No. 333-133371) of ICON plc and in the prospectus contained therein, and this report on Form 6-K shall be deemed a part of such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by ICON plc under the Securities Act of 1933 or the Securities Exchange Act of 1934.

2

GENERAL

As used herein, “ICON”, the “Company” and “we” refer to ICON plc and its consolidated subsidiaries, unless the context requires otherwise.

Business

ICON public limited company (“ICON”) is a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies.  Our vision is to be the Global CRO partner of choice for the Biopharma industry by delivering best in class information, solutions and performance in clinical and outcomes research.

We believe that we are one of a select group of CROs with the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. At March 31, 2016 we had approximately 12,235 employees, in 89 locations in 37 countries. During the three months ended March 31, 2016 we derived approximately 45.9%, 44.1% and 10.0% of our net revenue in the United States, Europe and Rest of World, respectively.

We began operations in 1990 and have expanded our business predominately through organic growth, together with a number of strategic acquisitions to enhance our capabilities and expertise in certain areas of the clinical development process.  We are incorporated in Ireland and our principal executive office is located at: South County Business Park, Leopardstown, Dublin 18, Republic of Ireland. The contact telephone number of this office is 353 (1) 291 2000.
 
Recent Developments

Acquisitions

On December 4, 2015, Inclinix-PMG Holdings, Inc (‘PMG’) was acquired by ICON Clinical Research LLC a subsidiary of the Company, resulting in initial net cash outflows of $63.5 million (including certain payments made on behalf of PMG totaling $9.9 million). PMG is an integrated network of clinical research sites operating from 14 metropolitan areas throughout the US. PMG conducts clinical trials in all major therapeutic areas with particular experience in cardiology, dermatology, endocrinology, gastroenterology, men's health, neurology, pulmonology, rheumatology, vaccine, and women's health trials. In addition to a proprietary research database of clinical trial participants, PMG also has access to over 2 million active patient lives via electronic health records through their unique partnerships with healthcare systems and community physician practices.  The acquisition agreement provides for working capital targets to be achieved by PMG within 90 days of acquisition.  In March 2016, the Company agreed to pay an additional $1.6 million on completion of this working capital review (see note 3 Business Combinations for further information).

Share repurchase program

The Company completed a share buyback program in December 2015.  During the year ended December 31, 2015, the Company redeemed a total of 6,198,481 ordinary shares for a total consideration of $457.9 million.

Financing

On December 15, 2015, ICON Investments Five Unlimited Company issued Senior Notes for aggregate gross proceeds of $350.0 million in a private placement. The Senior Notes will mature on December 15, 2020. Interest payable is fixed at 3.64%, and is payable semi-annually on the Senior Notes on each June 15 and December 15, commencing June 15, 2016. The Senior Notes are guaranteed by ICON plc.  In October 2015, the Company entered into an interest rate hedge in respect of the planned issuance of the Senior Notes in December 2015. The interest rate hedge matured in November 2015 when the interest rate on the Senior Notes was fixed. The interest rate hedge was effective in accordance with Financial Accounting Standards Board (“FASB”) ASC 815 Derivatives and Hedging.  The cash proceeds, representing the realized gain on the interest rate hedge were received on maturity in November 2015.
 
3

Changes in Board composition

In March 2016, the Company announced that Mr. Thomas Lynch, non-executive Chairman of the Board of Directors, had notified ICON that he will retire as Chairman on 31 March 2016 and will not stand for re-election to the Board at the Company's annual general meeting in July 2016. Mr. Lynch has been a non-executive Director of ICON since 1994 and served as senior independent Director from 2010 to 2012 and as Chairman since January 2013. ICON's senior independent Director, Mr. Declan McKeon, will serve as acting Chairman from Mr. Lynch's retirement as Chairman and the Board has initiated a process to appoint a new Chairman.

New accounting pronouncements

Accounting Standards Update (‘ASU’) 2015-03 ‘Interest – Imputation of Interest (Subtopic 835-30) – Simplifying the Presentation of Debt Issuance Costs’ was issued in April 2015 to simplify the presentation of debt issuance costs.  The guidance requires debt issuance costs related to term loans to be presented as a direct deduction from the carrying amount of the associated debt liability.  The standard is effective for financial statements issued for fiscal years beginning after December 15, 2015 and interim periods within those fiscal years.  The new guidance is reflected in the Condensed Consolidated Financial Statements (unaudited) presented.  The new guidance is also required to be applied on a retrospective basis.  The Condensed Consolidated Balance Sheet at December 31, 2015 has therefore been restated to reflect the accounting standards update.
 
4

ICON plc
CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT MARCH 31, 2016 AND DECEMBER 31, 2015

   
(Unaudited)
    
(Audited)
  
   
March
31,
    
December
31,
  
   
2016
      
2015*
 
ASSETS
  
(in thousands)
  
Current Assets:
              
Cash and cash equivalents
  
$
161,337
    
$
103,911
  
Short term investments - available for sale
    
86,520
      
85,990
  
Accounts receivable, net
    
362,322
      
409,165
  
Unbilled revenue
    
238,645
      
173,649
  
Other receivables
    
34,566
      
30,935
  
Prepayments and other current assets
    
34,653
      
36,128
  
 Income taxes receivable
    
20,436
      
22,961
  
Total current assets
938,479
    
862,739
  
                 
Other Assets:
                
Property, plant and equipment, net
    
149,886
      
150,218
  
Goodwill
    
593,885
      
588,434
  
Non-current other assets
    
13,081
      
11,591
  
Non-current income taxes receivable
    
12,439
      
11,362
  
         Non-current deferred tax asset
    
26,755
      
26,738
  
         Intangible assets
    
61,610
      
66,127
  
Total Assets
  
$
1,796,135
    
$
1,717,209
  
LIABILITIES AND SHAREHOLDERS’ EQUITY
                
Current Liabilities:
                
Accounts payable
  
$
5,647
    
$
7,021
  
Payments on account
    
318,061
      
318,697
  
Other liabilities
    
224,221
      
231,879
  
Income taxes payable
    
17,775
      
14,203
  
         Total current liabilities
    
565,704
      
571,800
  
Other Liabilities:
                
Non-current bank credit lines and loan facilities
    
348,278
      
348,306
  
Non-current other liabilities
    
13,715
      
12,224
  
Non-current government grants
    
978
      
959
  
Non-current income taxes payable
    
19,743
      
16,180
  
Non-current deferred tax liability
    
4,032
      
4,644
  
 Shareholders' Equity:
                
Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized,
                
55,065,080 shares issued and outstanding at March 31, 2016 and
                
54,958,912 shares issued and outstanding at December 31, 2015
    
4,682
      
4,679
  
  Additional paid‑in capital
    
398,361
      
383,395
  
          Capital redemption reserve
    
715
      
715
  
Accumulated other comprehensive income
    
(58,980
)
    
(61,636
)
Retained earnings
    
498,907
      
435,943
  
Total Shareholders' Equity
    
843,685
      
763,096
  
Total Liabilities and Shareholders' Equity
  
$
1,796,135
    
$
1,717,209
  
*The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
 
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
5
 
ICON plc
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND MARCH 31, 2015
 (UNAUDITED)
 
   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
             
   
(in thousands)
  
Revenue:
            
Gross revenue
  
$
542,583
    
$
503,366
  
Reimbursable expenses
    
(142,061
)
    
(115,135
)
                 
Net revenue
    
400,522
      
388,231
  
                 
Costs and expenses:
                
Direct costs
    
228,603
      
228,078
  
Selling, general and administrative expense
    
80,789
      
79,555
  
Depreciation and amortization
    
15,120
      
13,925
  
                 
Total costs and expenses
    
324,512
      
321,558
  
                 
Income from operations
    
76,010
      
66,673
  
Interest income
    
334
      
276
  
Interest expense
    
(3,215
)
    
(279
)
                 
Income before provision for income taxes
    
73,129
      
66,670
  
Provision for income taxes
    
(10,165
)
    
(10,801
)
                 
Net income
  
$
62,964
    
$
55,869
  
                 
Net income per Ordinary Share:
                
                 
Basic
  
$
1.14
    
$
0.93
  
                 
     Diluted
  
$
1.12
    
$
0.90
  
                 
Weighted average number of Ordinary Shares outstanding:
                
                 
     Basic
    
55,011,019
      
60,281,059
  
                 
Diluted
    
56,242,164
      
61,856,347
  

The accompanying notes are an integral part of these condensed consolidated financial statements.


6

ICON plc
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2016 AND MARCH 31, 2015
(UNAUDITED)
 
   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Cash flows from operating activities:
            
Net income
  
$
62,964
    
$
55,869
  
Adjustments to reconcile net income to net cash provided by operating activities:
                
Loss on disposal of property, plant and equipment
    
7
      
4
  
Depreciation expense
    
10,161
      
9,907
  
Amortization of intangibles
    
4,959
      
4,018
  
Amortization of grants
    
(11
)
    
(11
)
Accrued interest on short term investments    
(210
)
    
-
  
Share compensation expense
    
9,591
      
6,043
  
Amortization of gain on interest rate hedge
    
(210
)
    
-
  
Amortization of financing costs    
130
      
-
  
Deferred taxes
    
(626
)
    
(173
)
Changes in assets and liabilities:
                
Decrease in accounts receivable
    
47,407
      
16,381
  
Increase in unbilled revenue
    
(64,516
)
    
(11,716
)
Increase in other receivables
    
(3,730
)
    
(2,699
)
Decrease/(increase) in prepayments and other current assets
    
1,586
      
(2,522
)
Increase in other non-current assets
    
(1,413
)
    
(1,254
)
Decrease in payments on account
    
(687
)
    
(31,093
)
(Decrease)/increase in other current liabilities
    
(10,494
)
    
13,462
  
Increase in other non-current liabilities
    
1,520
      
1,757
  
(Decrease)/increase in accounts payable
    
(1,383
)
    
406
  
Increase in income taxes payable
    
8,626
      
2,734
  
Change in deferred tax liability    
(4,233
)
    
-
  
Net cash provided by operating activities
    
59,438
      
61,113
  
                 
Cash flows from investing activities:
                
Purchase of property, plant and equipment
    
(7,658
)
    
(10,688
)
Purchase of subsidiary undertakings
    
-
      
(103,138
)
Purchase of short term investments
    
(98
)
    
(60
)
Sale of short term investments    
158
      
1,037
  
Net cash used in investing activities
    
(7,598
)
    
(112,849
)
                 
Cash flows from financing activities:
                
Proceeds from exercise of equity compensation
    
1,137
      
8,146
  
Share issuance costs
    
-
      
(4
)
Tax benefit from the exercise of share options
    
4,241
      
1,923
  
Drawdown of bank credit lines and loan facilities
    
-
      
20,000
  
Financing costs
    
(118
)
    
-
  
Net cash provided by financing activities
    
5,260
      
30,065
  
Effect of exchange rate movements on cash
    
326
      
(1,988
)
Net increase/(decrease) in cash and cash equivalents
    
57,426
      
(23,659
)
Cash and cash equivalents at beginning of period
    
103,911
      
118,900
  
                 
Cash and cash equivalents at end of period
  
$
161,337
    
$
95,241
  
The accompanying notes are an integral part of these condensed consolidated financial statements.
          
 
7
 
ICON plc

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY AND COMPREHENSIVE INCOME
(UNAUDITED)

   
Shares
    
Amount
    
Additional
Paid-in
Capital
    
Capital
Redemption
Reserve
    
Accumulated
Other
Comprehensive
Income
    
Retained
Earnings
    
Total
  
                                           
   
(dollars in thousands, except share data)
        
                                           
Balance at December 31, 2015
    
54,958,912
    
$
4,679
    
$
383,395
    
$
715
    
$
(61,636
)
  
$
435,943
    
$
763,096
  
                                                         
Comprehensive Income:
                                                        
Net income
    
-
      
-
      
-
      
-
      
-
      
62,964
      
62,964
  
Currency translation adjustment
    
-
      
-
      
-
      
-
      
1,700
      
-
      
1,700
  
Currency impact of long term funding
    
-
      
-
      
-
      
-
      
1,095
      
-
      
1,095
  
Tax on currency impact of long term funding
    
-
      
-
      
-
      
-
      
(309
)
    
-
      
(309
)
Unrealized capital gain – investments
  
-
      
-
      
-
      
-
      
380
      
-
      
380
  
Amortization of interest rate hedge     -       -       -       -      
(210
)
     -      
(210
)
                                                         
Total comprehensive income
    
-
      
-
      
-
      
-
      
2,656
      
62,964
      
65,620
  
                                                         
Exercise of share options
    
48,840
      
3
      
1,130
      
-
      
-
      
-
      
1,133
  
Issue of restricted share units
    
57,328
      
-
      
4
      
-
      
-
      
-
      
4
  
Share issuance costs
    
-
      
-
      
-
      
-
      
-
      
-
      
-
  
Non-cash stock compensation expense
    
-
      
-
      
9,591
      
-
      
-
      
-
      
9,591
  
Tax benefit on exercise of options
    
-
      
-
      
4,241
      
-
      
-
      
-
      
4,241
  
                                                         
Balance at March 31, 2016
    
55,065,080
    
$
4,682
    
$
398,361
    
$
715
    
$
(58,980
)
  
$
498,907
    
$
843,685
  
The accompanying notes are an integral part of these condensed consolidated financial statements.
 
8
 
ICON plc

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
March 31, 2016

1. Basis of Presentation

These condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”), have not been audited. The condensed consolidated financial statements reflect all adjustments, which are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the condensed consolidated financial statements. Actual results could differ from those estimates.

The condensed consolidated financial statements should be read in conjunction with the accounting policies and notes to the consolidated financial statements included in ICON’s Form 20-F for the year ended December 31, 2015. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the fiscal period ending December 31, 2016.
 
2. Goodwill

 
Three months ended
  
Year ended
  
 
March 31,
  
December 31,
  
 
2016
  
2015
  
 
(in thousands)
  
         
Opening balance
  
$
588,434
    
$
463,324
  
Current period acquisitions (Note 3)
    
-
      
133,123
  
Prior period acquisitions (Note 3)    
5,773
      
4,418
  
Foreign exchange movement
    
(322
)
    
(12,431
)
                 
Closing balance
  
$
593,885
    
$
588,434
  


9

3. Business Combinations
Acquisitions - PMG

On December 4, 2015 the Company acquired PMG, resulting in an initial net cash outflow of $63.5 million, including certain payments made on behalf of PMG totaling $9.9 million.  PMG is an integrated network of 48 clinical research sites in North Carolina, South Carolina, Tennessee and Illinois.  The site network includes wholly owned facilities and dedicated clinical research sites.  PMG conducts clinical trials in all major therapeutic areas and has particular expertise in vaccine, gastroenterology, cardiovascular, neurology and endocrinology studies.  It has a proprietary database of clinical trial participants.   It also has access to in excess of 2 million active patients via electronic medical records through its partnerships with healthcare institutions and community physical practices.   The acquisition agreement provides for working capital targets to be achieved by PMG within 90 days of acquisition.  In March 2016, the Company agreed to pay an additional $1.6 million on completion of this working capital review.

The acquisition of PMG has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations.  The Company has made a provisional assessment of the fair value of assets acquired and liabilities assumed as at that date.  The table following summarizes the Company’s provisional estimates of the fair values of the assets acquired and liabilities assumed;

   
December 4,
  
   
2015
  
   
(in thousands)
  
Cash
  
$
194
  
Property, plant and equipment    
712
  
Goodwill*
    
46,812
  
Intangible assets**    
10,582
  
Accounts receivable
    
12,747
  
Prepayments and other current assets
    
1,329
  
Accounts payable
    
(530
)
Other liabilities     (2,459 )
Non-current deferred tax liability
    
(4,233
)
         
Net assets acquired
    
65,154
  
         
Cash consideration     53,681  
Other liabilities assumed     9,860  
Working capital adjustment
    
1,613
  
Total cash outflows
    
65,154
  
*Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.
**The Company has made an initial estimate of separate intangible assets acquired, being customer lists and order backlog, of $10.6 million.  This assessment is under review and will be finalized within 12 months of the date of acquisition.

10

Acquisitions - MediMedia Pharma Solutions

On February 27, 2015 the Company acquired MediMedia Pharma Solutions for cash consideration of $104.7 million (net of working capital adjustments of $3.9 million).  In addition to the cash consideration, certain payments were made on behalf of MediMedia Pharma Solutions on completion totaling $11.3 million. Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions includes MediMedia Managed Markets and Complete Healthcare Communications. MediMedia Managed Markets is a leading provider of strategic payer-validated market access solutions. Complete Healthcare Communications is one of the leading medical and scientific communication agencies working with medical affairs, commercial and brand development teams within life science companies. The acquisition agreement also provided for certain working capital targets to be achieved by MediMedia Pharma Solutions.

The acquisition of MediMedia Pharma Solutions has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations. The following table summarizes the Company’s estimate of the fair values of the assets acquired and liabilities assumed:
   
February 27,
  
   
2015
  
   
(in thousands)
  
Property, plant and equipment
  
$
1,049
  
Goodwill*
    
92,084
  
Customer lists    
22,752
  
Order backlog
    
2,521
  
Accounts receivable
    
5,240
  
Unbilled Revenue    
4,324
  
Prepayments and other current assets
    
621
  
Accounts payable     (749 )
Payments on account
    
(4,186
)
Deferred tax liability
    
(2,171
)
Other liabilities
    
(5,483
)
         
Net assets acquired
  
$
116,002
  
         
Cash consideration
  
$
108,717
  
Other liabilities assumed**
    
11,283
  
Gross cash outflows
    
120,000
  
Working capital adjustment
    
(3,998
)
Net cash outflows
  
$
116,002
  
 
* Goodwill represents the acquisition of an established workforce with experience in the provision of strategic payer-validated market access solutions while the acquisition of Complete Healthcare Communications comprises an established workforce with significant communication experience working with medical affairs, commercial and brand development teams within the life science industry.
** Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged.


11
 
Acquisitions - Aptiv Solutions

On May 7, 2014 the Company acquired 100% of the common stock of Aptiv Solutions (“Aptiv”), a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials for cash consideration of $143.5 million, including certain payments to be made on behalf of the company on completion totaling $22.4 million. The acquisition agreement provided for working capital targets to be achieved.  On March 25, 2015, the Company received $2.0 million in respect of these targets on completion of the working capital review.  Aptiv offers full-service clinical trial consulting and regulatory support for drugs, medical devices and diagnostics with a specific focus on strategies to increase product development efficiency and productivity. It is a market leader in the integrated design and execution of adaptive clinical trials for exploratory and late phase development as well as being an industry leader in medical device and diagnostic development in key medical technology segments.
The acquisition of Aptiv has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations. The following table summarizes the fair values of the assets acquired and the liabilities assumed:
   
May 7,
  
   
2014
  
   
(in thousands)
  
Property, plant and equipment
  
$
6,924
  
Goodwill*
    
125,627
  
Customer relationships
    
21,400
  
Order backlog
    
7,900
  
Cash and cash equivalents
    
3,484
  
Accounts receivable
    
25,091
  
Unbilled revenue
    
21,154
  
Prepayments and other current assets
    
4,180
  
Non-current assets
    
2,911
  
Accounts payable
    
(9,565
)
Other liabilities
    
(29,782
)
Payments on account
    
(31,094
)
Non-current other liabilities
    
(11,303
)
Loan notes payable**
    
(17,790
)
         
Net assets acquired
  
$
119,137
  
         
Cash consideration
  
$
143,500
  
Working capital adjustment
    
(1,964
)
     
141,536
  
Adjustments to cash consideration**
    
(22,399
)
Net purchase consideration
  
$
119,137
  
*Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.  Goodwill related to the US portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time liabilities (including loan notes) identified at the acquisition date which have subsequently been paid.

12

4. Income Taxes

The provision for income taxes recognized during the three months ended March 31, 2016 is comprised of:

 
Three Months Ended
  
 
March 31,
  
March 31,
  
 
2016
  
2015
  
 
(in thousands)
  
     
Provision for income taxes  
$
10,165
    
$
10,801
  


As at March 31, 2016 the Company maintains a $32.0 million liability (December 31, 2015: $31.4 million) for unrecognized tax benefit, which is comprised of $28.6 million (December 31, 2015: $28.1 million) related to items generating unrecognized tax benefits and $3.4 million (December 31, 2015: $3.3 million) for interest and related penalties for such items. The Company recognizes interest accrued on unrecognized tax benefits as an additional provision for income taxes.

The Company has analyzed filing positions in all of the significant federal, state and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. The only periods subject to examination by the major tax jurisdictions where the Company does business are 2011 through 2015 tax years. The Company does not believe that the outcome of any examination will have a material impact on its financial statements.

5. Net income per ordinary share

Basic net income per ordinary share has been computed by dividing net income available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income per ordinary share is computed by adjusting the weighted average number of ordinary shares outstanding during the period for all potentially dilutive ordinary shares outstanding during the period and adjusting net income for any changes in income or loss that would result from the conversion of such potential ordinary shares. There is no difference in net income used for basic and diluted net income per ordinary share.

The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows:

    
Three Months Ended
  
     
March 31,
    
March 31,
  
   
2016
    
2015
  
             
Weighted average number of ordinary shares outstanding for basic net income per ordinary share
    
55,011,019
      
60,281,059
  
Effect of dilutive share options outstanding
    
1,231,145
      
1,575,288
  
Weighted average number of ordinary shares for diluted net income per ordinary share
    
56,242,164
      
61,856,347
  


13

6. Share-based Awards

Share Options

On July 21, 2008 the Company adopted the Employee Share Option Plan 2008 (the “2008 Employee Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any employee, or any Director holding a salaried office or employment with the Company or a Subsidiary for the purchase of ordinary shares. On the same date, the Company also adopted the Consultants Share Option Plan 2008 (the “2008 Consultants Plan”), pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any consultant, adviser or non-executive Director retained by the Company or any Subsidiary for the purchase of ordinary shares.
Each option granted under the 2008 Employee Plan or the 2008 Consultants Plan (together the “2008 Option Plans”) will be an employee stock option, or Non-qualifying Stock Options (‘NSO’), as described in Section 422 or 423 of the Internal Revenue Code. Each grant of an option under the 2008 Options Plans will be evidenced by a Stock Option Agreement between the optionee and the Company. The exercise price will be specified in each Stock Option Agreement, however option prices will not be less than 100% of the fair market value of an ordinary share on the date the option is granted.
An aggregate of 6.0 million ordinary shares have been reserved under the 2008 Employee Plan, as reduced by any shares issued or to be issued pursuant to options granted under the 2008 Consultants Plan, under which a limit of 400,000 shares applies.  Further, the maximum number of ordinary shares with respect to which options may be granted under the 2008 Employee Option Plan, during any calendar year to any employee shall be 400,000 ordinary shares.  There is no individual limit under the 2008 Consultants Plan.   No options may be granted under the 2008 Option Plans after July 21, 2018.
On January 17, 2003 the Company adopted the Share Option Plan 2003 (the “2003 Share Option Plan”) pursuant to which the Compensation and Organization Committee of the Board could grant options to officers and other employees of the Company or its subsidiaries for the purchase of ordinary shares.  An aggregate of 6.0 million ordinary shares were reserved under the 2003 Share Option Plan; and, in no event could the number of ordinary shares issued pursuant to options awarded under this plan exceed 10% of the outstanding shares, as defined in the 2003 Share Option Plan, at the time of the grant, unless the Board expressly determined otherwise. Further, the maximum number of ordinary shares with respect to which options could be granted under the 2003 Share Option Plan during any calendar year to any employee was 400,000 ordinary shares.  The 2003 Share Option Plan expired on January 17, 2013.  No new options may be granted under this plan.
Share option awards are granted with an exercise price equal to the market price of the Company’s shares at date of grant.  Share options typically vest over a period of five years from date of grant and expire eight years from date of grant.  The maximum contractual term of options outstanding at March 31, 2016 is eight years.
The following table summarizes option activity for the three months ended March 31, 2016:
 
   
Options
Outstanding
Number of Shares
    
Weighted
 Average
 Exercise
Price
    
Weighted
 Average
Fair Value
    
Weighted
 Average
 Remaining
 Contractual
 Life
  
                         
Outstanding at December 31, 2015
    
1,626,582
    
$
34.87
    
$
11.94
        
                               
Granted
    
161,791
    
$
71.95
    
$
20.78
        
Exercised
    
(48,840
)
  
$
23.19
    
$
9.27
        
Forfeited
    
(6,835
)
  
$
22.51
    
$
9.61
        
                               
Outstanding at March 31, 2016
    
1,732,698
    
$
38.71
    
$
12.85
      
4.86
  
                                 
Exercisable at March 31, 2016
    
795,005
    
$
27.80
    
$
10.23
      
3.55
  
 
14
 
The Company has granted options with fair values ranging from $5.88 to $20.78 per option or a weighted average fair value of $10.45 per option. The Company issues ordinary shares for all options exercised. The total amount of fully vested share options which remained outstanding at March 31, 2016, was 795,005. Fully vested share options at March 31, 2016, have an average remaining contractual term of 3.55 years, an average exercise price of $27.80 and a total intrinsic value of $37.6 million. The total intrinsic value of options exercised during the three months ended March 31, 2016 was $2.2 million (March 31, 2015: $12.6 million).

The following table summarizes the movement in non-vested share options for the three months ended March 31, 2016:
 
   
Options
Outstanding
Number of Shares
    
Weighted Average
Exercise Price
    
Weighted Average
 Fair Value
  
                   
Non vested outstanding at December 31, 2015
    
968,853
    
$
42.14
    
$
13.69
  
                         
Granted
    
161,791
    
$
71.95
    
$
20.78
  
Vested
    
(187,409
)
  
$
39.36
    
$
13.02
  
Forfeited
    
(5,542
)
  
$
21.89
    
$
9.47
  
                         
Non vested outstanding at  March 31, 2016
    
937,693
    
$
47.96
    
$
15.07
  

Fair value of Stock Options Assumptions

The weighted average fair value of options granted during the three months ended March 31, 2016 and March 31, 2015 was calculated using the Black-Scholes option pricing model.  The weighted average fair values and assumptions used were as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
             
Weighted average fair value
  
$
20.78
    
$
19.78
  
                 
Assumptions:
                
Expected volatility
    
30
%
    
30
%
Dividend yield
    
0
%
    
0
%
Risk-free interest rate
    
1.39
%
    
1.41
%
Expected life
  
5 years
    
5 years
  

Expected volatility is based on the historical volatility of our common stock over a period equal to the expected term of the options; the expected life represents the weighted average period of time that options granted are expected to be outstanding given consideration to vesting schedules and our historical experience of past vesting and termination patterns. The risk-free rate is based on the U.S. government zero-coupon bonds yield curve in effect at time of the grant for periods corresponding with the expected life of the option.

Restricted Share Units and Performance Share Units
On July 21, 2008 the Company adopted the 2008 Employees Restricted Share Unit Plan (the “2008 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any Director holding a salaried office or employment with the Company, or a Subsidiary to receive an award under the plan.  An aggregate of 1.0 million ordinary shares have been reserved for issuance under the 2008 RSU Plan.
15

On April 23, 2013 the Company adopted the 2013 Employees Restricted Share Unit and Performance Share Unit Plan (the “2013 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any Director holding a salaried office or employment with the Company, or a Subsidiary to receive an award under the plan.  On May 11, 2015 the 2013 RSU Plan was amended and restated in order to increase the number of shares that can be issued under the RSU Plan by 2.5 million shares.  Accordingly, an aggregate of 4.1 million ordinary shares have been reserved for issuance under the 2013 RSU Plan.  The shares are awarded at par value and vest over a service period. Awards under the 2013 RSU Plan may be settled in cash or shares at the option of the Company.
The Company has awarded RSUs and PSUs to certain key individuals of the Group. The following table summarizes RSU and PSU activity for the three months ended March 31, 2016:
 
   
 
PSU
 Outstanding
Number of
 Shares
    
PSU
Weighted
 Average
Fair
Value
    
PSU
Weighted
 Average
 Remaining
 Contractual
 Life
    
 
RSU
 Outstanding
Number of
 Shares
    
 
RSU
Weighted
 Average
Fair Value
    
RSU
Weighted
Average
 Remaining
 Contractual
 Life
  
                                     
Outstanding at December 31, 2015
    
901,773
    
$
72.55
      
2.49
      
1,067,613
    
$
48.30
      
1.48
  
                                                 
Granted
    
233,634
    
$
71.95
              
70,087
    
$
71.95
          
Shares vested
    
-
      
-
              
(57,328
)
  
$
25.30
          
Forfeited
    
(436
)
  
$
31.49
              
(32,947
)
  
$
47.08
          
                                                 
Outstanding at March 31, 2016
    
1,134,971
    
$
53.16
      
1.37
      
1,047,425
    
$
51.18
      
1.41
  
 
The fair value of RSUs vested for the three months ended March 31, 2016 totaled $1.5 million (full year 2015: $7.0 million).

No PSUs vested during the three months ended March 31 2016 (the fair value of RSUs vested for the full year 2015 was $0.3million).

The PSUs vest based on service and specified EPS targets over the period 2013 – 2016, 2014 – 2017 and 2015 - 2018. Since 2013, we granted 573,303 PSUs (net of forfeitures).  Depending on the actual amount of EPS from 2013 to 2018, up to an additional 561,668 PSUs may also be granted.

Non-cash stock compensation expense

Non-cash stock compensation expense for the three months ended March 31, 2016 has been allocated as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Direct costs
  
$
5,285
    
$
3,330
  
Selling, general and administrative
    
4,306
      
2,713
  
                 
   
$
9,591
    
$
6,043
  

Total non-cash stock compensation expense not yet recognized at March 31, 2016 amounted to $76.5 million.  The weighted average period over which this is expected to be recognized is 2.37 years  . Total tax benefit recognized in additional paid in capital related to the non-cash compensation expense amounted to $4.2 million for the three months ended March 31, 2016 (March 31, 2015: $1.9 million).
 
16

7. Business Segment Information

The Company determines and presents operating segments based on the information that is internally provided to the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, who together are considered the Company’s chief operating decision maker, in accordance with FASB ASC 280-10 Disclosures about Segments of an Enterprises and Related Information.

The Company is a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. It specializes in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies.  The Company has the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and has the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution.  The Company has expanded predominately through internal growth, together with a number of strategic acquisitions to enhance its expertise and capabilities in certain areas of the clinical development process.

The Company is generally awarded projects based upon responses to requests for proposals received from companies in the pharmaceutical, biotechnology and medical device industries or work orders executed under our strategic partnership arrangements.  Contracts with customers are generally entered into centrally, in most cases with ICON Clinical Research Limited (“ICON Ireland”), the Company’s principal operating subsidiary in Ireland.  Revenues, which consist primarily of fees earned under these contracts, are allocated to individual entities within the Group, based on where the work is performed in accordance with the Company’s global transfer pricing model.

ICON Ireland acts as the group entrepreneur under the Company’s global transfer pricing model given its role in the development and management of the group, it’s ownership of key intellectual property and customer relationships, its key role in the mitigation of risks faced by the group and its responsibility for maintaining the Company’s  global network.  As such it enters into the majority of the Company’s customer contracts.

ICON Ireland remunerates other operating entities in the ICON Group on the basis of a guaranteed cost plus mark up for the services they perform in each of their local territories.  The cost plus mark up for each ICON entity is established to ensure that each of ICON Ireland and the ICON entities that are involved in the conduct of services for customers, earn an appropriate arms-length return having regard to the assets owned, risks borne, and functions performed by each entity from these intercompany transactions. The cost plus mark-up policy is reviewed annually to ensure that it is market appropriate.

The geographic split of revenue disclosed for each region outside Ireland is the cost plus revenue attributable to these entities. The residual revenues of the Group, once each ICON entity has been paid its respective intercompany service fee, generally fall to be retained by ICON Ireland.  As such revenues and income from operations in Ireland are a function of this global transfer pricing model and comprise net revenues of the Group after deducting the cost plus revenues attributable to the activities performed outside Ireland.

The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Turkey, Poland, Czech Republic, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Switzerland, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa.

Segment information as at March 31, 2016 and December 31, 2015 and for the three months ended March 31, 2016 and March 31, 2015 is as follows:
 
17

a) The distribution of net revenue by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
100,835
    
$
114,090
  
Rest of Europe
    
75,642
      
84,088
  
U.S.
    
184,090
      
150,064
  
Rest of World
    
39,955
      
39,989
  
                 
Total
  
$
400,522
    
$
388,231
  
* All sales shown for Ireland are export sales.

b) The distribution of income from operations by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
 
(in thousands)
  
       
Ireland
  
$
59,551
    
$
47,566
  
Rest of Europe
    
3,444
      
6,785
  
U.S.
    
10,784
      
9,854
  
Rest of World
    
2,231
      
2,468
  
                 
Total
  
$
76,010
    
$
66,673
  

c) The distribution of property, plant and equipment, net, by geographical area was as follows:

   
March 31,
    
December 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
103,716
    
$
101,736
  
Rest of Europe
    
7,225
      
7,334
  
U.S.
    
32,564
      
34,520
  
Rest of World
    
6,381
      
6,628
  
                 
Total
  
$
149,886
    
$
150,218
  
 
18

d) The distribution of depreciation and amortization by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
5,904
    
$
4,913
  
Rest of Europe
    
1,715
      
2,268
  
U.S.
    
6,649
      
5,718
  
Rest of World
    
852
      
1,026
  
                 
Total
  
$
15,120
    
$
13,925
  

e) The distribution of total assets by geographical area was as follows:

   
March 31,
    
December 31,
  
   
2016
      
2015*
 
   
(in thousands)
  
Ireland
  
$
734,612
    
$
663,060
  
Rest of Europe
    
356,787
      
343,733
  
U.S.
    
636,751
      
641,769
  
Rest of World
    
67,985
      
68,647
  
                 
Total
  
$
1,796,135
    
$
1,717,209
  
*The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
 
19

ICON plc

Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and accompanying notes included elsewhere herein and the Consolidated Financial Statements and related notes thereto included in our  Form 20-F for the year ended December 31, 2015. The Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States.

Overview

We are a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies. Our vision is to be the Global CRO partner of choice in drug development by delivering best in class information, solutions and performance in clinical and outcomes research.

We believe that we are one of a select group of CRO’s with the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. At March 31, 2016, we employed approximately 12,235 employees, in 89 locations in 37 countries. During the three months ended March 31, 2016 we derived approximately 45.9%, 44.1% and 10.0% of our net revenue in the United States, Europe and Rest of World, respectively.

Revenue consists primarily of fees earned under contracts with third-party clients. In most cases, a portion of the contract fee is paid at the time the study or trial is started, with the balance of the contract fee generally payable in installments over the study or trial duration, based on the achievement of certain performance targets or "milestones". Revenue from contracts is recognized on a proportional performance method based on the relationship between time incurred and the total estimated duration of the trial or on a fee-for-service basis according to the particular circumstances of the contract. As is customary in the CRO industry, we contract with third party investigators in connection with clinical trials. All investigator fees and certain other costs, where reimbursed by clients, are, in accordance with industry practice, deducted from gross revenue to arrive at net revenue. As these costs vary from contract to contract, we view net revenue as our primary measure of revenue growth.

As the nature of our business involves the management of projects having a typical duration of one to four years, the commencement or completion of projects in a fiscal year can have a material impact on revenues earned with the relevant clients in such years. In addition, as we typically work with some, but not all, divisions of a client, fluctuations in the number and status of available projects within such divisions can also have a material impact on revenues earned from such clients from year to year.

Termination or delay in the performance of an individual contract may occur for various reasons, including, but not limited to, unexpected or undesired results, production problems resulting in shortages of the drug, adverse patient reactions to the drug, the client’s decision to de-emphasize a particular trial or inadequate patient enrolment or investigator recruitment.   In the event of termination the Company is usually entitled to all sums owed for work performed through the notice of termination and certain costs associated with the termination of the study. In addition, contracts generally contain provisions for renegotiation in the event of changes in the scope, nature, duration, or volume of services of the contract.

Our backlog consists of potential net revenue yet to be earned from projects awarded by clients. At March 31, 2016 we had a backlog of approximately $4.0 billion, compared with approximately $3.9 billion at December 31, 2015. We believe that our backlog as of any date is not necessarily a meaningful predictor of future results, due to the potential for cancellation or delay of the projects underlying the backlog, and no assurances can be given on the extent to which we will be able to realize this backlog as net revenue.

Although we are domiciled in Ireland, we report our results in U.S. dollars. As a consequence the results of our non-U.S. based operations, when translated into U.S. dollars, could be materially affected by fluctuations in exchange rates between the U.S. dollar and the currencies of those operations.
 
20
 
In addition to translation exposures, we are also subject to transaction exposures because the currency in which contracts are priced can be different from the currencies in which costs relating to those contracts are incurred.  Our operations in the United States are not materially exposed to such currency differences as the majority of our revenues and costs are in U.S. dollars. However, outside the United States the multinational nature of our activities means that contracts are usually priced in a single currency, most often U.S. dollars or euro, while costs arise in a number of currencies, depending, among other things, on which of our offices provide staff for the contract and the location of investigator sites. Although many such contracts benefit from some degree of natural hedging, due to the matching of contract revenues and costs in the same currency, where costs are incurred in currencies other than those in which contracts are priced, fluctuations in the relative value of those currencies could have a material effect on our results of operations. We regularly review our currency exposures and usually negotiate currency fluctuation clauses in our contracts which allow for price negotiation if changes in the relative value of those currencies exceed predetermined tolerances.

As we conduct operations on a global basis, our effective tax rate has depended and will depend on the geographic distribution of our revenue and earnings among locations with varying tax rates. Our results therefore may be affected by changes in the tax rates of the various jurisdictions. In particular, as the geographic mix of our results of operations among various tax jurisdictions changes, our effective tax rate may vary significantly from period to period.

Results of Operations

Three Months Ended March 31, 2016 compared with Three Months Ended March 31, 2015

The following table sets forth for the periods indicated certain financial data as a percentage of net revenue and the percentage change in these items compared to the prior comparable period. The trends illustrated in the following table may not be indicative of future results.

 
Three Months Ended
      
 
March 31,
2016
  
March 31,
2015
  
2016
to 2015
  
         
Percentage
  
 
Percentage of Net Revenue
  
Increase
  
             
Net revenue
  
100.0
%
  
100.0
%
  
3.2
%
                   
Costs and expenses:
                  
Direct costs
  
57.1
%
  
58.7
%
  
0.2
%
Selling, general and administrative
  
20.2
%
  
20.5
%
  
1.6
%
Depreciation   2.5 %   2.6 %   2.6 %
Amortization
  
1.2
%
  
1.0
%
  
23.4
%
                   
Income from operations
  
19.0
%
  
17.2
%
  
14.0
%

Net revenue for the period increased by $12.3 million, or 3.2%, from $388.2 million for the three months ended March 31, 2015 to $400.5 million for the three months ended March 31, 2016. Net revenue increased by 4.9% in constant currency, and by 1.2% in constant dollar organic.  The primary reason for the increase in revenues in the three months ended March 31, 2016 were the additional net revenues from the acquisition of MediMedia Pharma Solutions and PMG which were acquired on February 27, 2015 and December 4, 2015 respectively.  During the three months ended March 31, 2016 we derived approximately 45.9%, 44.1% and 10.0% of our net revenue in the United States, Europe and Rest of World, respectively.  During the three months ended March 31, 2016 $179.2 million or 44.7% of our net revenues were derived from our top five customers compared to $202.6 million or 52.2% of net revenues derived from our top five customers during the three months ended March 31, 2015.  The largest of these customers related to a Strategic Partnership with a large global pharmaceutical company.  Net revenue from this customer contributed 29.2% of net revenue for the quarter, compared to 34% of net revenue in respect of the three months ended March 31, 2015. The addition of new customer accounts, particularly mid-tier pharma customers and biotech customers continues to result in a reduction in concentration of revenues from our top five customers.
 
21

Net revenue in Ireland decreased from $114.1 million for the three months ended March 31, 2015 to $100.8 million for the three months ended March 31, 2016. Net revenue in Ireland is principally a function of the Company’s global transfer pricing model (see note 7 Business Segmental Information for further details).  Net revenue in our Rest of Europe region decreased from $84.1 million for the three months ended March 31, 2015 to $75.6 million for the three months ended March 31, 2016. Net revenues in non-U.S. dollar operations in this region were impacted by foreign currency translation and the movement in local rates to the U.S. dollar over the comparative quarter.  In addition, the previous closure of the Company’s early phase operations in the United Kingdom contributed to a reduction in net revenues in this region for the three months ended March 31, 2015.  Net revenue in the U.S. region increased from $150.1 million for the three months ended March 31, 2015 to $184.1 million for the three months ended March 31, 2016. Net revenues in the U.S. region for the three months ended March 31, 2016 were impacted positively by the acquisitions of MediMedia, which was acquired on February 27, 2015 and PMG, which was acquired on December 4, 2015.  Net revenues in our Rest of World region of $40.0 million remained in line with the net revenues for the three months ended March 31, 2015.

Direct costs for the period increased by $0.5 million, or 0.2%, from $228.1 million for the three months ended March 31, 2015 to $228.6 million for the three months ended March 31, 2016. Direct costs consist primarily of compensation, associated fringe benefits and share based compensation expense for project-related employees and other direct project driven costs. The increase in direct costs during the period arose from an increase in headcount and a corresponding increase in personnel related expenditure of $8.2 million and an increase in laboratory costs of $1.7 million offset, in part, by a decrease in other direct project related costs of $9.7 million.  As a percentage of net revenue, direct costs have decreased from 58.7% for the three months ended March 31, 2015 to 57.1% for the three months ended March 31, 2016.

Selling, general and administrative expenses for the period increased by $1.2 million, or 1.6%, from $79.6 million for the three months ended March 31, 2015 to $80.8 million for the three months ended March 31, 2016. Selling, general and administrative expenses comprise primarily of compensation, related fringe benefits and share based compensation expense for non-project-related employees, recruitment expenditure, professional service costs, advertising costs and all costs related to facilities and information systems. The increase in selling, general and administration expenses for the period arose primarily from an increase in personnel related expenditure of $1.9 million, a decrease in facilities and related costs expenditure of $0.6 million, and a decrease in general and administrative expenses net of foreign exchange movements of $0.1 million.  As a percentage of net revenue, selling, general and administrative expenses, decreased from 20.5% for the three months ended March 31, 2015 to 20.2% for the three months ended March 31, 2016.

Depreciation expense for the period increased by $0.3 million, or 2.6%, from $9.9 million for three months ended March 31, 2015 to $10.2 million for three months ended March 31, 2016 and principally arises from continued investment in facilities, information systems and equipment to support the Company’s growth. As a percentage of net revenue, depreciation expense decreased from 2.6% of net revenues for the three months ended March 31, 2015 to 2.5% of net revenues for the three months ended March 31, 2016.  Amortization expense for the period increased by $0.9 million, or 23.4%, from $4.0 million for the three months ended March 31, 2015 to $5.0 million for the three months ended March 31, 2016. Amortization expense represents the amortization of intangible assets acquired on business combinations. The increase in the amortization expense for the period relates to the MediMedia and PMG acquisitions. As a percentage of net revenue, amortization expense increased from 1.0% of net revenues for the three months ended March 31, 2015 to 1.2% for the three months ended March 31, 2016.

As a result of the above, income from operations for the three months increased by $9.3 million, or 14.0%, from $66.7 million for the three months ended March 31, 2015 to $76.0 million for the three months ended March 31, 2016. As a percentage of net revenue, income from operations increased from 17.2% of net revenues for the three months ended March 31, 2015 to 19.0% of net revenues for the three months ended March 31, 2016.

Income from operations in Ireland increased from a profit of $47.6 million for the three months ended March 31, 2015 to a profit of $59.6 million for the three months ended March 31, 2016. Income from operations in Ireland is impacted by the Group’s global transfer pricing model (see note 7 Business Segmental Information for further details). Income from operations in our Rest of Europe region decreased from $6.8 million for the three months ended March 31, 2015 to $3.4 million for the three months ended March 31, 2016. Income from operations in the U.S. region increased from $9.9 million for the three months ended March 31, 2015 to $10.8 million for the three months ended March 31, 2016.  Income from operations in the U.S. region for the three months ended March 31, 2016 was impacted positively by the acquisition of MediMedia, which was acquired on February 27, 2015 and PMG, which was acquired on December 4, 2015.  Income from operations in the Rest of World region decreased from $2.5 million for the three months ended March 31, 2015 to $2.2 million for the three months ended March 31, 2016.
 
22

Interest income remained at $0.3 million for the three months ended March 31, 2015 and the three months ended March 31, 2016. Interest expense for the period increased by $2.9 million from $0.3 million for the three months ended March 31, 2015 to $3.2 million for the three months ended March 31, 2016.  This increase is reflective of the drawdown of the Senior Notes issued in December 2015 and the bridge facility of $350 million in place from September 2015, which are discussed in the Liquidity and Capital Resources section below.

Provision for income taxes for the period decreased from $10.8 million for the three months ended March 31, 2015 to $10.2 million for the three months ended March 31, 2016.  The Company’s effective tax rate for the three months ended March 31, 2016 was 13.9% compared with 16.2% for the three months ended March 31, 2015. The Company’s effective tax rate is principally a function of the distribution of pre-tax profits amongst the territories in which it operates.

Liquidity and Capital Resources

The CRO industry is generally not capital intensive. The Group’s principal operating cash needs are payment of salaries, office rents, travel expenditures and payments to investigators. Investing activities primarily reflect capital expenditures for facilities and information systems enhancements, the purchase and sale of short term investments and acquisitions.

Our clinical research and development contracts are generally fixed price with some variable components and range in duration from a few weeks to several years. Revenue from contracts is generally recognized as income on the basis of the relationship between time incurred and the total estimated contract duration or on a fee-for-service basis. The cash flow from contracts typically consists of a small down payment at the time the contract is entered into, with the balance paid in installments over the contract's duration, in some cases on the achievement of certain milestones. Accordingly, cash receipts do not correspond to costs incurred and revenue recognized on contracts.

The Company’s cash and short term investment balances at March 31, 2016 amounted to $247.9 million compared with cash and short term investment balances of $189.9 million at December 31, 2015.  The Company’s cash and short term investment balances at March 31, 2016 comprised of cash and cash equivalents of $161.4 million and short-term investments of $86.5 million. The Company’s cash and short term investment balances at December 31, 2015 comprised of cash and cash equivalents of $103.9 million and short-term investments of $86.0 million.

On December 15, 2015, ICON Investments Five Unlimited Company issued Senior Notes for aggregate gross proceeds of $350.0 million in a private placement. The Senior Notes will mature on December 15, 2020. Interest payable is fixed at 3.64%, and is payable semi-annually on the Senior Notes on each June 15 and December 15, commencing June 15, 2016. The Senior Notes are guaranteed by ICON plc.  In October 2015, the Company entered into an interest rate hedge in respect of the planned issuance of the Senior Notes in December 2015. The interest rate hedge matured in November 2015 when the interest rate on the Senior Notes was fixed. The interest rate hedge was effective in accordance with Financial Accounting Standards Board (“FASB”) ASC 815 Derivatives and Hedging.  The cash proceeds, representing the realized gain on the interest rate hedge were received on maturity in November 2015.

On July 27, 2015 the Company entered into a 364 day bridge facility for $350.0 million with two financial institutions.   The facility bore interest at LIBOR plus a margin and included certain guarantees and indemnities in favor of the two financial institutions. The bridge facility was repaid in full in December 2015.

On June 30, 2014 the Company entered into a five year committed multi-currency Revolving Credit Facility for $100.0 million with Citibank, JP Morgan, Santander and Barclays Bank (“Revolving Credit Facility”). Each bank subject to the agreement has committed $25 million to the facility, with equal terms and conditions in place with all institutions.   In December 2015 the Revolving Credit Facility was amended to remove certain guarantees, the facility is guaranteed by ICON plc. The facility bears interest at LIBOR plus a margin,  No amounts were drawn at March 31, 2016 or at December 31, 2015 in respect of the Revolving Credit Facility.  Amounts available to the Group under the facility at both March 31, 2016 and December 31, 2015 were $100.0 million.
 
23

Net cash provided by operating activities was $59.4 million for the three months ended March 31, 2016 compared with cash provided by operating activities of $61.1 million for the three months ended March 31, 2015.  The most significant influence on our operating cash flows has been an increase to revenues and underlying profitability of the Company. This was offset by an increase in revenue outstanding which comprised of accounts receivable and unbilled revenue, less payments on account. The dollar value of these balances and the related number of days revenue outstanding (i.e. revenue outstanding as a percentage of revenue for the period, multiplied by the number of days in the period) can vary over a study or trial duration. Contract fees are generally payable in installments based on the achievement of certain performance targets or “milestones” (e.g. target patient enrollment rates, clinical testing sites initiated or case report forms completed), such milestones being specific to the terms of each individual contract, while revenues on contracts are recognized as contractual obligations are performed. Days revenue outstanding can vary therefore due to, amongst others, the scheduling of contractual milestones over a study or trial duration, the achievement of a particular milestone during the period or the timing of cash receipts from customers.  A decrease in the number of days revenue outstanding during a period will result in cash inflows to the Company while an increase in days revenue outstanding will lead to cash outflows. The number of days revenue outstanding at March 31, 2016 was 47 days compared to 41 days at December 31, 2015.  The number of days revenue outstanding at March 31, 2015 was 47 days compared to 40 days at December 31, 2014.

Net cash used in investing activities was $7.6 million for the three months ended March 31, 2016 compared to net cash used in investing activities of $112.8 million for the three months ended March 31, 2015. Net cash used in the three months ended March 31, 2016 principally relates to capital expenditure of $7.7 million, which mainly comprised of expenditure on global infrastructure and information technology systems to support the Company’s growth. Net cash used in the three months ended March 31, 2015 arose principally from cash paid in respect of the purchase of MediMedia Pharma Solutions.

Net cash provided by financing activities during the three months ended March 31, 2016 amounted to $5.3 million compared with net cash provided by financing activities of $30.1 million for the three months ended March 31, 2015. During the three months ended March 31, 2016 $4.2 million was recognized in relation to the tax benefit from the exercise of share options.  In addition, $1.1 million was received by the Company from the exercise of share options. This compares to $2.0 million and $8.2 million in respect of the cash tax benefit and share option proceeds respectively, in the three months ended March 31, 2015.  During the three months ended March 31, 2015 $20.0 million was drawn down by the Company under its negotiated banking facility.

As a result of these cash flows, cash and cash equivalents increased by $57.4 million during the three months ended March 31, 2016 compared to a decrease of $23.7 million for the three months ended March 31, 2015.

Inflation

We believe the effects of inflation generally do not have a material adverse impact on our operations or financial condition.

Legal Proceedings

We are not party to any litigation or other legal proceedings that we believe could reasonably be expected to have a material adverse effect on our business, results of operations and financial condition.
 
24

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 
 
 
 
ICON plc
 
 
 
     
 
 
 
 
 
/s/ Brendan Brennan
Date: May 4, 2016
 
Brendan Brennan
 
 
Chief Financial Officer
 
 
 
 
 
 
 
 
 
 
 
 

25
v3.4.0.3
Document and Entity Information
 3 Months Ended
Mar. 31, 2016
Document Information [Line Items]  
Document Type 6-K
Amendment Flag false
Document Period End Date Mar. 31, 2016
Document Fiscal Year Focus 2016
Document Fiscal Period Focus Q1
Trading Symbol ICLR
Entity Registrant Name ICON PLC
Entity Central Index Key 0001060955
Current Fiscal Year End Date --12-31
v3.4.0.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
 [1]
Current Assets:    
Cash and cash equivalents $ 161,337 $ 103,911
Short term investments - available for sale 86,520 85,990
Accounts receivable, net 362,322 409,165
Unbilled revenue 238,645 173,649
Other receivables 34,566 30,935
Prepayments and other current assets 34,653 36,128
Income taxes receivable 20,436 22,961
Total current assets 938,479 862,739
Other Assets:    
Property, plant and equipment, net 149,886 150,218
Goodwill 593,885 588,434
Non-current other assets 13,081 11,591
Non-current income taxes receivable 12,439 11,362
Non-current deferred tax asset 26,755 26,738
Intangible assets 61,610 66,127
Total Assets 1,796,135 1,717,209
Current Liabilities:    
Accounts payable 5,647 7,021
Payments on account 318,061 318,697
Other liabilities 224,221 231,879
Income taxes payable 17,775 14,203
Total current liabilities 565,704 571,800
Other Liabilities:    
Non-current bank credit lines and loan facilities 348,278 348,306
Non-current other liabilities 13,715 12,224
Non-current government grants 978 959
Non-current income taxes payable 19,743 16,180
Non-current deferred tax liability 4,032 4,644
Shareholders' Equity:    
Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized, 55,065,080 shares issued and outstanding at March 31, 2016 and 54,958,912 shares issued and outstanding at December 31, 2015 4,682 4,679
Additional paid-in capital 398,361 383,395
Capital redemption reserve 715 715
Accumulated other comprehensive income (58,980) (61,636)
Retained earnings 498,907 435,943
Total Shareholders' Equity 843,685 763,096
Total Liabilities and Shareholders' Equity $ 1,796,135 $ 1,717,209
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Condensed Consolidated Balance Sheets (Parenthetical) - € / shares
Mar. 31, 2016
Dec. 31, 2015
 [1]
Ordinary shares, par value € 0.06 € 0.06
Ordinary shares, shares authorized 100,000,000 100,000,000
Ordinary shares, shares issued 55,065,080 54,958,912
Ordinary shares, shares outstanding 55,065,080 54,958,912
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Revenue:    
Gross revenue $ 542,583 $ 503,366
Reimbursable expenses (142,061) (115,135)
Net revenue 400,522 388,231
Costs and expenses:    
Direct costs 228,603 228,078
Selling, general and administrative expense 80,789 79,555
Depreciation and amortization 15,120 13,925
Total costs and expenses 324,512 321,558
Income from operations 76,010 66,673
Interest income 334 276
Interest expense (3,215) (279)
Income before provision for income taxes 73,129 66,670
Provision for income taxes (10,165) (10,801)
Net income $ 62,964 $ 55,869
Net income per Ordinary Share:    
Basic $ 1.14 $ 0.93
Diluted $ 1.12 $ 0.90
Weighted average number of Ordinary Shares outstanding:    
Basic 55,011,019 60,281,059
Diluted 56,242,164 61,856,347
v3.4.0.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Cash flows from operating activities:    
Net income $ 62,964 $ 55,869
Adjustments to reconcile net income to net cash provided by operating activities:    
Loss on disposal of property, plant and equipment 7 4
Depreciation expense 10,161 9,907
Amortization of intangibles 4,959 4,018
Amortization of grants (11) (11)
Accrued interest on short term investments (210)  
Share compensation expense 9,591 6,043
Amortization of gain on interest rate hedge (210)  
Amortization of financing costs 130  
Deferred taxes (626) (173)
Changes in assets and liabilities:    
Decrease in accounts receivable 47,407 16,381
Increase in unbilled revenue (64,516) (11,716)
Increase in other receivables (3,730) (2,699)
Decrease/(increase) in prepayments and other current assets 1,586 (2,522)
Increase in other non-current assets (1,413) (1,254)
Decrease in payments on account (687) (31,093)
(Decrease)/increase in other current liabilities (10,494) 13,462
Increase in other non-current liabilities 1,520 1,757
(Decrease)/increase in accounts payable (1,383) 406
Increase in income taxes payable 8,626 2,734
Change in deferred tax liability (4,233)  
Net cash provided by operating activities 59,438 61,113
Cash flows from investing activities:    
Purchase of property, plant and equipment (7,658) (10,688)
Purchase of subsidiary undertakings   (103,138)
Purchase of short term investments (98) (60)
Sale of short term investments 158 1,037
Net cash used in investing activities (7,598) (112,849)
Cash flows from financing activities:    
Proceeds from exercise of equity compensation 1,137 8,146
Share issuance costs   (4)
Tax benefit from the exercise of share options 4,241 1,923
Drawdown of bank credit lines and loan facilities   20,000
Financing costs (118)  
Net cash provided by financing activities 5,260 30,065
Effect of exchange rate movements on cash 326 (1,988)
Net increase/(decrease) in cash and cash equivalents 57,426 (23,659)
Cash and cash equivalents at beginning of period 103,911 [1] 118,900
Cash and cash equivalents at end of period $ 161,337 $ 95,241
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income - 3 months ended Mar. 31, 2016 - USD ($)
$ in Thousands
Total
Ordinary Shares
Additional Paid-in Capital
Capital Redemption Reserve
Accumulated Other Comprehensive Income
Retained Earnings
Balance (in shares) at Dec. 31, 2015 54,958,912 [1] 54,958,912        
Balance at Dec. 31, 2015 $ 763,096 [1] $ 4,679 $ 383,395 $ 715 $ (61,636) $ 435,943
Comprehensive Income:            
Net income 62,964         62,964
Currency translation adjustment 1,700       1,700  
Currency impact of long term funding 1,095       1,095  
Tax on currency impact of long term funding (309)       (309)  
Unrealized capital gain - investments 380       380  
Amortization of interest rate hedge (210)       (210)  
Total comprehensive income 65,620       2,656 62,964
Exercise of share options (in shares)   48,840        
Exercise of share options 1,133 $ 3 1,130      
Issue of restricted/performance share units (in shares)   57,328        
Issue of restricted/performance share units 4   4      
Share issuance costs 0 $ 0 0 0 0 0
Non-cash stock compensation expense 9,591   9,591      
Tax benefit on exercise of options $ 4,241   4,241      
Balance (in shares) at Mar. 31, 2016 55,065,080 55,065,080        
Balance at Mar. 31, 2016 $ 843,685 $ 4,682 $ 398,361 $ 715 $ (58,980) $ 498,907
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Basis of Presentation
 3 Months Ended
Mar. 31, 2016
Basis of Presentation
1. Basis of Presentation

These condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles (“US GAAP”), have not been audited. The condensed consolidated financial statements reflect all adjustments, which are, in the opinion of management, necessary to present a fair statement of the operating results and financial position for the periods presented. The preparation of the condensed consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect reported amounts and disclosures in the condensed consolidated financial statements. Actual results could differ from those estimates.

The condensed consolidated financial statements should be read in conjunction with the accounting policies and notes to the consolidated financial statements included in ICON’s Form 20-F for the year ended December 31, 2015. Operating results for the three months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the fiscal period ending December 31, 2016.
v3.4.0.3
Goodwill
 3 Months Ended
Mar. 31, 2016
Goodwill
2. Goodwill

 
Three months ended
  
Year ended
  
 
March 31,
  
December 31,
  
 
2016
  
2015
  
 
(in thousands)
  
         
Opening balance
  
$
588,434
    
$
463,324
  
Current period acquisitions (Note 3)
    
-
      
133,123
  
Prior period acquisitions (Note 3)    
5,773
      
4,418
  
Foreign exchange movement
    
(322
)
    
(12,431
)
                 
Closing balance
  
$
593,885
    
$
588,434
  
v3.4.0.3
Business Combinations
 3 Months Ended
Mar. 31, 2016
Business Combinations
3. Business Combinations
Acquisitions - PMG

On December 4, 2015 the Company acquired PMG, resulting in an initial net cash outflow of $63.5 million, including certain payments made on behalf of PMG totaling $9.9 million.  PMG is an integrated network of 48 clinical research sites in North Carolina, South Carolina, Tennessee and Illinois.  The site network includes wholly owned facilities and dedicated clinical research sites.  PMG conducts clinical trials in all major therapeutic areas and has particular expertise in vaccine, gastroenterology, cardiovascular, neurology and endocrinology studies.  It has a proprietary database of clinical trial participants.   It also has access to in excess of 2 million active patients via electronic medical records through its partnerships with healthcare institutions and community physical practices.   The acquisition agreement provides for working capital targets to be achieved by PMG within 90 days of acquisition.  In March 2016, the Company agreed to pay an additional $1.6 million on completion of this working capital review.

The acquisition of PMG has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations.  The Company has made a provisional assessment of the fair value of assets acquired and liabilities assumed as at that date.  The table following summarizes the Company’s provisional estimates of the fair values of the assets acquired and liabilities assumed;

   
December 4,
  
   
2015
  
   
(in thousands)
  
Cash
  
$
194
  
Property, plant and equipment    
712
  
Goodwill*
    
46,812
  
Intangible assets**    
10,582
  
Accounts receivable
    
12,747
  
Prepayments and other current assets
    
1,329
  
Accounts payable
    
(530
)
Other liabilities     (2,459 )
Non-current deferred tax liability
    
(4,233
)
         
Net assets acquired
    
65,154
  
         
Cash consideration     53,681  
Other liabilities assumed     9,860  
Working capital adjustment
    
1,613
  
Total cash outflows
    
65,154
  
*Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.
**The Company has made an initial estimate of separate intangible assets acquired, being customer lists and order backlog, of $10.6 million.  This assessment is under review and will be finalized within 12 months of the date of acquisition.

Acquisitions - MediMedia Pharma Solutions.

On February 27, 2015 the Company acquired MediMedia Pharma Solutions for cash consideration of $104.7 million (net of working capital adjustments of $3.9 million).  In addition to the cash consideration, certain payments were made on behalf of MediMedia Pharma Solutions on completion totaling $11.3 million. Headquartered in Yardley, Pennsylvania, MediMedia Pharma Solutions includes MediMedia Managed Markets and Complete Healthcare Communications. MediMedia Managed Markets is a leading provider of strategic payer-validated market access solutions. Complete Healthcare Communications is one of the leading medical and scientific communication agencies working with medical affairs, commercial and brand development teams within life science companies. The acquisition agreement also provided for certain working capital targets to be achieved by MediMedia Pharma Solutions.

The acquisition of MediMedia Pharma Solutions has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations. The following table summarizes the Company’s estimate of the fair values of the assets acquired and liabilities assumed:
   
February 27,
  
   
2015
  
   
(in thousands)
  
Property, plant and equipment
  
$
1,049
  
Goodwill*
    
92,084
  
Customer lists    
22,752
  
Order backlog
    
2,521
  
Accounts receivable
    
5,240
  
Unbilled Revenue    
4,324
  
Prepayments and other current assets
    
621
  
Accounts payable     (749 )
Payments on account
    
(4,186
)
Deferred tax liability
    
(2,171
)
Other liabilities
    
(5,483
)
         
Net assets acquired
  
$
116,002
  
         
Cash consideration
  
$
108,717
  
Other liabilities assumed**
    
11,283
  
Gross cash outflows
    
120,000
  
Working capital adjustment
    
(3,998
)
Net cash outflows
  
$
116,002
  
 
* Goodwill represents the acquisition of an established workforce with experience in the provision of strategic payer-validated market access solutions while the acquisition of Complete Healthcare Communications comprises an established workforce with significant communication experience working with medical affairs, commercial and brand development teams within the life science industry.
** Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged.

Acquisitions - Aptiv Solutions

On May 7, 2014 the Company acquired 100% of the common stock of Aptiv Solutions (“Aptiv”), a global biopharmaceutical and medical device development services company and leader in adaptive clinical trials for cash consideration of $143.5 million, including certain payments to be made on behalf of the company on completion totaling $22.4 million. The acquisition agreement provided for working capital targets to be achieved.  On March 25, 2015, the Company received $2.0 million in respect of these targets on completion of the working capital review.  Aptiv offers full-service clinical trial consulting and regulatory support for drugs, medical devices and diagnostics with a specific focus on strategies to increase product development efficiency and productivity. It is a market leader in the integrated design and execution of adaptive clinical trials for exploratory and late phase development as well as being an industry leader in medical device and diagnostic development in key medical technology segments.
The acquisition of Aptiv has been accounted for as a business combination in accordance with FASB ASC 805 Business Combinations. The following table summarizes the fair values of the assets acquired and the liabilities assumed:
   
May 7,
  
   
2014
  
   
(in thousands)
  
Property, plant and equipment
  
$
6,924
  
Goodwill*
    
125,627
  
Customer relationships
    
21,400
  
Order backlog
    
7,900
  
Cash and cash equivalents
    
3,484
  
Accounts receivable
    
25,091
  
Unbilled revenue
    
21,154
  
Prepayments and other current assets
    
4,180
  
Non-current assets
    
2,911
  
Accounts payable
    
(9,565
)
Other liabilities
    
(29,782
)
Payments on account
    
(31,094
)
Non-current other liabilities
    
(11,303
)
Loan notes payable**
    
(17,790
)
         
Net assets acquired
  
$
119,137
  
         
Cash consideration
  
$
143,500
  
Working capital adjustment
    
(1,964
)
     
141,536
  
Adjustments to cash consideration**
    
(22,399
)
Net purchase consideration
  
$
119,137
  
*Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.  Goodwill related to the US portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time liabilities (including loan notes) identified at the acquisition date which have subsequently been paid.
v3.4.0.3
Income Taxes
 3 Months Ended
Mar. 31, 2016
Income Taxes
4. Income Taxes

The provision for income taxes recognized during the three months ended March 31, 2016 is comprised of:

 
Three Months Ended
  
 
March 31,
  
March 31,
  
 
2016
  
2015
  
 
(in thousands)
  
     
Provision for income taxes  
$
10,165
    
$
10,801
  


As at March 31, 2016 the Company maintains a $32.0 million liability (December 31, 2015: $31.4 million) for unrecognized tax benefit, which is comprised of $28.6 million (December 31, 2015: $28.1 million) related to items generating unrecognized tax benefits and $3.4 million (December 31, 2015: $3.3 million) for interest and related penalties for such items. The Company recognizes interest accrued on unrecognized tax benefits as an additional provision for income taxes.

The Company has analyzed filing positions in all of the significant federal, state and foreign jurisdictions where it is required to file income tax returns, as well as open tax years in these jurisdictions. The only periods subject to examination by the major tax jurisdictions where the Company does business are 2011 through 2015 tax years. The Company does not believe that the outcome of any examination will have a material impact on its financial statements.
v3.4.0.3
Net income per ordinary share
 3 Months Ended
Mar. 31, 2016
Net income per ordinary share
5. Net income per ordinary share

Basic net income per ordinary share has been computed by dividing net income available to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period. Diluted net income per ordinary share is computed by adjusting the weighted average number of ordinary shares outstanding during the period for all potentially dilutive ordinary shares outstanding during the period and adjusting net income for any changes in income or loss that would result from the conversion of such potential ordinary shares. There is no difference in net income used for basic and diluted net income per ordinary share.

The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows:

    
Three Months Ended
  
     
March 31,
    
March 31,
  
   
2016
    
2015
  
             
Weighted average number of ordinary shares outstanding for basic net income per ordinary share
    
55,011,019
      
60,281,059
  
Effect of dilutive share options outstanding
    
1,231,145
      
1,575,288
  
Weighted average number of ordinary shares for diluted net income per ordinary share
    
56,242,164
      
61,856,347
  
v3.4.0.3
Share-based Awards
 3 Months Ended
Mar. 31, 2016
Share-based Awards
6. Share-based Awards

Share Options

On July 21, 2008 the Company adopted the Employee Share Option Plan 2008 (the “2008 Employee Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any employee, or any Director holding a salaried office or employment with the Company or a Subsidiary for the purchase of ordinary shares. On the same date, the Company also adopted the Consultants Share Option Plan 2008 (the “2008 Consultants Plan”), pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may grant options to any consultant, adviser or non-executive Director retained by the Company or any Subsidiary for the purchase of ordinary shares.
Each option granted under the 2008 Employee Plan or the 2008 Consultants Plan (together the “2008 Option Plans”) will be an employee stock option, or Non-qualifying Stock Options (‘NSO’), as described in Section 422 or 423 of the Internal Revenue Code. Each grant of an option under the 2008 Options Plans will be evidenced by a Stock Option Agreement between the optionee and the Company. The exercise price will be specified in each Stock Option Agreement, however option prices will not be less than 100% of the fair market value of an ordinary share on the date the option is granted.
An aggregate of 6.0 million ordinary shares have been reserved under the 2008 Employee Plan, as reduced by any shares issued or to be issued pursuant to options granted under the 2008 Consultants Plan, under which a limit of 400,000 shares applies.  Further, the maximum number of ordinary shares with respect to which options may be granted under the 2008 Employee Option Plan, during any calendar year to any employee shall be 400,000 ordinary shares.  There is no individual limit under the 2008 Consultants Plan.   No options may be granted under the 2008 Option Plans after July 21, 2018.
On January 17, 2003 the Company adopted the Share Option Plan 2003 (the “2003 Share Option Plan”) pursuant to which the Compensation and Organization Committee of the Board could grant options to officers and other employees of the Company or its subsidiaries for the purchase of ordinary shares.  An aggregate of 6.0 million ordinary shares were reserved under the 2003 Share Option Plan; and, in no event could the number of ordinary shares issued pursuant to options awarded under this plan exceed 10% of the outstanding shares, as defined in the 2003 Share Option Plan, at the time of the grant, unless the Board expressly determined otherwise. Further, the maximum number of ordinary shares with respect to which options could be granted under the 2003 Share Option Plan during any calendar year to any employee was 400,000 ordinary shares.  The 2003 Share Option Plan expired on January 17, 2013.  No new options may be granted under this plan.
Share option awards are granted with an exercise price equal to the market price of the Company’s shares at date of grant.  Share options typically vest over a period of five years from date of grant and expire eight years from date of grant.  The maximum contractual term of options outstanding at March 31, 2016 is eight years.
The following table summarizes option activity for the three months ended March 31, 2016:
 
   
Options
Outstanding
Number of Shares
    
Weighted
 Average
 Exercise
Price
    
Weighted
 Average
Fair Value
    
Weighted
 Average
 Remaining
 Contractual
 Life
  
                         
Outstanding at December 31, 2015
    
1,626,582
    
$
34.87
    
$
11.94
        
                               
Granted
    
161,791
    
$
71.95
    
$
20.78
        
Exercised
    
(48,840
)
  
$
23.19
    
$
9.27
        
Forfeited
    
(6,835
)
  
$
22.51
    
$
9.61
        
                               
Outstanding at March 31, 2016
    
1,732,698
    
$
38.71
    
$
12.85
      
4.86
  
                                 
Exercisable at March 31, 2016
    
795,005
    
$
27.80
    
$
10.23
      
3.55
  
 
 
The Company has granted options with fair values ranging from $5.88 to $20.78 per option or a weighted average fair value of $10.45 per option. The Company issues ordinary shares for all options exercised. The total amount of fully vested share options which remained outstanding at March 31, 2016, was 795,005. Fully vested share options at March 31, 2016, have an average remaining contractual term of 3.55 years, an average exercise price of $27.80 and a total intrinsic value of $37.6 million. The total intrinsic value of options exercised during the three months ended March 31, 2016 was $2.2 million (March 31, 2015: $12.6 million).

The following table summarizes the movement in non-vested share options for the three months ended March 31, 2016:
 
   
Options
Outstanding
Number of Shares
    
Weighted Average
Exercise Price
    
Weighted Average
 Fair Value
  
                   
Non vested outstanding at December 31, 2015
    
968,853
    
$
42.14
    
$
13.69
  
                         
Granted
    
161,791
    
$
71.95
    
$
20.78
  
Vested
    
(187,409
)
  
$
39.36
    
$
13.02
  
Forfeited
    
(5,542
)
  
$
21.89
    
$
9.47
  
                         
Non vested outstanding at  March 31, 2016
    
937,693
    
$
47.96
    
$
15.07
  

Fair value of Stock Options Assumptions

The weighted average fair value of options granted during the three months ended March 31, 2016 and March 31, 2015 was calculated using the Black-Scholes option pricing model.  The weighted average fair values and assumptions used were as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
             
Weighted average fair value
  
$
20.78
    
$
19.78
  
                 
Assumptions:
                
Expected volatility
    
30
%
    
30
%
Dividend yield
    
0
%
    
0
%
Risk-free interest rate
    
1.39
%
    
1.41
%
Expected life
  
5 years
    
5 years
  

Expected volatility is based on the historical volatility of our common stock over a period equal to the expected term of the options; the expected life represents the weighted average period of time that options granted are expected to be outstanding given consideration to vesting schedules, and our historical experience of past vesting and termination patterns. The risk-free rate is based on the U.S. government zero-coupon bonds yield curve in effect at time of the grant for periods corresponding with the expected life of the option.

Restricted Share Units and Performance Share Units
On July 21, 2008 the Company adopted the 2008 Employees Restricted Share Unit Plan (the “2008 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any Director holding a salaried office or employment with the Company, or a Subsidiary to receive an award under the plan.  An aggregate of 1.0 million ordinary shares have been reserved for issuance under the 2008 RSU Plan.

On April 23, 2013 the Company adopted the 2013 Employees Restricted Share Unit and Performance Share Unit Plan (the “2013 RSU Plan”) pursuant to which the Compensation and Organization Committee of the Company’s Board of Directors may select any employee, or any Director holding a salaried office or employment with the Company, or a Subsidiary to receive an award under the plan.  On May 11, 2015 the 2013 RSU Plan was amended and restated in order to increase the number of shares that can be issued under the RSU Plan by 2.5 million shares.  Accordingly, an aggregate of 4.1 million ordinary shares have been reserved for issuance under the 2013 RSU Plan.  The shares are awarded at par value and vest over a service period. Awards under the 2013 RSU Plan may be settled in cash or shares at the option of the Company.
The Company has awarded RSUs and PSUs to certain key individuals of the Group. The following table summarizes RSU and PSU activity for the three months ended March 31, 2016:
 
   
 
PSU
 Outstanding
Number of
 Shares
    
PSU
Weighted
 Average
Fair
Value
    
PSU
Weighted
 Average
 Remaining
 Contractual
 Life
    
 
RSU
 Outstanding
Number of
 Shares
    
 
RSU
Weighted
 Average
Fair Value
    
RSU
Weighted
Average
 Remaining
 Contractual
 Life
  
                                     
Outstanding at December 31, 2015
    
901,773
    
$
72.55
      
2.49
      
1,067,613
    
$
48.30
      
1.48
  
                                                 
Granted
    
233,634
    
$
71.95
              
70,087
    
$
71.95
          
Shares vested
    
-
      
-
              
(57,328
)
  
$
25.30
          
Forfeited
    
(436
)
  
$
31.49
              
(32,947
)
  
$
47.08
          
                                                 
Outstanding at March 31, 2016
    
1,134,971
    
$
53.16
      
1.37
      
1,047,425
    
$
51.18
      
1.41
  
 
The fair value of RSUs vested for the three months ended March 31, 2016 totaled $1.5 million (full year 2015: $7.0 million).

No PSUs vested during the three months ended March 31 2016 (the fair value of RSUs vested for the full year 2015 was $0.3million).

The PSUs vest based on service and specified EPS targets over the period 2013 – 2016, 2014 – 2017 and 2015 - 2018. Since 2013, we granted 573,303 PSUs (net of forfeitures).  Depending on the actual amount of EPS from 2013 to 2018, up to an additional 561,668 PSUs may also be granted.

Non-cash stock compensation expense

Non-cash stock compensation expense for the three months ended March 31, 2016 has been allocated as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Direct costs
  
$
5,285
    
$
3,330
  
Selling, general and administrative
    
4,306
      
2,713
  
                 
   
$
9,591
    
$
6,043
  

Total non-cash stock compensation expense not yet recognized at March 31, 2016 amounted to $76.5 million.  The weighted average period over which this is expected to be recognized is 2.37 years  . Total tax benefit recognized in additional paid in capital related to the non-cash compensation expense amounted to $4.2 million for the three months ended March 31, 2016 (March 31, 2015: $1.9 million).
v3.4.0.3
Business Segment Information
 3 Months Ended
Mar. 31, 2016
Business Segment Information
7. Business Segment Information

The Company determines and presents operating segments based on the information that is internally provided to the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, who together are considered the Company’s chief operating decision maker, in accordance with FASB ASC 280-10 Disclosures about Segments of an Enterprises and Related Information.

The Company is a contract research organization (“CRO”), providing outsourced development services on a global basis to the pharmaceutical, biotechnology and medical device industries. It specializes in the strategic development, management and analysis of programs that support all stages of the clinical development process - from compound selection to Phase I-IV clinical studies.  The Company has the expertise and capability to conduct clinical trials in most major therapeutic areas on a global basis and has the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution.  The Company has expanded predominately through internal growth, together with a number of strategic acquisitions to enhance its expertise and capabilities in certain areas of the clinical development process.

The Company is generally awarded projects based upon responses to requests for proposals received from companies in the pharmaceutical, biotechnology and medical device industries or work orders executed under our strategic partnership arrangements.  Contracts with customers are generally entered into centrally, in most cases with ICON Clinical Research Limited (“ICON Ireland”), the Company’s principal operating subsidiary in Ireland.  Revenues, which consist primarily of fees earned under these contracts, are allocated to individual entities within the Group, based on where the work is performed in accordance with the Company’s global transfer pricing model.

ICON Ireland acts as the group entrepreneur under the Company’s global transfer pricing model given its role in the development and management of the group, it’s ownership of key intellectual property and customer relationships, its key role in the mitigation of risks faced by the group and its responsibility for maintaining the Company’s  global network.  As such it enters into the majority of the Company’s customer contracts.

ICON Ireland remunerates other operating entities in the ICON Group on the basis of a guaranteed cost plus mark up for the services they perform in each of their local territories.  The cost plus mark up for each ICON entity is established to ensure that each of ICON Ireland and the ICON entities that are involved in the conduct of services for customers, earn an appropriate arms-length return having regard to the assets owned, risks borne, and functions performed by each entity from these intercompany transactions. The cost plus mark-up policy is reviewed annually to ensure that it is market appropriate.

The geographic split of revenue disclosed for each region outside Ireland is the cost plus revenue attributable to these entities. The residual revenues of the Group, once each ICON entity has been paid its respective intercompany service fee, generally fall to be retained by ICON Ireland.  As such revenues and income from operations in Ireland are a function of this global transfer pricing model and comprise net revenues of the Group after deducting the cost plus revenues attributable to the activities performed outside Ireland.

The Company's areas of operation outside of Ireland include the United States, United Kingdom, France, Germany, Italy, Spain, The Netherlands, Sweden, Turkey, Poland, Czech Republic, Latvia, Russia, Ukraine, Hungary, Israel, Romania, Switzerland, Canada, Mexico, Brazil, Colombia, Argentina, Chile, Peru, India, China, South Korea, Japan, Thailand, Taiwan, Singapore, The Philippines, Australia, New Zealand, and South Africa.

Segment information as at March 31, 2016 and December 31, 2015 and for the three months ended March 31, 2016 and March 31, 2015 is as follows:
 

a) The distribution of net revenue by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
100,835
    
$
114,090
  
Rest of Europe
    
75,642
      
84,088
  
U.S.
    
184,090
      
150,064
  
Rest of World
    
39,955
      
39,989
  
                 
Total
  
$
400,522
    
$
388,231
  
* All sales shown for Ireland are export sales.

b) The distribution of income from operations by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
 
(in thousands)
  
       
Ireland
  
$
59,551
    
$
47,566
  
Rest of Europe
    
3,444
      
6,785
  
U.S.
    
10,784
      
9,854
  
Rest of World
    
2,231
      
2,468
  
                 
Total
  
$
76,010
    
$
66,673
  

c) The distribution of property, plant and equipment, net, by geographical area was as follows:

   
March 31,
    
December 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
103,716
    
$
101,736
  
Rest of Europe
    
7,225
      
7,334
  
U.S.
    
32,564
      
34,520
  
Rest of World
    
6,381
      
6,628
  
                 
Total
  
$
149,886
    
$
150,218
  
 

d) The distribution of depreciation and amortization by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
5,904
    
$
4,913
  
Rest of Europe
    
1,715
      
2,268
  
U.S.
    
6,649
      
5,718
  
Rest of World
    
852
      
1,026
  
                 
Total
  
$
15,120
    
$
13,925
  

e) The distribution of total assets by geographical area was as follows:

   
March 31,
    
December 31,
  
   
2016
      
2015*
 
   
(in thousands)
  
Ireland
  
$
734,612
    
$
663,060
  
Rest of Europe
    
356,787
      
343,733
  
U.S.
    
636,751
      
641,769
  
Rest of World
    
67,985
      
68,647
  
                 
Total
  
$
1,796,135
    
$
1,717,209
  
*The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Goodwill (Tables)
 3 Months Ended
Mar. 31, 2016
Goodwill
 
Three months ended
  
Year ended
  
 
March 31,
  
December 31,
  
 
2016
  
2015
  
 
(in thousands)
  
         
Opening balance
  
$
588,434
    
$
463,324
  
Current period acquisitions (Note 3)
    
-
      
133,123
  
Prior period acquisitions (Note 3)    
5,773
      
4,418
  
Foreign exchange movement
    
(322
)
    
(12,431
)
                 
Closing balance
  
$
593,885
    
$
588,434
  
v3.4.0.3
Business Combinations (Tables)
 3 Months Ended
Mar. 31, 2016
PMG  
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed
The table following summarizes the Company’s provisional estimates of the fair values of the assets acquired and liabilities assumed;

   
December 4,
  
   
2015
  
   
(in thousands)
  
Cash
  
$
194
  
Property, plant and equipment    
712
  
Goodwill*
    
46,812
  
Intangible assets**    
10,582
  
Accounts receivable
    
12,747
  
Prepayments and other current assets
    
1,329
  
Accounts payable
    
(530
)
Other liabilities     (2,459 )
Non-current deferred tax liability
    
(4,233
)
         
Net assets acquired
    
65,154
  
         
Cash consideration     53,681  
Other liabilities assumed     9,860  
Working capital adjustment
    
1,613
  
Total cash outflows
    
65,154
  
*Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.
**The Company has made an initial estimate of separate intangible assets acquired, being customer lists and order backlog, of $10.6 million.  This assessment is under review and will be finalized within 12 months of the date of acquisition.
MediMedia Pharma Solutions  
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed
The following table summarizes the Company’s estimate of the fair values of the assets acquired and liabilities assumed:
   
February 27,
  
   
2015
  
   
(in thousands)
  
Property, plant and equipment
  
$
1,049
  
Goodwill*
    
92,084
  
Customer lists    
22,752
  
Order backlog
    
2,521
  
Accounts receivable
    
5,240
  
Unbilled Revenue    
4,324
  
Prepayments and other current assets
    
621
  
Accounts payable     (749 )
Payments on account
    
(4,186
)
Deferred tax liability
    
(2,171
)
Other liabilities
    
(5,483
)
         
Net assets acquired
  
$
116,002
  
         
Cash consideration
  
$
108,717
  
Other liabilities assumed**
    
11,283
  
Gross cash outflows
    
120,000
  
Working capital adjustment
    
(3,998
)
Net cash outflows
  
$
116,002
  
 
* Goodwill represents the acquisition of an established workforce with experience in the provision of strategic payer-validated market access solutions while the acquisition of Complete Healthcare Communications comprises an established workforce with significant communication experience working with medical affairs, commercial and brand development teams within the life science industry.
** Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged.
Aptiv Solutions  
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed
The following table summarizes the fair values of the assets acquired and the liabilities assumed:
   
May 7,
  
   
2014
  
   
(in thousands)
  
Property, plant and equipment
  
$
6,924
  
Goodwill*
    
125,627
  
Customer relationships
    
21,400
  
Order backlog
    
7,900
  
Cash and cash equivalents
    
3,484
  
Accounts receivable
    
25,091
  
Unbilled revenue
    
21,154
  
Prepayments and other current assets
    
4,180
  
Non-current assets
    
2,911
  
Accounts payable
    
(9,565
)
Other liabilities
    
(29,782
)
Payments on account
    
(31,094
)
Non-current other liabilities
    
(11,303
)
Loan notes payable**
    
(17,790
)
         
Net assets acquired
  
$
119,137
  
         
Cash consideration
  
$
143,500
  
Working capital adjustment
    
(1,964
)
     
141,536
  
Adjustments to cash consideration**
    
(22,399
)
Net purchase consideration
  
$
119,137
  
*Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.  Goodwill related to the US portion of the business acquired is tax deductible.
**Adjustments to cash consideration represent certain one-time liabilities (including loan notes) identified at the acquisition date which have subsequently been paid.
v3.4.0.3
Income Taxes (Tables)
 3 Months Ended
Mar. 31, 2016
Income Taxes Recognized During Period
The provision for income taxes recognized during the three months ended March 31, 2016 is comprised of:

 
Three Months Ended
  
 
March 31,
  
March 31,
  
 
2016
  
2015
  
 
(in thousands)
  
     
Provision for income taxes  
$
10,165
    
$
10,801
  
v3.4.0.3
Net income per ordinary share (Tables)
 3 Months Ended
Mar. 31, 2016
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share
The reconciliation of the number of shares used in the computation of basic and diluted net income per ordinary share is as follows:

    
Three Months Ended
  
     
March 31,
    
March 31,
  
   
2016
    
2015
  
             
Weighted average number of ordinary shares outstanding for basic net income per ordinary share
    
55,011,019
      
60,281,059
  
Effect of dilutive share options outstanding
    
1,231,145
      
1,575,288
  
Weighted average number of ordinary shares for diluted net income per ordinary share
    
56,242,164
      
61,856,347
  
v3.4.0.3
Share-based Awards (Tables)
 3 Months Ended
Mar. 31, 2016
Summary of Stock Option Activity
The following table summarizes option activity for the three months ended March 31, 2016:
 
   
Options
Outstanding
Number of Shares
    
Weighted
 Average
 Exercise
Price
    
Weighted
 Average
Fair Value
    
Weighted
 Average
 Remaining
 Contractual
 Life
  
                         
Outstanding at December 31, 2015
    
1,626,582
    
$
34.87
    
$
11.94
        
                               
Granted
    
161,791
    
$
71.95
    
$
20.78
        
Exercised
    
(48,840
)
  
$
23.19
    
$
9.27
        
Forfeited
    
(6,835
)
  
$
22.51
    
$
9.61
        
                               
Outstanding at March 31, 2016
    
1,732,698
    
$
38.71
    
$
12.85
      
4.86
  
                                 
Exercisable at March 31, 2016
    
795,005
    
$
27.80
    
$
10.23
      
3.55
  
Summary of Movement in Non-Vested Share Options
The following table summarizes the movement in non-vested share options for the three months ended March 31, 2016:
 
   
Options
Outstanding
Number of Shares
    
Weighted Average
Exercise Price
    
Weighted Average
 Fair Value
  
                   
Non vested outstanding at December 31, 2015
    
968,853
    
$
42.14
    
$
13.69
  
                         
Granted
    
161,791
    
$
71.95
    
$
20.78
  
Vested
    
(187,409
)
  
$
39.36
    
$
13.02
  
Forfeited
    
(5,542
)
  
$
21.89
    
$
9.47
  
                         
Non vested outstanding at  March 31, 2016
    
937,693
    
$
47.96
    
$
15.07
  
Weighted Average Fair Values and Assumptions Used
The weighted average fair values and assumptions used were as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
             
Weighted average fair value
  
$
20.78
    
$
19.78
  
                 
Assumptions:
                
Expected volatility
    
30
%
    
30
%
Dividend yield
    
0
%
    
0
%
Risk-free interest rate
    
1.39
%
    
1.41
%
Expected life
  
5 years
    
5 years
  
RSU and PSU Activity
The following table summarizes RSU and PSU activity for the three months ended March 31, 2016:
 
   
 
PSU
 Outstanding
Number of
 Shares
    
PSU
Weighted
 Average
Fair
Value
    
PSU
Weighted
 Average
 Remaining
 Contractual
 Life
    
 
RSU
 Outstanding
Number of
 Shares
    
 
RSU
Weighted
 Average
Fair Value
    
RSU
Weighted
Average
 Remaining
 Contractual
 Life
  
                                     
Outstanding at December 31, 2015
    
901,773
    
$
72.55
      
2.49
      
1,067,613
    
$
48.30
      
1.48
  
                                                 
Granted
    
233,634
    
$
71.95
              
70,087
    
$
71.95
          
Shares vested
    
-
      
-
              
(57,328
)
  
$
25.30
          
Forfeited
    
(436
)
  
$
31.49
              
(32,947
)
  
$
47.08
          
                                                 
Outstanding at March 31, 2016
    
1,134,971
    
$
53.16
      
1.37
      
1,047,425
    
$
51.18
      
1.41
  
Schedule of Non-cash Stock Compensation Expense
Non-cash stock compensation expense for the three months ended March 31, 2016 has been allocated as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Direct costs
  
$
5,285
    
$
3,330
  
Selling, general and administrative
    
4,306
      
2,713
  
                 
   
$
9,591
    
$
6,043
  
v3.4.0.3
Business Segment Information (Tables)
 3 Months Ended
Mar. 31, 2016
Distribution of Net Revenue by Geographical Area
a) The distribution of net revenue by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
100,835
    
$
114,090
  
Rest of Europe
    
75,642
      
84,088
  
U.S.
    
184,090
      
150,064
  
Rest of World
    
39,955
      
39,989
  
                 
Total
  
$
400,522
    
$
388,231
  
* All sales shown for Ireland are export sales.
Distribution of Income from Operations by Geographical Area
b) The distribution of income from operations by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
 
(in thousands)
  
       
Ireland
  
$
59,551
    
$
47,566
  
Rest of Europe
    
3,444
      
6,785
  
U.S.
    
10,784
      
9,854
  
Rest of World
    
2,231
      
2,468
  
                 
Total
  
$
76,010
    
$
66,673
  
Distribution of Property, Plant and Equipment, Net, by Geographical Area
c) The distribution of property, plant and equipment, net, by geographical area was as follows:

   
March 31,
    
December 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
103,716
    
$
101,736
  
Rest of Europe
    
7,225
      
7,334
  
U.S.
    
32,564
      
34,520
  
Rest of World
    
6,381
      
6,628
  
                 
Total
  
$
149,886
    
$
150,218
  
Distribution of Depreciation and Amortization by Geographical Area
d) The distribution of depreciation and amortization by geographical area was as follows:

   
Three Months Ended
  
   
March 31,
    
March 31,
  
   
2016
    
2015
  
   
(in thousands)
  
Ireland
  
$
5,904
    
$
4,913
  
Rest of Europe
    
1,715
      
2,268
  
U.S.
    
6,649
      
5,718
  
Rest of World
    
852
      
1,026
  
                 
Total
  
$
15,120
    
$
13,925
  
Distribution of Total Assets by Geographical Area
e) The distribution of total assets by geographical area was as follows:

   
March 31,
    
December 31,
  
   
2016
      
2015*
 
   
(in thousands)
  
Ireland
  
$
734,612
    
$
663,060
  
Rest of Europe
    
356,787
      
343,733
  
U.S.
    
636,751
      
641,769
  
Rest of World
    
67,985
      
68,647
  
                 
Total
  
$
1,796,135
    
$
1,717,209
  
*The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Goodwill (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Goodwill [Line Items]    
Opening balance $ 588,434 [1] $ 463,324
Current period acquisitions (Note 3)   133,123
Prior period acquisitions (Note 3) 5,773 4,418
Foreign exchange movement (322) (12,431)
Closing balance $ 593,885 $ 588,434 [1]
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Business Combinations - Additional Information (Detail)
$ in Thousands
Mar. 31, 2016
USD ($)
Dec. 04, 2015
USD ($)
Patient
Site
Mar. 25, 2015
USD ($)
Feb. 27, 2015
USD ($)
May. 07, 2014
USD ($)
PMG          
Business Acquisition [Line Items]          
Net cash outflow   $ 63,500      
Other liabilities assumed   $ 9,860      
Number of clinical research sites acquired | Site   48      
Working capital targets achievement period   90 days      
Working capital adjustment $ 1,600 $ 1,613      
Cash consideration   $ 53,681      
PMG | Minimum          
Business Acquisition [Line Items]          
Number of active patients via electronic medical records acquired | Patient   2,000,000      
MediMedia Pharma Solutions          
Business Acquisition [Line Items]          
Net cash outflow       $ 116,002  
Other liabilities assumed [1]       11,283  
Working capital adjustment       3,998  
Cash consideration, net of working capital adjustment       104,700  
Cash consideration       $ 108,717  
Aptiv Solutions          
Business Acquisition [Line Items]          
Working capital adjustment     $ 2,000   $ 1,964
Percentage of common stock acquired         100.00%
Cash consideration         $ 143,500
Adjustments to cash consideration [2]         $ 22,399
[1] Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged.
[2] Adjustments to cash consideration represent certain one-time liabilities (including loan notes) identified at the acquisition date which have subsequently been paid.
v3.4.0.3
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Dec. 04, 2015
Mar. 31, 2015
Dec. 31, 2015
 [1]
Dec. 31, 2014
Business Acquisition [Line Items]          
Goodwill $ 593,885     $ 588,434 $ 463,324
Total cash outflows     $ 103,138    
PMG          
Business Acquisition [Line Items]          
Cash   $ 194      
Property, plant and equipment   712      
Goodwill [2]   46,812      
Intangible assets [3]   10,582      
Accounts receivable   12,747      
Prepayments and other current assets   1,329      
Accounts payable   (530)      
Other liabilities   (2,459)      
Non-current deferred tax liability   (4,233)      
Net assets acquired   65,154      
Cash consideration   53,681      
Other liabilities assumed   9,860      
Working capital adjustment $ 1,600 1,613      
Total cash outflows   $ 65,154      
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
[2] *Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.
[3] **The Company has made an initial estimate of separate intangible assets acquired, being customer lists and order backlog, of $10.6 million. This assessment is under review and will be finalized within 12 months of the date of acquisition.
v3.4.0.3
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail) - PMG
$ in Thousands
Dec. 04, 2015
USD ($)
Business Acquisition [Line Items]  
Intangible asset $ 10,582 [1]
Customer Lists  
Business Acquisition [Line Items]  
Intangible asset $ 10,600
[1] **The Company has made an initial estimate of separate intangible assets acquired, being customer lists and order backlog, of $10.6 million. This assessment is under review and will be finalized within 12 months of the date of acquisition.
v3.4.0.3
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail) - USD ($)
$ in Thousands
Feb. 27, 2015
Mar. 31, 2016
Dec. 31, 2015
 [1]
Dec. 31, 2014
Business Acquisition [Line Items]        
Goodwill   $ 593,885 $ 588,434 $ 463,324
MediMedia Pharma Solutions        
Business Acquisition [Line Items]        
Property, plant and equipment $ 1,049      
Goodwill [2] 92,084      
Accounts receivable 5,240      
Unbilled revenue 4,324      
Prepayments and other current assets 621      
Accounts payable (749)      
Payments on account (4,186)      
Deferred tax liability (2,171)      
Other liabilities (5,483)      
Net assets acquired 116,002      
Cash consideration 108,717      
Other liabilities assumed [3] 11,283      
Gross cash outflows 120,000      
Working capital adjustment (3,998)      
Net cash outflows 116,002      
MediMedia Pharma Solutions | Customer Lists        
Business Acquisition [Line Items]        
Intangible asset 22,752      
MediMedia Pharma Solutions | Order Backlog        
Business Acquisition [Line Items]        
Intangible asset $ 2,521      
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
[2] Goodwill represents the acquisition of an established workforce with experience in the provision of strategic payer-validated market access solutions while the acquisition of Complete Healthcare Communications comprises an established workforce with significant communication experience working with medical affairs, commercial and brand development teams within the life science industry.
[3] Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged.
v3.4.0.3
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail)
$ in Thousands
Feb. 27, 2015
USD ($)
MediMedia Pharma Solutions  
Business Acquisition [Line Items]  
Other liabilities assumed $ 11,283 [1]
[1] Payments made at acquisition date of $11.3 million were in respect of certain one-time liabilities which have subsequently been discharged.
v3.4.0.3
Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail) - USD ($)
$ in Thousands
Mar. 25, 2015
May. 07, 2014
Mar. 31, 2016
Dec. 31, 2015
 [1]
Dec. 31, 2014
Business Acquisition [Line Items]          
Goodwill     $ 593,885 $ 588,434 $ 463,324
Aptiv Solutions          
Business Acquisition [Line Items]          
Property, plant and equipment   $ 6,924      
Goodwill [2]   125,627      
Cash and cash equivalents   3,484      
Accounts receivable   25,091      
Unbilled revenue   21,154      
Prepayments and other current assets   4,180      
Non-current assets   2,911      
Accounts payable   (9,565)      
Other liabilities   (29,782)      
Payments on account   (31,094)      
Non-current other liabilities   (11,303)      
Loan notes payable [3]   (17,790)      
Net assets acquired   119,137      
Cash consideration   143,500      
Working capital adjustment $ (2,000) (1,964)      
Gross cash outflows   141,536      
Adjustments to cash consideration [3]   (22,399)      
Net assets acquired/Net purchase consideration   119,137      
Aptiv Solutions | Customer Relationships          
Business Acquisition [Line Items]          
Intangible asset   21,400      
Aptiv Solutions | Order Backlog          
Business Acquisition [Line Items]          
Intangible asset   $ 7,900      
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
[2] Goodwill represents the acquisition of an established workforce with experience in clinical trial consulting and regulatory support for the development of drugs, medical devices and diagnostics, with a specific focus on strategy to increase efficiency and productivity in product development.
[3] Adjustments to cash consideration represent certain one-time liabilities (including loan notes) identified at the acquisition date which have subsequently been paid.
v3.4.0.3
Income Taxes Recognized During Period (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Reconciliation of Provision of Income Taxes [Line Items]    
Provision for income taxes $ 10,165 $ 10,801
v3.4.0.3
Income Taxes - Additional Information (Detail) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]    
Liability for unrecognized tax benefit $ 32.0 $ 31.4
Items generating unrecognized tax benefits 28.6 28.1
Interest and related penalties $ 3.4 $ 3.3
Earliest Tax Year    
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]    
Tax year subject to examination by major tax jurisdictions 2011  
Latest Tax Year    
Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Line Items]    
Tax year subject to examination by major tax jurisdictions 2015  
v3.4.0.3
Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail) - shares
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Schedule of Weighted Average Number of Diluted Shares Outstanding [Line Items]    
Weighted average number of ordinary shares outstanding for basic net income per ordinary share 55,011,019 60,281,059
Effect of dilutive share options outstanding 1,231,145 1,575,288
Weighted average number of ordinary shares outstanding for diluted net income per ordinary share 56,242,164 61,856,347
v3.4.0.3
Share-based Awards - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended 36 Months Ended
May. 11, 2015
Mar. 31, 2016
Mar. 31, 2015
Dec. 31, 2015
Dec. 31, 2015
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Non-cash stock compensation expense not yet recognized   $ 76,500      
Unrecognized stock-based compensation expense, weighted average period (years)   2 years 4 months 13 days      
Tax benefit on exercise of options   $ 4,241 $ 1,923    
Restricted Stock Units (RSUs)          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Fair value of stock units vested   $ 1,500   $ 7,000  
Stock units vested   57,328      
Stock units granted   70,087      
Performance Share Unit (PSUs)          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Fair value of stock units vested       $ 300  
Stock units vested   0      
Stock units granted   233,634      
PSUs Based on Service and EPS Targets          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Stock units granted         573,303
PSUs Based on Service and EPS Targets | Minimum          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Cumulative EPS vesting period   2013      
PSUs Based on Service and EPS Targets | Maximum          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Stock units to be granted   561,668      
Cumulative EPS vesting period   2018      
Employee Stock Plan, 2008 Plan          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Ordinary shares which have been reserved for issuance   6,000,000      
Employee Stock Plan, 2008 Plan | Individual Employee          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Ordinary shares which have been reserved for issuance   400,000      
Employee Stock Plan, 2008 Plan | Minimum          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Percentage of option price for fair value of ordinary share   100.00%      
Employee Stock Plan, 2003 Plan          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Ordinary shares which have been reserved for issuance   6,000,000      
Maximum number of award as percentage of shares outstanding   10.00%      
Employee Stock Plan, 2003 Plan | Individual Employee          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Ordinary shares which have been reserved for issuance   400,000      
Employee Stock Option          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Shares vesting period   5 years      
Shares expiration period   8 years      
Weighted average contractual term of options outstanding   4 years 10 months 10 days      
Weighted average fair value per option   $ 10.45      
Exercisable - number of shares   795,005      
Exercisable - weighted average remaining contractual life   3 years 6 months 18 days      
Exercisable - weighted average exercise price   $ 27.80      
Fully vested total intrinsic value   $ 37,600      
Intrinsic value of option exercised   $ 2,200 $ 12,600    
Employee Stock Option | Minimum          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Options granted fair value   $ 5.88      
Employee Stock Option | Maximum          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Weighted average contractual term of options outstanding   8 years      
Options granted fair value   $ 20.78      
Restricted Stock Units 2008          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Ordinary shares which have been reserved for issuance   1,000,000      
Restricted Stock Units 2013          
Compensation Related Costs Share Based Payments Disclosure [Line Items]          
Ordinary shares which have been reserved for issuance 4,100,000        
Number of additional shares authorized for issuance 2,500,000        
v3.4.0.3
Summary of Stock Option Activity (Detail) - Employee Stock Option - $ / shares
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Options Outstanding Number of Shares    
Outstanding at beginning of period 1,626,582  
Granted 161,791  
Exercised (48,840)  
Forfeited (6,835)  
Outstanding at end of period 1,732,698  
Exercisable at end of period 795,005  
Weighted Average Exercise Price    
Outstanding at beginning of period $ 34.87  
Granted 71.95  
Exercised 23.19  
Forfeited 22.51  
Outstanding at end of period 38.71  
Exercisable at end of period 27.80  
Weighted Average Fair Value    
Outstanding at beginning of period 11.94  
Granted 20.78 $ 19.78
Exercised 9.27  
Forfeited 9.61  
Outstanding at end of period 12.85  
Exercisable at end of period $ 10.23  
Weighted Average Remaining Contractual Life    
Outstanding at end of period 4 years 10 months 10 days  
Exercisable at end of period 3 years 6 months 18 days  
v3.4.0.3
Summary of Movement in Non-Vested Share Options (Detail) - Employee Stock Option - $ / shares
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Options Outstanding Number of Shares    
Beginning Balance 968,853  
Granted 161,791  
Vested (187,409)  
Forfeited (5,542)  
Ending Balance 937,693  
Weighted Average Exercise Price    
Beginning balance $ 42.14  
Granted 71.95  
Vested 39.36  
Forfeited 21.89  
Ending balance 47.96  
Weighted Average Fair Value    
Beginning Balance 13.69  
Granted 20.78 $ 19.78
Vested 13.02  
Forfeited 9.47  
Ending Balance $ 15.07  
v3.4.0.3
Schedule of Weighted Average Fair Values and Assumptions Used (Detail) - Employee Stock Option - $ / shares
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Weighted average fair value $ 20.78 $ 19.78
Assumptions:    
Expected volatility 30.00% 30.00%
Dividend yield 0.00% 0.00%
Risk-free interest rate 1.39% 1.41%
Expected life 5 years 5 years
v3.4.0.3
Summary of RSU and PSU Activity (Detail) - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2016
Dec. 31, 2015
Performance Share Unit (PSUs)    
Outstanding Number of Shares    
Outstanding at beginning of period 901,773  
Granted 233,634  
Shares vested 0  
Forfeited (436)  
Outstanding at ending of period 1,134,971 901,773
Weighted Average Fair Value    
Outstanding at beginning of period $ 72.55  
Granted 71.95  
Forfeited 31.49  
Outstanding at end of period $ 53.16 $ 72.55
Weighted Average Remaining Contractual Life    
Outstanding at end of period 1 year 4 months 13 days 2 years 5 months 27 days
Restricted Stock Units (RSUs)    
Outstanding Number of Shares    
Outstanding at beginning of period 1,067,613  
Granted 70,087  
Shares vested (57,328)  
Forfeited (32,947)  
Outstanding at ending of period 1,047,425 1,067,613
Weighted Average Fair Value    
Outstanding at beginning of period $ 48.30  
Granted 71.95  
Shares vested 25.30  
Forfeited 47.08  
Outstanding at end of period $ 51.18 $ 48.30
Weighted Average Remaining Contractual Life    
Outstanding at end of period 1 year 4 months 28 days 1 year 5 months 23 days
v3.4.0.3
Schedule of Non-cash Stock Compensation Expense (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 9,591 $ 6,043
Direct costs    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense 5,285 3,330
Selling, general and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based compensation expense $ 4,306 $ 2,713
v3.4.0.3
Distribution of Net Revenue by Geographical Area (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Segment Reporting Information [Line Items]    
Net Revenue $ 400,522 $ 388,231
Ireland    
Segment Reporting Information [Line Items]    
Net Revenue 100,835 114,090
Rest Of Europe    
Segment Reporting Information [Line Items]    
Net Revenue 75,642 84,088
United States    
Segment Reporting Information [Line Items]    
Net Revenue 184,090 150,064
Rest of World    
Segment Reporting Information [Line Items]    
Net Revenue $ 39,955 $ 39,989
v3.4.0.3
Distribution of Income from Operations by Geographical Area (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Segment Reporting Information [Line Items]    
Income from operations $ 76,010 $ 66,673
Ireland    
Segment Reporting Information [Line Items]    
Income from operations 59,551 47,566
Rest Of Europe    
Segment Reporting Information [Line Items]    
Income from operations 3,444 6,785
United States    
Segment Reporting Information [Line Items]    
Income from operations 10,784 9,854
Rest of World    
Segment Reporting Information [Line Items]    
Income from operations $ 2,231 $ 2,468
v3.4.0.3
Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
Segment Reporting Information [Line Items]    
Property, plant and equipment, net $ 149,886 $ 150,218 [1]
Ireland    
Segment Reporting Information [Line Items]    
Property, plant and equipment, net 103,716 101,736
Rest Of Europe    
Segment Reporting Information [Line Items]    
Property, plant and equipment, net 7,225 7,334
United States    
Segment Reporting Information [Line Items]    
Property, plant and equipment, net 32,564 34,520
Rest of World    
Segment Reporting Information [Line Items]    
Property, plant and equipment, net $ 6,381 $ 6,628
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs.
v3.4.0.3
Distribution of Depreciation and Amortization by Geographical Area (Detail) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Segment Reporting Information [Line Items]    
Depreciation and amortization $ 15,120 $ 13,925
Ireland    
Segment Reporting Information [Line Items]    
Depreciation and amortization 5,904 4,913
Rest Of Europe    
Segment Reporting Information [Line Items]    
Depreciation and amortization 1,715 2,268
United States    
Segment Reporting Information [Line Items]    
Depreciation and amortization 6,649 5,718
Rest of World    
Segment Reporting Information [Line Items]    
Depreciation and amortization $ 852 $ 1,026
v3.4.0.3
Distribution of Total Assets by Geographical Area (Detail) - USD ($)
$ in Thousands
Mar. 31, 2016
Dec. 31, 2015
 [1]
Segment Reporting Information [Line Items]    
Assets $ 1,796,135 $ 1,717,209
Ireland    
Segment Reporting Information [Line Items]    
Assets 734,612 663,060
Rest Of Europe    
Segment Reporting Information [Line Items]    
Assets 356,787 343,733
United States    
Segment Reporting Information [Line Items]    
Assets 636,751 641,769
Rest of World    
Segment Reporting Information [Line Items]    
Assets $ 67,985 $ 68,647
[1] The December 31, 2015 Balance Sheet has been retrospectively restated as required to reflect the requirements of new guidance in respect of the presentation of debt issue costs. 
begin 644 Financial_Report.xlsx
M4$L#!!0    ( &Q_I$@J5XXWQ0$  ,$9   3    6T-O;G1E;G1?5'EP97-=
M+GAM;,V9S4[#,!"$7Z7*%36N;?Y%N0!7J 0O8))M8S6.+=N4]NVQ4T!0%42!
M2G/)3V>],\DZWZ47#RM'8; T;1?&11.C.V%\JY5EK6Z6J4M(OXV+I(8?.6PN_"Z9
M-GEHKIM]6I'O?_DL&R]Q8=IKKY[UAL%B;V/*Y](HW6T;U;/U\T=KY_^Y32@_
M54WUT/E4Z*/>LDM2\22I@:76?_)^VRF5]?0CPURXQX^B49[J^^C3?+=_&Q\+
M]I!*D>A*D?!*D?A*DQW8OG*\M"_V/Z'D4X$G1H>)%]2-F Q+M*;V"
M^GH A3&^.R6:E((C-Z."N[_8_ )02P,$%     @ ;'^D2!.#K'*E 0  ]1@ 
M !H   !X;"]?HZZZ<=OV!8B.8I1+F&E:W[[416,O\Z4+DV\#@4G._%<_""R;D"^>_+F,
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M^@-02P,$%     @ ;'^D2)QF"N 3 P   PL  !    !D;V-0&ULO5;?;]HP$/Y7+)XZ:2R,L3X@&HE"MU5:6U0H?3;V)5A-[,AG*.ROWR6!
M+% 7* _C@5PN]]V/SW>V>QI;W9$U&5BG -DJ331V27G5F#N7=8, Q1Q2CE_(
M1-/7R-B4.WJU<6"B2 D8&K%(0;N@W6I=!K!RH"7(9E8Y;82]/$H_RQ(EN%-&
MAW=*6(,FY]R"I* [WBME8?-K374F.78PYSH&
M6;=]^W'+Q10LYI5^;7]IT:^B8*LO?0.72LT&E
M+,2Z;5U6G;#3*BQ(VK4,JLK"#6T[=>>:B7()X$,TXM;])RJ*FK9$=%J-6O5;
M%XQKR6ZTHW9DM[H,18M7IZ22!H;F0B-(1A*:1$EJ,\FN><*U '8&YMM',&-'
M#\KY#,SW,S"77LPU1X7,1&QD 8F_]]GZ:8Q\54GB=[- I0&1(JW!,E48TJ9 ,=G$B'2<6X.&%D$>H&8+C*OD(-4W6
MEU*1[,]^D:9YA=22-^@4I0%%?_Z@G8=-^<F)2%DEQZ$&A]AU>RQ[N=KPBF)(,*:C 86#[*65*^F*VQC2G8H"^+Z+@2
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MT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\
M!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%#BVR]*+41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&
M^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\
MW*.76!4!EQC?-*HU+,76>)7 \:V@S&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX
M?H;5,VPLCO='U!=*Y \FIS_I,C0'HYI9";V$5FJ?JH,@H%\;D>/N5Z
M> HWEL:\4*Z">P'_T=HWPJOX@L Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;
MQ/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0C
MI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[
MY\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4
MX&1@+: '@Z]1 O)256 Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM
M(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9KF4Q9Z;RWRT,
M"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[
M2$R<><41 71% B.5' 86%S+D4.Z2D 83  >LX=S
MFWJXPD6L_UC6'ODRWSEPVSK> U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ
M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 
M6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<
M_N\-L,+$CN'MB[\!4$L#!!0    ( &Q_I$@V^H(L; (  $0,   -    >&PO
M='QTSN_\=4F.X^=J3_']%F,%2D9Y'L"M
M4MD[Q\GC+68HGXH,Y )Q*O3:)3
M'UKHIX)W9S>#UA'Z^2/8(:KC/1,>"RHD4/IRZ J5AR.&;<0MHB22Q#A3Q C=
M6_?,.*K[5,6BCEX-9GF$TL/E:4?H9T@I
M+/E*/X#:7N\SO3@N.+8BJ[@ST1N)]MYLT4NH!ETW$C+!LJWLP<85^A2G2B=(
MLMF:48G,2!=*"::-A*"-X(@:9)-1&QH;8TKOS;?W2WK +E-@8\P9NQ 8%8VI
M-Z(VNVM0;:K3IUEV'SM_%1>4:5M 9Z,LH_OWE&PXPU:L=:U$_70.[YW ASYJ
MJ& K)'G4\>8BQ-J!)00[+!6)^YYO$F5K7*KZ!CME>DKA:Y?\-S7]^5WKU.@K
M^*^WY[\6[Y]-]36$1WJ><11W!8NP7%6_O"\7-K\JK3Y[RISZG;:Z]D'';OU@J@@5!'>2$#F'>O.R*8'S;3KUIJ9E%VCKF85
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M)^'O7X=_,Z;82Z5(Q <2\2'RP=I)#&9;&,KL,S8 K]M#T@0%BBH(V?$SD4(N%J),/;3O;!%IQG4
MR#2BY'/O%[!I)LO_S! J9!HQ\C3N[!U.<07N#QI,)4PC%D93$"51"].(AC0;
M40"U+XWH=S$M[!U%41/3B(JO$Q-M$=4SO>1G)$,(I"BJ:AIQ]25),_!"*MH.
M3H7E$6'C2;IBTP(7+FDHBBK+8\K691D&%6?YC?,2^P+-E/\JI&4/@J(Z?]2(
MOQ=1G/Y2.5681Q2^C!I0%!6:1X2^C**_54Z-YA&C+Z/HCY53MWG$[<[DN(?<
M;'18NMFLMKB\=]8QZC:/N-U!/3N@A6KMI"CJ-X_X'1JBL/?[(Y5FZ=
M#%+;LXCMYZ@9X 8B/[HOZ)*;4=NSB.WGJ*7!HIM-G<-:& >+%H'4]D'_6$*_
M5,VX=AHX*&M(@;#L+B$Z^^X^9@D88> FX%:J2]X[X?^
MQXBFCF[)IZW%Y_\ 4$L#!!0    ( &Q_I$BO@M!]'@(  ,X&   8    >&PO
M=V]R:W-H965T&ULC979CML@%(9?!?D!!N,MBQQ+DZFJ]J+2
M:"[::Y*0V!HP+I!X^O9E<3R8L>3["$7WB;?F4BLS :L2CKY3PT@K&]X"0>GU@DC]P_FX&/T^[*#8Y$$J.RH3 NKF1%T*IB:3)?X>@GTQC]/OWZ-_M
M6BKY<($T9&!SDW:
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MA1L  !@   !X;"]W;W)KCJ5E_^*ZEB_W2UA
M^=[PU^'IN>T:5MO-ZMKOX7"JSLVA/B\NU>/=\E=8[ZWI)+WB[T/UUHC/B\[\
ME[K^VGWYX^%N:3H/U;&Z;[LA2O[WK=I5QV,W$I_YWW'0'^?L.LK/[Z/_UI?+
M]K^43;6KC_\<'MIG=FN6BX?JL7P]MG_5;[]78PVN&_"^/C;]W\7]:]/6I_OADKZ'/9E
M6VXWE_IMT;R4W>R -:LOW1@\\(*+;_JO?;Q#Z[ 
M!Z),/74D,Q0 ;E=H$S=6NG&JFT'B>TGN77J]1C.1RH5@;GMQB1'?;C4_<>.E&O0"%%Z=!RKU5 ]Q)&63D;;CM)DO<9-)-KKK)
M9#;6>37!7:0R@68DDR=>0N(E""^DSLPBR*MD
M+.FY1"H,?L9: I-BS4@WH+H9-<.) N4V4Q/<1;K<8T8S9@W\!%H0!"-]L?2=
M/AXVY2*@+%2]N,6H&:>]#7FN!Q_KG$&8,0T@I2I(K)*.U5$SG,EQ]KF^7F-=
MGELQWK2CE*P@T4HZ6D%2$\CDZIS9Q3)P8<[D3.D*$J_Z(BA @A/0TL38G3M^>HMQY0LCT];V+99YGY6T_E(*6)&B=#EJ2"+5F8M,8J[R=<:4H!2W)
MS:F;.,_-S2FEM"1)2_W)HR",[.<3)X]5=]B4 *.4W<36)=
M3A1F/+U1RDJ2K-1W5 5)!DXMUTG1M)>4DB0WI4[?E)+<;?[B\I#K&X]8Q[LS
MFH$S2@%+$K!.!RQ)^S>FZ;MM-Z3UF[7>ZNUN_7>
M:>U^O?=:>[;>9UI[OM[G6GM8[X/6#F:]!Z,> 3X"ZA$N&M2J@ :@;(&:": 7(&J&: G &J&2!G@&H&Q!F0F@%Q!J1F0)P!Z;._F_YJ
M!L09D)H!<0:D9D"< :D9$&= :@;$&9"6 9.%CV@9,!S>?W!:_5C]V\U+^53]
M65Z>#N=F\:5NV_K4_XKR6-=MQ4PQG_A&]5R5#]"\"  # !@  &    'AL+W=O
MNJ5H")'@BS:M6'F5E%T&
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M0Z8#'1F31-7N+]1CJ=1Q,BX:&@5_P!02P,$%   
M  @ ;'^D2)P*HKEP P  !PX  !@   !X;"]W;W)KNB>%9NVA4JB5Y+C]M^7'XHR
MXM*P+I%$OS?SAAR^D.N;[G[V9Z6&Y%=3M_W+ZCP,E^AKEKUK4OZ:].4W>^M
MJO7M9457[P/?J]-YL /I9IU.O$/5J+:O=)MTZOBR^D2?=\ LQ"%^5.K6H_?$
MBG_5^J?]^.?PLB)6@ZK5?K A2O-X4SM5US:2R?S?&/0CIR7B]_?H7URY1OYK
MV:N=KO^M#L/9J"6KY*".Y;4>ONO;WVJL@=N >UWW[F^RO_:#;MXIJZ0I?_EG
MU;KGS?^2LY$6)\!(@(DPY8D3V$A@'X3,5>J5N;H^ET.Y67?ZEO27TJXV?3;P
MS@8QD1-33.\^W73YT;>-$.OTS<:90;8> @Y")T1J@D>7\PEMKX(#\D=A&? )8O!=C,880S-Z%TU/%##
MD9J<1-5XB'"0OV@&1-"HG#F.K4!Y,D(X0%0.AC$I@2WH
MICQ0DZ.USN$Q7P9\B:N)+N)6(ID 4I#X6@@LPH
MB@N:XRCG"U:+0J@(L*(\K@CP4@A"[\P0A@DA4"_>UQ,:'V58CXSK8;AR%FVR
MW0P$^0+7HJ&)4NRB>=Q%1\QH2'89XFIF,$#![LL)791B&Y5Q&Z78'W-&(;ZW
M9C"[5&2!GM!%*;91&;=1*F9^3:BX,S\!3I(%1DI#)Z4Y5A3=-ML1X_^A"2C$
MG?;!,+.UQ)(5"YV92F3M'XGIHA!0%)
M"5]25^B P!9,,C8W+B #>J>/9TA!)1XVG\">SX/QK;GS^!O*1YC-^E*>U->R.U5MG[SJP9S^W<'_J/6@C$3R9,SH
M;&YETT>MCH-]S&PO=V]R:W-H965T&ULE9E-;^,V$(;_
MBN%[5IP9DI(,Q\ Z0M$>"BSVT)Z56(F-M2Q74N+MOZ^^[.4PHX2]Q);R#N<=
MBGQ(T>M+5?]H]D71+GZ6QU-SO]RW[7D512[(:@\1JB4CRS.M_M\6QNMPO
M87F]\?WPLF_[&]%F'=WB=H>R.#6'ZK2HB^?[Y5=89=KVDD'QUZ&X-,[W16_^
ML:I^]!=_[.Z7JO=0'(NGMF\B[S[>BH?B>.Q;ZC+_,S7Z*VNQ_5Y=?B^F&DS?X%-U;(:_BZ?7IJW*:\AR
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M(D\]Y .3&#!!GN;$2:@(*"27ST)B+ 29A<0H)^]K,BZR =LG
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M+:>1[M[._K]B?Q[MW=_"*@/I/JX>)'U7[BK3
M1HK0]OKS0O3+TF9]SE^*/_/ZY7!J%H]5VU;E<&C^7%5MT16JOG3+R+[(=[>+
M8_'<]E_C[GL]_B8P7K35^?H3Q^UWELU_4$L#!!0    ( &Q_I$A$ :@)Z@, 
M +@1   8    >&PO=V]R:W-H965T&ULC9A-DZ(\$,>_"N5]
M%O)*L!RKUE''Y[!56WO8/3,:E5I>7,!QGV^_ 2*39#KJ12#^NO-/)W23S"Y5
M_;LY2MD&?XN\;)XGQ[8]3<.PV1YED39?JI,LU3_[JB[25CW6A[ YU3+=]49%
M'N(HXF&19N5D/NO;OM?S675N\ZR4W^[email protected]=%6O^_D'EU>9Z@R;7A1W8XMEU#
M.)^%H]TN*V399%49U'+_//F*IAN,.Z0G?F;RTACW02?^K:I^=P__[9XG4:=!
MYG+;=BY2=7F7+S+/.T^JYS_:Z4>?G:%Y?_6^[H>KY+^EC7RI\E_9KCTJM=$D
MV,E]>L[;']5E(_486.=P6^5-_QMLSTU;%5>325"D?X=K5O;7R_"/B+09;("U
M 7[4@&@#,AK0FSS5/!UYQ&\:,&W 1@,]SA)-9^-XY
MLIC%P."!(1'$+&T&04<)YR"H_%37BW*;$C
M)3:E4+"716SV$L'KY=4+>:4(1XJPI"!0BC!Z>5*O"BC%"WFE)(Z4Q)("KY;$
MZ(4(>'Y\C%<(BMQZ$%E2""A%0WK$&,%B_)1?SJ?RA"PYX!NRT)!^11C''CTF
MAA4'OFZVL\?>-^06#V15#PJNX"4R4SX5@CX2(#?A(ROC4[A.:4B_+)_*ZE6/
ME:G!7.XZ>D2QFUD1M12#-6JI(5T.8X(?R,#(3<&(63T).#9F?@77U\J#^(6X
M^1=9"1A>G@MD)E<066HD]B.K^U[6]Y'7^\C&@_B#XE8"9)<"N"HA,\TG+ &S
M],I/^>6XU0!9Y8!YYDB8GQ88+AHK9!8$B_++<2L"LDH"@ZL3,O,]8Q%G$5P8
MEK=)_T>Q6QZP51X87*DT-$1)4,(%G  MCG+X*VEE4201A(/!6%N<[PO2@I[4
M1S8G]""_I?4A*YO@
MK6K5UK7?M>ZKJI5*>/1%)=*C3'?C0R[W;7<;J_MZ.%@8'MKJ=#TG&0]KYO\ 
M4$L#!!0    ( &Q_I$C7!<.XE $  ' #   8    >&PO=V]R:W-H965T&ULA5/+;MLP$/P5@A\0RK3=%(8L('81M(<"00[)F996$A&2JY"4
ME?Q]^; 5.PC2B[B[FIF=U5+EA/;%]0">O&EEW);VW@\;QES=@Q;N!@;%7BZ)4T\&")&[46]GT'"JI:-[X/9@I(&6C$J
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M)-U*00A>&MLY/CZ.W7Q L[)"TR*/L2=3Y-@[*30\&6)[I;CYV(+$
M84-3>@H\BZ9U(<"*G$UYE5"@K4!-#-0;>IVNMXN B( 7 8.=V21HWR'N@_-0
M;6@2)("$T@4&[H\#W("4@<@7?CMR?I4,B7/[Q'X7N_7J=]S"#;Y#M",DB
M))T0S)/_6B'[7F&;S=*S_],7/P0N8OKR+X%S2+I:_:C!9@^BP#1Q[):4V&LW
M=CY%I\VZSN*#?L&+O.,-/'+3"&W)#IT?2YQ(C>C BTC.5I2T?O
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M P  &0   'AL+W=O,V:(!Q>T%MJ#]3H5&<>=34S/;&N!E)"G)TB2Y8HH+3?,LUEY,
MGF'GI-#P8HCME.+F:PT2^Q6=T4/A5=2-"P669VSBE4*!M@(U,5"MZ-ULN9X'
M1 2\">CM44R"]RWB+B1/Y8HFP0)(*%Q0X'[9PP:D#$*^\<>H^=,R$(_C@_I#
MG-:[WW(+&Y3OHG2--YM04D+%.^E>L7^$<81%$"Q0VO@E16<=J@.%$L4_AU7H
MN/;CSGRD_4Y(1T(Z$6Z2:'QH%&W><\?SS&!/;,O#W(F8_L@=()9#YATP$P(YM5_;9&>MEBG1_3T?_K\S.$\TB__='B*N3UK
MPHZ.1(&IX\U;4F"GW3#[5)T>UUT:C_0'GFJ-!(M0G! 0AS@[":;Q*KM#;;3P-_C1QO:"L$EWEW/S,[:3C&B
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MI$ARFRGID $  ' #   9    >&PO=V]R:W-H965T?&AEW)JVWGR4-/%GB>JV%_=R PF%-%W1?>)9-ZV.!%3F;>9748)Q$
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M  @ ;'^D2,TY:"N4 0  < ,  !D   !X;"]W;W)K&ULA5/;3N,P$/T5RQ^ 4Y>R;)5&HJQ6\+ 2XH%]=I-)8F%[LK;3P-_C2QO:
M"K$O\^V'-F*M[T,)=X0 F[+1HM? AM1US
M@P71)))6C!?%#=-"&EJ5J?9DJQ)'KZ2!)TO\07V/RV&QH$2V @MI'!1&6
M/=R#4E$H-/YWT/QL&8FG\5']=YHVN-\)!_>H_LK&]\%L04D#K1B5?\;I 0XC
MK*)@C+27?2(GH()HJK%25]>/YSHJ#U,?P18IM?1$X\#L?W/?]D
MU0=02P,$%     @ ;'^D2',R^(^5 0  ;P,  !D   !X;"]W;W)K&ULA5/!3H0P$/V5IA]@@=75;%@25V/T8&(\Z+D+ S2V'6S+
MHG]O6UADS29>Z,STO3=OVI(/:#YL"^#(EY+:;FGK7+=AS)8M*&XOL /M=VHT
MBCN?FH;9S@"O(DE)EB7)FBDN-"WR6'LQ18Z]DT+#BR&V5XJ;[QU('+8TITMMTLUL%1 2\"1CL(B;!^Q[Q(R1/U98FP0)(
M*%U0X'XYP!U(&81\X\])\[=E("[CH_I#G-:[WW,+=RC?1>5:;S:AI(*:]]*]
MXO (TPA70;!$:>.7E+UUJ(X42A3_&E>AXSI,.S<3[3PAFPC93+A)HO&Q4;1Y
MSQTO-;B$I.OK/SW8XD04F"9>O"4E]MJ-H\_5
M^6W=9O%$?^%%WO$&GKEIA+9DC\[?2[R2&M&!-Y%<7%'2^M<_)Q)J%\)K'YOQ
M08R)P^[XO.=_K/@!4$L#!!0    ( &Q_I$@$675/R0$  /T$   9    >&PO
M=V]R:W-H965TIS[RI+96L8%?"N
MD&XY)^K?"9CL#L$JN"8^:%4;E\!9BD=>03D(3:5 "LI#<%SM3XE#>,!O"IV>
M[)'S?I;RTP6OQ2$(G05@D!NG0.QR@1=@S G9PG\'S>^2CCC=7]5_^FZM^S/1
M\"+9'UJ8VIH- U1 25IF/F3W"X86MDXPETS[+\I;;22_4@+$R5>_4N'7KO\3
M/P^TVX1H($0C(0F]\;Z0M_F#&)*E2G9(-\2=W6IOX+/%.>:!)K>+(MN9P -M[A8"NP=&ULA5/;;N,@
M$/T5Q <4QVF:*'(L-:E6NP\K57W8?2;VV$8%Q@4<=_]^N3AN$D7JBYD9SCES
M!G QHGFW'8 CGTIJNZ.=<_V6,5MUH+A]P!ZTWVG0*.Y\:EIF>P.\CB0E69YE
M3TQQH6E9Q-JK*0L!-MYT*!E06;>;50H*U 
M30PT._J\V.Z7 1$!?P2,]B(FP?L1\3TDO^H=S8(%D%"YH,#]QF?U'W%:[_[(+1Q0_A6UZ[S9C)(:&CY(]X;C3YA&6 7!"J6-7U(-
MUJ$Z4RA1_#.M0L=U3#O+S42[3\@G0CX3-EDTGAI%FR_<\;(P.!+;\W!WBZV'
MFR#BE8GW9F,:IT_54[E8/Q7L%(2N,/N$R1-F1C"O?K=%?MUBGU_0\^_IRQN'
MRTA_G!RN[SJ\QFQNFK"+(U%@VGCSEE0X:)=FGZOSXWK.XY%^P1/:PHJ3SSW].)#0NA&L?F_0B4N*P/[_O^2&ULA5/+3L,P$/P5RQ^ [email protected](@#G-UDDUC8WF [#?P]?K2A
MK2IQB7?7,[.SME.,:#YM!^#(MY+:+FGG7+]@S%8=*&XOL ?M=QHTBCN?FI;9
MW@"O(TE)EF?9-5-<:%H6L?9JR@(')X6&5T/LH!0W/VN0."[IC.X+;Z+M7"BP
MLF 3KQ8*M!6HB8%F25>SQ7H>$!'P+F"T!S$)WC>(GR%YKI;H*(5R;>FXUIG#Y5M^7LYJY@VR!TA%DG3)XP$X)Y];,M\N,6Z_R 
MGO]/GY\XG$?Z9>I^FYUU>(PY]<@.CD2!:>/-6U+AH%V:?:I.CVN5QR/]@Y=%
MSUMXX:85VI(-.G\Q\4X:1 ?>1'9Q14GGG_^42&A<"&]\;-*+2(G#?O^^IY^L
M_ 502P,$%     @ ;'^D2"4 JRS+ 0  ! 4  !D   !X;"]W;W)K&ULA53=CJ,@%'X5X@,,:FOM--9D.IO-[L4FD[G8O:9Z5#(@
M+F"=??L%M$XQ)MX(Y_C]H4 V"/FA&@"-/CEKU3EHM.Y.&*NB 4[4D^B@-6\J
M([email protected]/FA+9!GKG>F\PST6M&6WB32/6<$_GO DP,YR *
M[HUW6C?:-G">X9E74@ZMHJ)%$JIS\!*=+JE%.,!O"H-ZF".;_2K$ARU^EN<@
MM!& 0:&M C'##5Z!,2MDC/].FE^6EO@XOZM_=ZLUZ:]$P:M@?VBI&Q,V#% )
M%>F9?A?##YB6D%C!0C#EGJCHE1;\3@D0)Y_C2%LW#N.;))QHZX1X(L0SX>@(
M>#1R,;\13?),B@&ICMA_%YT,7%H1HXQ,-N5*M_JQ>\NC8YSAFQ7R,)<1$X^8
M&8&-^JI%[%M)CG<-LD79BDGD"T:N)CEC\>/VQ3#K)VIU&A
M0O2M'O?CW)T/_$OLMOD7/,\Z4L,O(FO:*G05VAP6=TXJ(328$.&3^9Z-N9+F
M@D&E[30UTK'0HKO?.?/%E_\'4$L#!!0    ( &Q_I$CWSOQ5S0$   0%
M   9    >&PO=V]R:W-H965T(#%$=G
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MZ&-VMTVV"Y.M)[!?-?$QR6V3W<)DYPG (  #((   9    >&PO=V]R:W-H965T@ 4RQ$Z9_7]L0
M LB3S";&EW//.?=B^29I>?,N,L:D\U$6E5BZF91U['GBD+&2BA=>LTJ].?&F
MI%)MF[,GZH;1HTDJ"P\!$'@ES2LW34SLM4D3?I%%7K'7QA&7LJ3-OS4K>+MT
MH7L+O.7G3.J ER;>D'?,2U:)G%=.PTY+=P7C'00:8A"_<]:*T;.CS>\Y?]>;
MG\>E"[0'5K"#U!14+5>V846AF93RWY[TKJD3Q\\W]N^F7&5_3P7;\.)/?I29
M<@ME'M^:56=ON#<%]FCT!
M]0EH2(C PP3<)^"[PD,\Z?%DP,/@88+?)_A3 :^KW/1M2R5-DX:WCJBI/DTP
M5NA&%8H-OFXMQ@\)R S F((2$\03DU671D=)C08/XH(MC9T,Z%"
M-J;MF(D$&"/RW+$_<^Q/'$=6G0X3=-\68XCP0$M\JX>7#8_BC8UGB^*=+;Y:Q+N%51?&PO=V]R
M:W-H965T[#SG3V
M8??9)B1QJI)5TG3_?@&-%SHQ"G
M^S!LMT=6Y>T=/[%:]NQY4^5"OC:'L#TU+-]I4E6&$$4DK/*BGBWGNNVY6<[Y
M691%S9Z;H#U75=[\>V EORQF:'9M^%4V8F6I(DGEOWW0
M#TU%'#]?HZ]UN3+]E[QE*U[^*7;B*+.-9L&.[?-S*7[QRW?6UY"H@%M>MOI_
ML#VW@E=7RBRH\O?NMZCU[Z7KH:2GN0G0$V @I-%- NX)>"  NDF(>T(\$##<
M)"0](?%5(#V!^!)H3Z 6(>Q&5\_-8R[RY;SAEZ ]Y6K%HGL);U00&3F0$]+J
M5SWE7>O;$A#,PS<5R,"L.@ST&.S"/)J8V(5Y,C&)"[,V,<2%[email protected]!"6:^S
M:+"*!AT@U@$0R:8#8"L U@%PGT$Z'2"V L2C# !E9IEU-Z0=AFH,P4D43*@02X48*LBITF&(QL0> T8M#6IH.-?IHXG!TR*I)9(:
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M>W\ 8W_ R&E:"^1T[0;&FX@\%C./[QT8]I"Z3TY%F!@L,=^
M K;-(;TU!E<=$V2OL7#TS5RQYJ#O0VVPY>=:=*RA=;AS/>AO;KL=R/T:B*-'
MEBI[J+,GE3WZ A=^B"_GI_S ?N;-H:C;X(4+>0_05X ]YX+)FJ([.:]'><<<
M7DJV%^J1RN>FNW5U+X*?KI?(X2:[_ ]02P,$%     @ ;'^D2$BZ*N'_ P  
MRA$  !D   !X;"]W;W)K&ULC5C+DILZ$/T5ROL$
M6B\>Y7'5G7',9)&J5!:Y:\:6'Q4>OH#'N7\?(62/I+2--P9:I_MT-^TC8'YN
MVE_=7LH^^%V5=?J
M#$D4B; J#O5L,=>V[^UBWISZ\E#+[VW0G:JJ:/]_EF5S?IK![&+X<=CM^\$0
M+N;AU6]SJ&3='9HZ:.7V:?8/9*^$#1"-^'F0Y\XZ#X;DWYKFUW#Q=?,TBX8<
M9"G7_1"B4(=W^2++ ZZ;L]&^P/G5]4UU<9D%5_!Z/AUH?S^-*$ADWW($8
M!_*H S4.].H [*X#,P[L40=N'/BC#L(XB$<=8N,07QWNXQ.#3SR"<+P;^EXN
MB[Y8S-OF''3'8IAPR!2\'8*HR(&Z@9V^U",R6M\7A/)Y^#X$TB3A*+4#2Q*&1WNU84Q02MAT)YB7-+.2)A3M
MQ!=F\4!$ 8>MV%3#N,?-+6X0*1J43P457E#QP*T54T%C+VCL= G-=!G;74K1
M.[:*IX@3CSBQB5F$$H\8H3$Q$)0XF2)./>+TSC"/D.?4:0K*NTRMW)A(;F27
M3F4'D2]JD9U?@N;G8 @#-$$#$F:X>8)GJ!.XG^)?N@L./=X? S+T)&8Q3@^3
M]+[$ ;'I\9$U&,-.<=0*)I40?"D$6PMO=9Y:Y)\X18=[I4/?)_GG3A<4'9GF*V2'*Y0=\%;TZN76?T>NVV:7JIACCZKO6XOB\WUHI3;
M?CB-U7D[?FH8+_KF>/ER&PO=V]R:W-H965TOL@%0
MZ(W13NZ\1JE^B[$\-<"(?.(]=/K-F0M&E Y%C64O@%26Q"@.?3_!C+2=5^0V
M]RR*G%\4;3MX%DA>&"/B[P$H'W9>X-T2+VW=*)/ 18XG7M4RZ&3+.R3@O//V
MP;;,#,("?K4PR+L],MZ/G+^:X$>U\WQC 2BKE""90:(7WPGU'S_4A#
MO-_?U+_9:K7[(Y%0JN!,+E2]\.$[C"7$1O#$J;1/=+I(Q=F-
MXB%&WMS:=G8=W)O,'VGKA' DA)\E;$;"9B)$ME!GS);UE2A2Y((/2/;$?.M@
MJ]'":&AAI&N1-K3=\_/B;U9A)[$W](R!:^LO7.WO](,T@4+TSANS^7@:CMA9;H
MQ"^=M'9/=PU9-S6'V3&(E=@T?7L#Q[+]? 8HC:=J6
M+S8TK_NIG]!#L#RWW<]^+^40_*JKIG]8[(?AF(=A_[*7==E_;8^R45=>VZXN
M!W7:O87]L9/E;DJJJQ 9B\.Z/#2+U7**?>M6R_8T5(=&?NN"_E379???6E;M
M^6$!BX_ ]\/;?A@#X6H97O)VAUHV_:%M@DZ^/BS^@/R)LQ$R(7XSEIJW^.>R&O1HM6P0[^5J>JN%[>_Y3ZAZBL>!+6_73;_!RZH>V_DA9!'7Y
M:_X_--/_>;Z2,IU&)Z!.P'L3N$[@EP00-Q.$3A#W)D0Z(;HW(=8)\27A-C[1
M^,0A"&=QIZEY+(=RM>S:<] ?R_&&A5S!N[&(JARH^>BGTVG&Y^C["B.V#-_'
M0A9F,V-08X#"/%H8"K&U$&21PH*059XL"$\NF%#U2C:,3L,X%>!Z&*E-TLQ#
M'7-N%N5.43X5%5-1+JB:CS,DF2!1QM,T(JDM6)H*NMJ3"1,QYRC\2@AGT,(8
M-"1(#D?XE(BQH0@PD9',L8\Y<9B3&Q,[0]8F
M!#DIXV;&Q!,F0Y:2D[I-?*-+G=&EEBXT=6I01U?$VZ8^YLQASDSFA"3.#&)A
MWJ F<>8C!N8:%C.IR6G>:,S,';MFHZFGRK>Y?S-+,+@%67:C,3/WE^3*C3B5
MODWN&A>@24Y/ML9H<@%I3+-[#0YH3DBO+<2^]Z%9AF)3C-
M+DSV2*0D; M>3P/7U""R%MH5^LB@!X@9HRT5O/8'KO^!98!(/CDV&J3Y69H 
MN2ZWX#5!<%T0+(]#PMD'75D=BB837YLAKA>!Z(5AF&%V9(],-06W*&>V'
MX#5$OC;=NVN_9K7S]#U,[3\3)!U-VCZ&6)"V]X6O7Z&KI^AL.2B;1J]3H6N
M4^$]^R_T.A"Z#H3Q/7*9>S#UC*#='[W^@Q?_:32[UP[0M0.T[(!\EUA;F/C3
M":ZSN(L>K47O;OX^:"Q0=,<["W=7-V>WO%7SV"#.'9[0>#&L9?0E?/BRLI\\ 3GR+>8%4G.<%I^(B+P05C_(BHN)Q7L14/,F+A(JG>9%2
M\2PO,BH.+"^ D5= 72%[!M4TD%V#:AO(OD$U#F3GH%H'LG=0S0/9/:CV@>P?
ME ! *@!* B U0*4!DAJ@T@#I>1\GGM0 E09(:H!* R0U0*4!DAJ@T@ I#903
MJ"N4!FHQJRN4!FK]J2N4!FK%J!MVTB#\7!&KY;%\DW^7W=NAZ8/G=AC:>OKX
M\MJV@U0+C7U5)KN7Y>YR4LG783Q,U'$W?^Z:3X;V^/'U[O()&PO=V]R:W-H965T=0M@T =G0N^BUIA^B[&N6^!4O\@>A-TY2<6IL:XZ
M8]TKH(T'<89)'.>8TTY$9>%CKZHLY,6P3L"K0OK".55_#L#DL(N2Z!9XZ\ZM
M<0%<%GC"-1T'H3LID(+3+MHGVRIW&3[A9P>#OK.1TWZ4\MTYWYM=%#L)P* V
MCH':Y0H5,.:(;.'?(^=G20>\MV_L7WVW5OV1:J@D^]4UIK5BXP@U<*(79M[D
M\ W&%C)'6$NF_1?5%VTDOT$BQ.E'6#OAUR'L;.(1]AA 1@#Y7T Z M()L/*-
M!F&^K2_4T+)0BU)MBGPU1'-<@XAAX2<
M))]RL.5_6(0LBA!/L/($R9H\)T@7!*DG2$<%F^<$JP7!ZDX!(?&\31':##GK
MH#(AF_31851SIN=*LFA69>_\?P+RA?3\<<'['S1+2=.%*'QW(SBHLQ\4C6IY
M$28Q _Y./LXD_ZLNCI&7Y0=>Z$1D=I[#7V-_@D
MI0$K.G[)(M3:UV5R&)R,,]?65F'@@F-D?WL^IC>L_ M02P,$%     @ ;'^D
M2$FU2S; !   P!8  !D   !X;"]W;W)K&ULC9C;
MG/ R[EX.LBNY+Q.K2SV8U)5AAA%25@5QWJQ6HYCW]K5LCGWY;&6W][email protected]=5T?ZWEF5S
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M($U!QQ0<"S ]CI#CDWBS*G*!N+\K$HXU3-KU-(.H;$@F593$I;85G&
MZ6I/9AA/&$/N=X([D^;&I"$E=;;ZIM>YDPOLXPAI3-#FO&,
M]B7S"0M'6%C"=-/"4,8X$D!*"Y\T1"[6(E.<='*C8[0X0$SW/=:^K?X)JF"J
M"UH=#'4.&;EBMV/IV^(NO !-\83V70?IW@70OH,7[B"DQ><4:K)D(+A3!HB*2*W\#)A:!LSB:Z=\+1G3!B!88Z?O!HPY*
M]242T?(;C*S3)!)Z):,7H.@"%"V QO190K!<@I@EM+Z7H?CI =!B*".?1-=V
MT,Q21K1H@TR0MX,M>E&++FJ16=<;?6M'=M]21B]LT84M
MYT/TXA%=/*+]B$CS$4T^(O"9*P^]>$07CVCC<6:M>HF&+M$PN\^P2!BD4IF?<\G**73E5Z[8[I,99OF/4.,]WG!J/\UU,C2?Y+J'&TWR74N-9OLNH<9'O!#4.4;Z#B#P"
MZ@C9,ZBF@>P:5-M ]@VJ<2 [!]4ZD+V#:A[([D&U#V3_H P T@%0%@#I 2H/
MD/0 E0=(G_?AQ),>H/( 20]0>8"D!Z@\0-(#5!X@Z0$J#Y#T )4'2'J [email protected]
M/%!<40N6\D"A01VA/%!7LSI">:"N/W5D]"#\?7VMEJ?B3?Y=M&_'N@N>F[YO
MJO'KW6O3]%)=MM$7=8<[R&)_W2GE:S]LIFJ[G3ZP3CM]<_KX7GS]:+WZ'U!+
M P04    " !L?Z1(WV7UAL1 ?JK?
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M+W=O=L].X@14&[.V$[IOO_XA)+A(H1?\P\Q\,S;8>;4(87B?>ZU.ES 0HTZE?0;[LU2<72EAP/"G
M:^O&MIU[LXIZVC0!]00T$(8ZTX2X)\0W0F*3.F;O10HBW)P,4(CS-9AD,7  0&T^F0)-"ZQ17=T-%6@'"%F
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M" !L?Z1(-<]LS D"  !O!0  &0   'AL+W=OJ*,1-]"=[H35P9TZZ31!\J)JA^DBUK[)N35((:&ZIS
MHEO%Z-&3!$\0 "01M&[BLO"Y=U46\F)XW;!W%>F+$%3]VS(NNTT,XUOBHSY7
MQB62LD@&WK$6K-&U;"+%3IOX!:YWQ"$\X'?-.CW:1\[[7LI/%_P\;F+@+##.
M#L8I4+M:[23_4Q]-9Y*"G+1-03T #8:BS3$A[
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M>(H$  !C&@  &0   'AL+W=O[S;ZTAV9?':+:;N]G?XB[9V-ZR:#X>V]/C7<<]Q=Y]_%AU[8H>D]=Y!_.Z?\Q>T/_^.S]>2BW2_\E
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M&4HEV/+UJ#J<2&,,O$@I_@@)!,) 3F7,]WLWX>:2K:4:@2(P;1%!RQ61T
M!657R-MC_"1\>B5G^ 2%5RC& #K1V%=.%$JOT)S1TUX4D-)(Q0A%Z10(SXSC
M@O(I)@,J**%B<;O@9R>Z@"$3SLU&"10804:V0.&"9&K!0*D!3$UXL7$B-\*)
M8)0+5ZLBH$ ,PH&R!7)RN10;P-@LPN7ZV&@CC&',?$#9 "2@4,!P2>&1"F41?))?(Q%(3K64'*E1',92("D3TDRN
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M&31B:E\-AO1_S-_M77K_M#TWT4K5M50YO\+=5U=K.73+O
M4M_9?',Y*>RV[0_3[K@>?P,93]KJ>/Y)Y_*[TNH_4$L#!!0    ( &Q_I$@%
MGF\4&@,  /8,   9    >&PO=V]R:W-H965TR9QI],>.I/)H3T36[:9 '*1'*?_OD(2!*DD5@XQR._N
MHQ6[ZV5U9?T+/U$J@K>VZ?@Z/ EQOHMCOCO1MN(1.]-.?G-@?5L)>=L?8W[N
M:;571FT30Y+D<5O57;A9J;7'?K-B%]'4'7WL WYIVZK_^T ;=EV'*!P7GNKC
M20P+\6853W;[NJ4=KUD7]/2P#N_1W1;R0:(4OVIZY;/K8-C\,V,OP\V/_3I,
MACW0AN[$X**2'Z]T2YMF\"3)?XS3=^9@.+\>O7]3X<;EGSN]Z+D]QM
M$@9[>J@NC7ABU^_4Q) -#G>LX>I_L+MPP=K1) S:ZDU_UIWZO.IO"F+,E@W 
M&,!DH$_B0P-L#/!D@%(5J=Z9BNMK):K-JF?7@)^KX6FC.RGO!R?2I6
M'9=>?=U@*%?QZ^#(TCQH#2@-FA2Q]+Z( !OQ #-S6 )LYXJ\N$W 3A!8V6,3
M!+GM('4W,:6#*2U,NH@IY\=68,A)>1M$
M'!"Q0-DBB,Q !+OXK7>21M49$M"B-2H_R0N"2P"-M
MC0CI,BY01'S.Q2UEA#TRUX@,"G"$/&H>N46/4H_D-:(1!5'F48W(+7N4>22P
M$1D4+J/"!^56/LH]4MB(QJB*R*-4D%O[J+!2V">QW+I&I4\*E_/-(IE8J0?*
MK6Q$?'*86.>21$6YI-L:G:XJ1.:RCW\6W18 B4>J&Y'9$8G XYC![12 /#+=
MB"92GI#YGP?6;1L 'ED/5MM $)4>;0/+<;P*?=8)R:+!'R2'EP6P%\V@I&CB5";CSQ;)QL:7]48S8/=NS2"3VR3:O3
M*'\/PSCJK#_($5\/Y.]N-JMS=:0_J_Y8=SQX9D(.NVK./3 FJ-Q=$LE3.,F7
MD.FFH0&PO=V]R:W-H965T.%?1>]MT?^DA>VI;U?S>\$==U#./;PG-]/*EA(:U6Z62W
MKUO>R5IT4<\/Z_@1/FP1&" &\:OF5^F,H\'Y%R%>A\F/_3H&@P^\X3LU4##]
M>.-;WC0#DU;^,Y)^: Z&[OC&_LV$J]U_89)O1?.[WJN3]A;$T9X?V*51S^+Z
MG8\QY /A3C32_$>[BU2BO9G$4[;/NS/-JWY1@-%LV0*,!F@PFG64#/!K@
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MGU_*$ =DU @:I1!,RH#4A7[1PWG59\M2F2N5D82&1.77/-H-%;B),B9&/\HH8D)+/([ Q 0LHEW';$V5R'U(7]WR.__F$9DH"E%SP(
MN&F@?P5 &I* U)6B24: \POY1OKW!@(!5QQR[PV8)\!/I-3Y^+>\/YJF2$8[
M<>F4_A=&MBNI*#$(IK
M_T"BT_RD6\9ITO"#&H9$CWO;1-F)$N=;3S@UIM4_4$L#!!0    ( &Q_I$@(
M.E=C' (  *H&   9    >&PO=V]R:W-H965T+42W\7U^K!&!?$4[U,HG9\H(%#)D%Y]W#,&3)A'L
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M+8'0:<3&N-^/))/9@!![*)G(P='>FV%^<[&[#A^7R(U0V;YG1S+9HH^9*JR@Q?T"[)+TW)P
MH$).*#VT%:"009FYG$G4Y[Z$PFA_9,;-EF L@%.4[_OB!D
M![8TEGLQ2'Z[;U?26[2+DVI>VKV4VGNKRKI=^GNM#W=AV*[WLLK;0!UDW?VS
M54V5ZV[8[,+VT,A\8XRJ,@1"XK#*B]K/%F;NLJRIO?C_(
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MXA-G\766%+&D8Y9X?F/2$0NEC*=B=F%7Z7]L("58E&1\UIAP6:L#*!I>+@04--80G@4NL6/_@$B "YW
M! NR3%P$Q.6LXV(!J<,WP8+L-X$&-)D_?NG-^\EP06'DUD\"PY6"48=/PA04
ML]E/ @+A^V0X:DLJV>Q,N]9Z:W6L]=!_7&8O+>$]F+;F'9XM#OE.?L^;75&W
MWK/277-D^J*M4EIV49"@D\F^:UHO@U)N=?\JNO=F:..&@5:'<.3/@2=9S\2%K0A3X9+25>Z]6JMOYOCS5A&'YPCO2ZB=G
M+AA6^B@J7W:"X-*2&/5#"!.?X:;U\LS&WD2>\8NB34O>!) 7QK#X=R"4]WLO
M\&Z!]Z:JE0GX>>:/O+)AI)4-;X$@Y[WW&NR* !J(1?QN2"\G>V#,'SG_,(>?
MY=Z#[email protected]*2,!-;+E12$4J.D,_\=1.\Y#7&ZOZE_M^5J^T8/C3K4UKU]X]V<"!MDX(!T(X
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M965T>9^PBJ[*A;]P3
ME[HF_-^65JS;^*%_VW@OSX74&T&>!8/=L:QI(TK6>)R>-OYKN-Z%B888Q.^2
M=F(T][3X/6,?>O'SN/&!UD K>I":@JCA2G>TJC23\ORW)[W[U(;C^8W]NPE7
MR=\307>L^E,>9:'4 M\[TA.Y5/*==3]H'T.L"0^L$N;7.UR$9/7-Q/=J\FG'
MLC%C9[]@T)O-&\#>  X&@Y]Y ]0;H+M!9"*URDQ<99YXF6Z'\[7"LX
MUR2*V5/!"+,TZ;*[UQPE. NNFFB"V5H,-)AP0 2*?=8%G+K8PI$YG'.P&R.2
M]+$'Y 2!C#WJ@U@])H@<@L@01)8@!5.1C0W#8E*#B0"((9R#[<8PA#%$"S(6
M.W+BB9P%!(E#D#R;D-0A2!RP P"B>3<@$%D9@!1[+P8XI --HV3:/Z,3& X A@O$/2E,S@"=G8)*7"2Y6#2=:(,DMYG!:S4LHW (,XZ<3XY9@F"Q)3#*^+5:K
M>+Z$7!AV!06C2[^F_&R:H? .[-)(>[$.NT/#?86Z:3C[6]V(33.YT^192\[T
M%^'GLA'>GDG5DDPW.C$FJ=('7E2Z"O54&!85/4D]3=6&ULE5;;CILP$/T5Q 0EV.;,F3.'#$/6,?XA"DJE]UE7C=CXA93M.@C$H: U$2^L
MI8VZ<9N\BJ;.@;]\2EK@G_
MLZ45ZS8^\.\'[^6YD/H@R+.@CSN6-6U$R1J/T]/&?P7K'4 :8A _2]J)P=K3
MXO>,?>C-]^/&#[4&6M&#U!1$7:YT1ZM*,ZG,OV^DCYPZ<+B^LW\UY2KY>R+H
MCE6_RJ,LE-K0]X[T1"Z5?&?=-WJK(=&$!U8)\^L=+D*R^A[B>S7YM->R,=?.
MWDG#6]AT +P%P#Z@SS,=$-T"HD= ;"JURDQ=7X@D><99YXF6Z*<[email protected]
M]E0QPFR-7?;TFDV"+2:)X@=@M@0Q(8 X['&QE9A(=A"4 C"*=1NB$((X6A>2^)H209:
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M!!0    ( &Q_I$A];XV=A0(  %8)   9    >&PO=V]R:W-H965T_OY
MAU!P42$W!=OG')_OI!]V=F/\31242N^]KAJQ\0LIVW40B$-!:R*>6$L;M7)B
MO"92#?DY$"VGY&A(=17 ,,1!3$_WNF%;MM
M?.#?)U[+/6U^S]B;
M'OP\;OQ0>Z 5/4@M0=3C2K>TJK22VOEO)_JQIR8.W^_JWTVYROZ>"+IEU9_R
M* OE-O2](SV12R5?V>T'[6J(M>"!5<+\]0X7(5E]I_A>3=[MLVS,\V97TK"C
M31-@1X!+":@CH)X HB\)44>(>H+!![82D\..2))GG-T\T1+]WP'6"LVUAA+V
M5/'"#$V\=O::HP1GP54+C3#/%@,-!DXAMB,$Z"&!,C#I CHNH.$CZP*OY@60
M(X",0&0%T-AC8ZNPD,1 0+1*4SP%VXY@<0A!.E7Q;K@AA/.&(\=P-#2<+(@L
M=@3B1R/#C@">C\Q"L,TB5#:G(QO#0(+PO)O$<9.,\E@0:.H(I(_FL7($5O-Y
MK :%)A#&DVF,0 A%\TY Z#9E.$H#+9#XU-?@T3R VY0 SB?286RU",8XFLQD
M#(MB&"[PX_8XYLB18M^M ]' J;M^!>$$J\> C@E$*ID,9H3!,%[CIF[CI
MW.B)KRENIX%D^M,U^N(/,=C]L8+!$5-3?C9'M? .[-)(&VX_:Z\#6WT=T$>4
M,Z_LJP4\L:(=:2,_U%^+ELA+=G4IV-YE@\,2:I,AX^J4P+=U#I=4^M,].X@2T@*GMA.W?UQ="P(L$>0GV<.;,F1/90]I1]L$+
M0H3S65<-W[F%$.W6\_BQ(#7F+[0EC7QSIJS&0F[9Q>,M(_BDD^K*@[Z/O!J7
MC9NE.O;&LI1>154VY(TY_%K7F/W;DXIV.Q>X]\![>2F$"GA9Z@UYI[(F#2]I
MXS!RWKFO8)L#I" :\;LD'1^M'27^0.F'VOP\[5Q?:2 5.0I%@>7C1G)258I)
M5O[;DSYJJL3Q^L[^7;XCHU_C3/LM'/SKS9^'W:? +L$^"0,-293PCZA."1$.I.C3+=
MUSK?!EL)9XI$,CNR&:ZWVBX3O65!'*?>31%-,'N#@1H#!H0G
MV6=+P&F)/1REP[D"^1B!XN4*@=5$H/,#TP1*E@E"BR#4!*$FB*.IQL9T82"Q
M,2$"T)]#Y1-4D,!H64MD:8E&6H)XA=_((D#/NA%;!/&R&P:"-"1*_'#6C#$H
M3$"PK&1C*=E,O(#+!(E%D#SK!?#M ^(ON]%C3*<@!K.H?(*"$&U6J/ER7,'$
MD166 FA3P*<]L<\;"%9X$HRZ12A,YCT9HZ(8K/'$/KP@G'@2KJ"PSQR(GO;$
M/G4 K? $C:Z'303G+1F#@ ^1)<8;7? U81<]^+ASI-=&F$MTB [#]16J 6'%
M]VKHZL'QH,G2%E_(+\PN9<.= Q5R_.C)&ULC5;!CILP$/T5Q /SFS;P!#Y-?>?LR 0NQ-K2O'$SZQ5.P?>-:54R^X8B'/'RKUQ:NH@"D,2-&75^NOV976MF53DOP/I
M9TSM>/]\8_]NY*KT7TO!MKS^4^WE264;^MZ>'
M[B(D;VXNOM>4'_V]:LW]VN\DX>#F=H@&AVBI QH^O[&M$D#]XUT02SZ3&1P40N
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M"*8+"C@VDW9(B,QJL \\W)_XR/E;VDPP7[I*G;%AW-!.'\';\TLHAQ]'<
MCS7;*"LB_:NU[2@KD,N.LP*[['%6Q"X[R0KBLM.LH"Y[DA6)RYYF1>JR0ZCF
MLM"YHR!4#4HV.'6#[email protected]:"D@TN[^@;4CDN]>HVW:3+X?$_K_%P>
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M\?VS=+[;B*3@4;+@SY,B+O;\52)[B-/DN\?%]]\]QJ:R>#OC^J/S0C6=WS/[^.$\%?%6*3_T?K"^_W6U%_.#K[??U/Y]!X
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M>"&R#4SO5N0%[C5..[J-XG4T6PL.O,]S>-OAWODCP11;W=
MAV06K]= FDS3@S7E-(+"
M%]$G84_0X<^[email protected][DK.KX70EQFHL*S8>WR[CI120G)O<;J-Y'B9IHL[($C]
M[V_3Y$Q/1*ZP>3IVN_BX5=JO+,2-@)\6^)(^>0:2:.>-SS1?
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MH3:S_M:5*  MP2M@TA*8?HOT-NU9<;]Y#)",5F)(@84<0I6\^?_^E_^
M6/'3\1)PL*7#_<>^(5GZV-86UQ])D&O<*;,+[T!XB<;'XQX;@#M2=24!@Z-+
M7@*_Y&UPXDK$F]DNRPF[B$];G+6K%($!6]Z_0(:0=ER][(S_#%@/F(M8QU&&
M8@U*?^GQI4@$8E#L*5ILXH3P+/*X[MC%@,"G\UAR*;VV 7 6_]CHURCCY4RV
MQ1#>9.F&IV9_&FR^0+EK42KF<3QW]W.]*UPQ^:.(ERM21&!BHZ7@R8X4&G)Z992*
MY+A8_!C1(<#^8IW>'2\Z],H-O6+O+EHL5*4MV&OQPTZ#?-*I\S0!3"(0J9H-
M2.DWI-FT$2V-H,;7^L&1T:YXVN42/X(6;#-I]O/\P]KXR86[FU^QR;#]K"/'NL3CFDZ*0T'M!#ESM _+B:^^H?^\5\
M-\OC18R*?@=*/"NBCTV0NO+*<5HC6M^CM:'<+B<=U4B!0U0K=487U;)T+L1"
MO2(^B6P>RW4) OH51=>L"A%R$DAN5$WO@4-F@(QNP#FF,1">V^,0% 6V:(0I
MS[+H;I'>D0[\+#?[1;?B;&31)L(Y<<>;&^5NB$]S*1>DS3?@G1L]@3VWH!>E
MUA;"4FOS8V-XK<$^=%UG8ADGZ B2(%#P]E[O"U2HK6\> VV:'$8:[J+BSBH,
M><9#H!I%[ 5&['DE1'\T.")XW.KW7#;S91E)0UBGP)&F^FUVCRXFJ J7F,U[]D( 8K=%1UF$8B;;.NK1L Z@\A,NT
M$W8X+/.\3<796WCT2X[IIE &M,+Y9O$/;AJC
MAJ@^\B*=?SP*#]NF@%J5BVU99@O7=Q[B65Q_H%T>D[JZM&)%]49^CS>V8^]7
M\ NL6JO#N:T.E0$!3LF-8O3XW2J>K_@*?$L*@S%"L9FT[PC5,AG,NHN+%?\ 
M)-=Z-=>1A?4>VXDM/&$*VZ&:WV; @?$6X#,_^?FGOWZXYB_/SR]__NE_3CTY
M6I(6QS#=?>8NX[$,9B#)?-F3; *#U>!ICW=QHF2)^ A<*+UN%NK5"^F1D#/Y/T-@41*-Q'QBK7'>LE
M2@H;^8:6[#ZK1I.T.%<
MQY*!%07%(=1>'-R!^7JWD"*")\ ___3?.7\!&\*"_MD+L_U[/,V5X,$)0O=T
MD-+B)GB/X7O%*A/" 1^56:257$TG%%]NJ-Z8!K3*)[D8 ?%;[[9JG.#;[X/>ER?*L(.UA?!
M_F3HPL>%DX@W" ?PT&(5>& R8
M/O)32XGF( M2($$#O84=YN$I.V-^&'I^$+)+:)5U-QYZXW'(!M[ GS#87A$O
MDQ)7:TC-3L(@8*?LQ ]@0C[\= &R4IOL-/0FDV$Y;>ZH_5V.OD..L&P&/-=H
M=T)0^TWMV+D]_3-^^>8E>Y>4NSA0!Q^XWXBJHF0O5XQJ'AI[BE5PTJCU$V F
MZ R8WL3?TEV!/ARRUJ-1V!OR#6PR#.1#$0M,Q(_&/\NS3[BJX,)G\-K>,)!)U7$
M0;!FJ9/>@M9:L8LH \E-(H]?PX17O/S]O4B0;,"2*.^O,#:>QKG4Q]@)TR,I
MV<[!AJ1HVL#+0VDQGIQ4B()D#563FA*K3DDN!S78;HX:3T\D=S"+S(J<@MZ#+C 8\L(\%&*I@76
MF2[W'FP6^!;I;933:VC@=O*1##8DBW0.=IG^PO("]@WG^DJ>@D44H,AB /W@
MFX#^BV8JF%"=/Y/SBK<1:7=X&]:4RB[FJ)!0D\8D*O@+O!\PM^BK>Y5.DK -?%:D[>
M?@+&H]A)"2 ?,MUL$"'N^7:USVF+MAF./A=JVRV9Y]$2M!692^5Q2VV,'$&<
MK< [$&8I9,1ZAAVL8G$KG7/<;IP3+'O:!]KM<=W,&@+HE"@UCEK.JPHC#D^'
MBR [*']1Z0(^\GLC+27DA\ [:U&"!T"!M6D"+][&XDY:47N52@#-B:F =6:OL+$?
M,&U7O@5U[TW@#TYVR+??,K_O#2 .^V
MB#N91B4+D*MUNM7H>Y'ME@#KM7: IRC&"IM&RR0%X9\C[H6
MW*(DD9$CJR5-ID:QY"Q+H"^L@R%6VW0/1)&V##8*_'7<77V4"@('O\^B^4=0
MUQZ97K_?&S%C,M^C\&-_>4Z4@M\H/,RE J!.:$=G@B&0E9$(I:;\0*,S!1<7
M:M(5I55#%F]@!_#?B%^"W[N)P,ZNI=+M(>)X(6;9#HU',.Z"'/5>F.F%%-'<
MY7^Y]D%O;#3A"4(3^+/2?5K8H[#$&*>D@[5J57"?1F.5T3R-9,K3E3L!
M-L:%,V8AK$Z.FJ8N,8_O]T(#>MAOP5OY"U ,(SSD3OP)[/=:@"*\!,"2[]>W
M41(#?&FG.S. I6SSAKP_\AH^ZG.U"SD9P7]KC":[D#9R+A5VKZ,'Y#.^%C*)
M5IE(/(!F2K! UH!6(CN[C;3GM*%7-2+(#9^8F;!R)KPZ$QPN38P?H\?5XH_"
MFJ/@%B3D<_M=,*4@T*@9M5$DM61>O4'7/O?0O&TPSJ,2(V:9A'6EUBE$M,FU
MK*SC&X")I"O0/T1VCKMA!"$B$[TGKE;H^'A,T2XFC::]G4<:+#YS+#[_^V\X %O/Y@:MGZ:>#U)^C9V;J1!6#+AP%[9ZM'%GC#P&\T_4,O&/29
MR?Y5R3S@UJ'3>!0@&-D]*SC 3\8#M/D-2:)HY/W)"(S\LQ80$'C^V&_"$@ R
MO,&D#1\ @0 Y]OM! T3 A_V)-_;'[2@!(9+O!="_S%RJX@ _H!3'+A!Q$GK3
MZ43-KOIV.;=OV=\ 26MDY;8
M(X^7"2HE9.ZJ7K*6\S4U$^E'6SO%X'(";?8(54KFE""EJ*Q! =/D<%$DAH*4TF&$RHH45%0.TAZ%([$!\$O.=4:A=
MO @*:)UFTMTB%H:NV);21>P)1@AV\3PE5XX)N392IU@S4K1B2F"JI*IT"(T_
MBKTA;B'F*QU_$DMY0-"$9J0\_T*A"JEY$+(,[@M91MX48$0)67P0B%$P+C%+
M)N2I-,6M6.![ ["Q5>PR]J;PM];T!Q8")A@T8AL8K#_U6?UJ$PZ#/OU1Z ;!
M2K\2NU / F_JN\"'G4R]X6C8C%Z"J3>>8#2\$1:%@.^F U8-E#BW3-@)@)2P
MCR#H-6;1R,,9-3H8M1-_[(VG_0Z,-/7\<-R"D0:A-SP ()#-7U G=AVN."[ ,A7%B
M#%8 18J@&^P:#@.<@X#HX$Z6V^&@'E8)^94V>VUX])1#/^24XOEI4=]/1H"K
M"R_1G1WG#HA*2'K?E$,[Z''[,7N_ZDI[I[ Z %2, BUV&->H55X
M%%J(P^S9GI\X1[!/H*U?0J13FLHNL6@$$V(J,T3G%-0H ?AF8H7G&P9AV,(O
M![%8.<;+VRJ+@N2T;7 I?(_".\!HYT=I^.U@:@0O['^D<_>U/*77
M'H,Z,E/R;OE9[$:@]*X]>4(OT/P.0YJ#'M ))O0R#+NM#%;M O+.>%
M%\%V60(:SL)"6"" 'N*AOLZ" /A:&4%2,$U G'7J!\CX#W19+ 5M'6TT3)GM
M:1GJ !"Z;9JIS>*+%#:BU'+P%/;QUF)+U:NQX%;,6GEQM=1207#'N_L
MA-%5&OO>B-NFQ)$HO'C'!G=@ =8'53BSWBVOF\..53M1J:-Z[^[4K1SFWLJI
MOE>YE6/K7O(2L*BNV%W[%:'C)J,30 A=P]9OP: E>)ZQ
M1CJA4XUY)>U=,6==ZL*9GJ6U.!H#^&UN+H P]00>K#$P11QZ1RD],C.AS-$&
M=RMBC#/)[#4L^8@[H;8V!M\^PQ1WWR;J8Q5"(=4Z/X7UH
M0/!]?\I&?2^8P(_#*2LSTPT[5?-/;6;RO0"F[ ^&\--P/(1.)O>9-?GT#BE9
MTUQ'7C ( &X,V,CW)O!K.!@[R3F4IGV&R1 +?GX794Z:=[/F&O6X^R:3MQ/>
M;4W8ZW<[D+& K'A_4@U\+=(M807XV_,-N.][(;C]/K\$GY31>R?8Z.>?_DJ_
MF,;X' -@Z)'@=0@R1!+)H-!?V.FQR(#OLF64Z-QCC('&12',08R:%Z:[L:2?'+(V &!..U) P\LK%)?B$]*,QR
M.8KJ=GM->,^E/-.#_@*4GYLI 9I9  PC$6!X@4M%CD .S6YD.MU?F3A-&:6O
M2W*S8\C-GD? 9G)""8@4VS:T=R9'>3)UW
MD^>L.U=!XJT\W(51,/[PEUVTCF_V5!6(GFN1//GYI___]OH=T/J4(.!"Y/,L
MGDGU?2UD2ND@"+"C01#J%%ZZFYS090R*P0#U%J+'B0AJ;\B?5P2I$H*IP>5"
M]*$]%QB8!8,E+7YEGOS/Y(&\WL'J,KT(ZD9-5R),MA;2?B>5:#TE5*NPIBRVH8A1M6PI
M":ATE,O5H,%3_--CYQBZA@DMU>G%R(HOU^V 26K7I2T6K(O_/%GI8;'3!$],
M3ZHD!S)H"EZ9_MV6;2UY+9QN\3.3@\D&*E6=K^--3"PRJ%4:V6[7=-;\8IFZL"99AWC*P.2:(2QK4)*.N", =*(G=M@[F* <>W8!\VL;6GU#.
MRN^BA,ZL?3IZZH>M%M@Q =2<628@=-M\/>,KU;[,G:?U,DO72Z.9V5%>O1UY
MS88@$V,ZI;E3JB,!!\WG.;CUQXH>'2-JJ:ON2P.5?HWSIKL:P!"H/@NUT J4
M9O5!.J0P0K!EC0R\AO%[ACFI=))H5),-<74=$M+Z-V0*%60OY\TJ0J$\:3H6
M51W2YJ!X*U6HMTY\0FB8K_=L(?#2&'5/>W4'*KD4<-XMX.P8 5?D:Q.-ABVP
MQ)MWB_<=.!]UR;8=+MXR *R?(O1I7>;\D&0::^<LAP62)0[$^36(?JM:*@F#'KN*/R1$,:]LYR[-X:
M=I977XU7Q\ZE5\?T74.\GS$7[O,7B"3^@!#"?78E,!*,XUR4]&&OXQMA3Z*Q
MD!;FQP8C2A]^Q,)!;S*FTYK>=,!>2IYB/GB(XZD/?Q_#WS$^'?1[XXF9\8*=
M#";>9( G4_ L[($#_(A->\$8+X_<"+SCQDY&WB0^>^/)Z"0]ZG^8Y[DS[%U7M!R,+><.@$
M8+4 :68B02+T1K -\!'FL6(T #GTT; 'GCG(TR,BA8P&2(XA!\T)2Y4]Z736
MP1#?4K:L&K@D]9XW>O<4"E;\I65XHB4JZ[)75NVUX5492$T,&3+#J$V"C!LCQ=.S7ZKI,CI\H VE0)M:
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M&<;@LJ^EB-3GRVPE6+]!2\%=@KQ1SK]B8+8[Y+F/5-+X*=K+!6GEO52M)
M1'"*:7Y=;4'ID+6T"H?[Y!B(PPBZTX%#G0=1J9?C4@*<+2=+ '9)]>8 MM(5
M<;"T^&*W)G>"*GEF-B7*U VGJ8?TGP ;TC*ZA"
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M)T!AFT?]7EC%WF8.I*4T)- L.Z?'=5D:Q>)F6Q(: K$>CB1P/M32=_Y5!IQX[HI;0
M,6TZ.(G5@&R9[@Q:;JZ+3W\^H*QEW=GU@E$4O(!J4@#=00B/*!B,=Z;ZT+4W
M)F4P]8;DF8Q O/35XN0(>N!)T9X*'YL,LJBHDT+NJ01>C\:C4K*J\)Q5 9UD
M31UCC^DF80W"6:/"PP#U@XRYM9;DN)9YZEU?=QE;E3D:FER>/"#SUX(4I;*,>
MR%NB]*PL36->NENES!S RDJS$O>*11T%\3EU8I;#%J!#*&$'ZQ!E7F>.?C#I
MG_E]X-2RXE T ]2MJ9JK@\/GN'!S)0MO]9&CQ]J(3OG'U3AW;$SFI7B&8'$#O<[%HOA>$*)'IVT54E4OM0/6>D8=7C\K;#]RZ=J1O
M4:A[%KHF!RE?NK1MRBZ5M]ZLJ7C,*O=$4HM9E*H\&*P#%-I&Y53I6R\8/P,[
MNC2G0\QDC]MKW&(9SARO:Y%216D&J5PH0*LVJRE@EF@L^CK<[1120H2Z8T54S9@-J2&9/8BRZ9PF3)%-P$7MD$741%.B3*
M08.G-VOQ*38#ZMM/[5O+"6^<16N\D2R[EC=0L!Z)3)VT[^8 #Y'A57T ,YDK
MB#*$;U,#*!&1@04CR6#:12N**INF>D"-PU\T:N+F%413D%]:(GYKUJ5D1\J
M_U75/D_GJ9AR>:315*\)"W%@J:!-A(2K$!8V!5:8D
MEX%"D5XP: )4LCN904]WT*34-EXL\V@*^"9.@RES 9P3+TU>*H:.E&!J[8@2J:]6:.?$)8RNG-7CY[F^32#9/I=<7^A$=Q7VJ]/7+,CP
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M(DEVI''!IEBT5-<]=$V :INX@*,#FS7:$O%,CEZLW3^>.YU)7J)6-YE9Y,4?,Y#*0]
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M H[Z/X#O]R#>2(P!,1M&)P(<#B;+?H
M$WOL'($:N#WP_EMQQ_]=1/)=)+3L_?P&#U%Z3'O:MF<<-5T6Q%?=[X"1HCKV
MW+CID+%V$2,ZI<4L,%Z"O*=XW^)EE+!2Y6",!M/AD/XWFW6#?\G-T@B(\9,U7^*D$I+2M(, 7
M04^4FO38K)EV<>-7HQK)R"09OUZTK"3C<.H-*55G,/:&HU&=B*$W& S8R!M/
MAHJ$??AYP*;>9%BG7T#4";S!:&*H-QYY?1_S&_HZ"DA3\ JDUDBD'?"_P)6S138]'UD;+CZ/ 5&<2;]JD4L3?UPSI-
M@%#P+FS\2$D8K'@PQ>+"L+HJ12;#  \K@E%)CZ'G!Y2S%7I3(*UHIH9*>I*@
M["@E\_E,,(;-'/D!\6L(*L)1*N$096$,FP[<$H9JT2'\$81H- !ZC*9U5AB#
M/AFRT01(,RX7[XVG(\^7"@Q+6WE!?\JH N/G?M61?86O.K(O_:JCJ6MP\IZ^
M+U7_ $+S=;*'BMI?7E&[C>+?7[YYZ=SZHZ-EZWITZ2%^JZU/M*N);Y5XSKJ$CT(AK!G4U0.,*@0Z%0);/=Q*HZLR">Z9S#R];/JP:EL@XA^OR* 3/NBL.=9*Y"NG&%3]
M9AG_H I!791%H/#I4U,$2I<#PQFH38/-X=6/QAZ]40_EJ?X)RU.U\J<5TZJ6
M>%&*]FBV>K@R_L]Z9=QEOY*GWEA7=1'!R5NJE5H0QY5..P+1/UP+_CN]%NPP
M2)THE0@ZVA7K+BN9QZ-9I.-2+^DZ^V%?E/N:BK_M MZQVO_A
M MX_UP4\UY*H*].$F_5%(HE3*I=RGS=^R+V99Q\N:*D+6O>ZW]0*()_5$@_0
M2;DJDYM>VGD'Y^#7U]]_R)'Z[!RI0UOQRLJ5>E?)E3JT*\V2\Y"295*R'-FI
MT[Z, 5^:&/#S,C?KK,@'L_+!#F[%LWIBV'DU,>PS-^$A#6W/\$K!^I2?\0_7S_C)HU/^"/WT]YKN]3?]H"( 
MK1W_^35 %OX*/U?R'_5&M8RV^N-CDMF.^/G
MY7=5*G!-$[R;S" QA6??ZQI8TABO4MR4Z6J&<>."S3EOS@=&0"0>8,S=PAAWD(
MZUCI/WD3F>JGB;J4AOJBXJ;DS/J;TSY?1'MG*]N/)QU.<\ZP&I(?8=IO8&&;
MW:9]Z9&\7;25S  N91QQN@B>I4 2K3)/_-H\^LFX1)4!V:_MWVJ*,7&ATJK#IS<%#>7LTD,7,O3 >X=
M/@P=/FQ(!6E2CK77\J_++_4?#CZ%] 17>+2ICJZA>;KS]'Y1OU]
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M=>2'T>K]#)32\_M&Z[4G'-5N?U^K\2-4#3"U_HTJ)7?FLU-'\6&[4+^K?&QJSJUD%K%R$ZVSH.
M037[_V#S,G)TL*E)(N96$C%_W2#D][Q^\66,\-3LXM/FO(4_-(*UYW(O6MXI
M.VU)AE"OMSSM=-D.737X,G+87DO%93@O:T6CFVRW4SZ#]'+NYRVVJS'[HH'+
MXD>6>2?D4;QE=*FOWSD^V<)?_F8!Y-B[S_$>>THYW&>
M%]__'U!+ 0(4 Q0    ( &Q_I$@J5XXWQ0$  ,$9   3              " 
M 0    !;0V]N=&5N=%]4>7!E&UL4$L! A0#%     @ ;'^D2$AU!>[%
M    *P(   L              ( !]@$  %]R96QS+RYR96QS4$L! A0#%   
M  @ ;'^D2!.#K'*E 0  ]1@  !H              ( !Y (  'AL+U]R96QS
M+W=O&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &Q_I$@V
M^H(L; (  $0,   -              "  ;$/  !X;"]S='EL97,N>&UL4$L!
M A0#%     @ ;'^D2+L@.!\7!   HPT   \              ( !2!(  'AL
M+W=O&PO=V]R
M:W-H965T&UL4$L! A0#%     @ ;'^D2!?[:G@O @  P 8 
M !@              ( !S1X  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ;'^D2$0!J GJ P  N!$  !@              ( !
M&RH  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 
M;'^D2( Q)]Z4 0  < ,  !@              ( !S3$  'AL+W=O&UL4$L! A0#
M%     @ ;'^D2*3BB]"0 0  < ,  !D              ( !7S4  'AL+W=O
M&PO=V]R:W-H965TTX
M  !X;"]W;W)K&UL4$L! A0#%     @ ;'^D2',R
M^(^5 0  ;P,  !D              ( !N#H  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ;'^D2/'VK,V1 0  < ,  !D 
M             ( !4D   'AL+W=O&PO
M=V]R:W-H965T&UL4$L! A0#%     @ ;'^D2#\F-\%X @  ,@@  !D              ( !
M($8  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%   
M  @ ;'^D2+.--/+R 0  =P4  !D              ( !EU   'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ;'^D2$FU2S; 
M!   P!8  !D              ( !;%D  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ;'^D2#7/;,P) @  ;P4  !D     
M         ( !PF(  'AL+W=O(H$  !C&@  &0              @ $"90  >&PO=V]R
M:W-H965T&UL
M4$L! A0#%     @ ;'^D2.K%D<#, @  I H  !D              ( !%&T 
M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ 
M;'^D2+VFS*0: @  808  !D              ( !\74  'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#%     @ ;'^D2#,%QCFN+0  ^LP  !0         
M     ( !]X4  'AL+W-H87)E9%-T&UL4$L%!@     Q #$ 20T 
' ->S      $!
 
end


/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){	
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}
		
	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};
	
Show.toggleNext = function( link ){
	var ref = link;
	
	do{
		ref = ref.nextSibling;	
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';
			
		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};


/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em; 
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}




  3.4.0.3
  
  html
  89
  219
  1
  true
  30
  0
  false
  7
  
    
      false
      false
      R1.htm
      101 - Document - Document and Entity Information
      Sheet
      http://www.iconclinical.com/taxonomy/role/DocumentandEntityInformation
      Document and Entity Information
      Cover
      1
    
    
      false
      false
      R2.htm
      103 - Statement - Condensed Consolidated Balance Sheets
      Sheet
      http://www.iconclinical.com/taxonomy/role/StatementOfFinancialPositionClassified
      Condensed Consolidated Balance Sheets
      Statements
      2
    
    
      false
      false
      R3.htm
      104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
      Sheet
      http://www.iconclinical.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical
      Condensed Consolidated Balance Sheets (Parenthetical)
      Statements
      3
    
    
      false
      false
      R4.htm
      105 - Statement - Condensed Consolidated Statements of Operations
      Sheet
      http://www.iconclinical.com/taxonomy/role/StatementOfIncomeAlternative
      Condensed Consolidated Statements of Operations
      Statements
      4
    
    
      false
      false
      R5.htm
      106 - Statement - Condensed Consolidated Statements of Cash Flows
      Sheet
      http://www.iconclinical.com/taxonomy/role/StatementOfCashFlowsIndirect
      Condensed Consolidated Statements of Cash Flows
      Statements
      5
    
    
      false
      false
      R6.htm
      107 - Statement - Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income
      Sheet
      http://www.iconclinical.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome
      Condensed Consolidated Statements of Shareholders' Equity and Comprehensive Income
      Statements
      6
    
    
      false
      false
      R7.htm
      108 - Disclosure - Basis of Presentation
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      Basis of Presentation
      Notes
      7
    
    
      false
      false
      R8.htm
      109 - Disclosure - Goodwill
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock
      Goodwill
      Notes
      8
    
    
      false
      false
      R9.htm
      110 - Disclosure - Business Combinations
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock
      Business Combinations
      Notes
      9
    
    
      false
      false
      R10.htm
      111 - Disclosure - Income Taxes
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock
      Income Taxes
      Notes
      10
    
    
      false
      false
      R11.htm
      112 - Disclosure - Net income per ordinary share
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock
      Net income per ordinary share
      Notes
      11
    
    
      false
      false
      R12.htm
      113 - Disclosure - Share-based Awards
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      Share-based Awards
      Notes
      12
    
    
      false
      false
      R13.htm
      114 - Disclosure - Business Segment Information
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock
      Business Segment Information
      Notes
      13
    
    
      false
      false
      R14.htm
      115 - Disclosure - Goodwill (Tables)
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlockTables
      Goodwill (Tables)
      Tables
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlock
      14
    
    
      false
      false
      R15.htm
      116 - Disclosure - Business Combinations (Tables)
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlockTables
      Business Combinations (Tables)
      Tables
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsBusinessCombinationDisclosureTextBlock
      15
    
    
      false
      false
      R16.htm
      117 - Disclosure - Income Taxes (Tables)
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlockTables
      Income Taxes (Tables)
      Tables
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsIncomeTaxDisclosureTextBlock
      16
    
    
      false
      false
      R17.htm
      118 - Disclosure - Net income per ordinary share (Tables)
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables
      Net income per ordinary share (Tables)
      Tables
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock
      17
    
    
      false
      false
      R18.htm
      119 - Disclosure - Share-based Awards (Tables)
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables
      Share-based Awards (Tables)
      Tables
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      18
    
    
      false
      false
      R19.htm
      120 - Disclosure - Business Segment Information (Tables)
      Sheet
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlockTables
      Business Segment Information (Tables)
      Tables
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsSegmentReportingDisclosureTextBlock
      19
    
    
      false
      false
      R20.htm
      121 - Disclosure - Goodwill (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureGoodwill
      Goodwill (Detail)
      Details
      http://www.iconclinical.com/taxonomy/role/NotesToFinancialStatementsGoodwillDisclosureTextBlockTables
      20
    
    
      false
      false
      R21.htm
      122 - Disclosure - Business Combinations - Additional Information (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureBusinessCombinationsAdditionalInformation
      Business Combinations - Additional Information (Detail)
      Details
      21
    
    
      false
      false
      R22.htm
      123 - Disclosure - Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfEstimatesOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedOfPMG
      Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Detail)
      Details
      22
    
    
      false
      false
      R23.htm
      124 - Disclosure - Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfEstimatesOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedOfPMGParenthetical
      Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of PMG (Parenthetical) (Detail)
      Details
      23
    
    
      false
      false
      R24.htm
      125 - Disclosure - Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfEstimatesOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedOfMediMediaPharmaSolutions
      Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Detail)
      Details
      24
    
    
      false
      false
      R25.htm
      126 - Disclosure - Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfEstimatesOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedOfMediMediaPharmaSolutionsParenthetical
      Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of MediMedia Pharma Solutions (Parenthetical) (Detail)
      Details
      25
    
    
      false
      false
      R26.htm
      127 - Disclosure - Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfEstimatesOfFairValuesOfAssetsAcquiredAndLiabilitiesAssumedOfAptivSolutions
      Summary of Estimates of Fair Values of Assets Acquired and Liabilities Assumed of Aptiv Solutions (Detail)
      Details
      26
    
    
      false
      false
      R27.htm
      128 - Disclosure - Income Taxes Recognized During Period (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureIncomeTaxesRecognizedDuringPeriod
      Income Taxes Recognized During Period (Detail)
      Details
      27
    
    
      false
      false
      R28.htm
      129 - Disclosure - Income Taxes - Additional Information (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureIncomeTaxesAdditionalInformation
      Income Taxes - Additional Information (Detail)
      Details
      28
    
    
      false
      false
      R29.htm
      130 - Disclosure - Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureReconciliationOfNumberOfSharesUsedInComputationOfBasicAndDilutedNetIncomePerOrdinaryShare
      Reconciliation of Number of Shares Used in Computation of Basic and Diluted Net Income Per Ordinary Share (Detail)
      Details
      29
    
    
      false
      false
      R30.htm
      131 - Disclosure - Share-based Awards - Additional Information (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSharebasedAwardsAdditionalInformation
      Share-based Awards - Additional Information (Detail)
      Details
      30
    
    
      false
      false
      R31.htm
      132 - Disclosure - Summary of Stock Option Activity (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfStockOptionActivity
      Summary of Stock Option Activity (Detail)
      Details
      31
    
    
      false
      false
      R32.htm
      133 - Disclosure - Summary of Movement in Non-Vested Share Options (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfMovementInNonVestedShareOptions
      Summary of Movement in Non-Vested Share Options (Detail)
      Details
      32
    
    
      false
      false
      R33.htm
      134 - Disclosure - Schedule of Weighted Average Fair Values and Assumptions Used (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureScheduleOfWeightedAverageFairValuesAndAssumptionsUsed
      Schedule of Weighted Average Fair Values and Assumptions Used (Detail)
      Details
      33
    
    
      false
      false
      R34.htm
      135 - Disclosure - Summary of RSU and PSU Activity (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureSummaryOfRSUAndPSUActivity
      Summary of RSU and PSU Activity (Detail)
      Details
      34
    
    
      false
      false
      R35.htm
      136 - Disclosure - Schedule of Non-cash Stock Compensation Expense (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureScheduleOfNoncashStockCompensationExpense
      Schedule of Non-cash Stock Compensation Expense (Detail)
      Details
      35
    
    
      false
      false
      R36.htm
      137 - Disclosure - Distribution of Net Revenue by Geographical Area (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureDistributionOfNetRevenueByGeographicalArea
      Distribution of Net Revenue by Geographical Area (Detail)
      Details
      36
    
    
      false
      false
      R37.htm
      138 - Disclosure - Distribution of Income from Operations by Geographical Area (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureDistributionOfIncomeFromOperationsByGeographicalArea
      Distribution of Income from Operations by Geographical Area (Detail)
      Details
      37
    
    
      false
      false
      R38.htm
      139 - Disclosure - Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureDistributionOfPropertyPlantAndEquipmentNetByGeographicalArea
      Distribution of Property, Plant and Equipment, Net, by Geographical Area (Detail)
      Details
      38
    
    
      false
      false
      R39.htm
      140 - Disclosure - Distribution of Depreciation and Amortization by Geographical Area (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureDistributionOfDepreciationAndAmortizationByGeographicalArea
      Distribution of Depreciation and Amortization by Geographical Area (Detail)
      Details
      39
    
    
      false
      false
      R40.htm
      141 - Disclosure - Distribution of Total Assets by Geographical Area (Detail)
      Sheet
      http://www.iconclinical.com/taxonomy/role/DisclosureDistributionOfTotalAssetsByGeographicalArea
      Distribution of Total Assets by Geographical Area (Detail)
      Details
      40
    
    
      false
      false
      All Reports
      Book
      All Reports
    
  
  
    iclr-20160331.xml
    iclr-20160331.xsd
    iclr-20160331_cal.xml
    iclr-20160331_def.xml
    iclr-20160331_lab.xml
    iclr-20160331_pre.xml
  
  
  
  true
  true




begin 644 0001157523-16-005462-xbrl.zip
M4$L#!!0    ( &Q_I$CSD]0GDJL  -T)#  1    :6-L2/>O]T@&!10EK
M$.  H-3RKW\S"P!OBI2$HT#6Q,RT)!*%RCLK*X]__+]OTT"X)W'B1^'/;Y2.
M_$8@H1>-_?#VYS?S1'(3S_??"$GJAF,WB$+R\YM'DKSY?[]\][=__!])$BXO
MA4$4AB0(R*/PWQX)2.RF1/@0XA,>@0^]^92$J2C'CIQ/"Z6Z7C1]*T@2<4K?L]V]TX0S(ZJ=O25CRZC>3A^)V@K
M?^K'Q$WAZ\(8]O%.4&7%E&1#DO5K17ZG6N]T\W]6OQW-'F/_]BX5?O!^A"_#
M-^$)3;CL7'96 /L/X2H*$_CV=.:&CT(W"(1+?"H1+DE"XGLR[N2+?KN) P%P
M&B8_OUD!#__+;M_ *[:V?8^=-]LUW^&GPQ/<#/_P3T;?X/OYA[?L/&OVV
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MV=UY&T9M_;?'4?+K[B7$:OT5.>0O?(+'O+1X S7#XF2B4-IZ;I_$36X-/
MWX .$02J18)W"96U2S(1J$B_PU5_?I/XTUF @D?_YL8>0G2<\J!/W,5D\O,;
M%">ID)C.MV3\ MURO-IZFX&5*X-WO7GBAR1)NMZ_YW[BH[K^0F(/S(1[2RXF
MOTN*99A?K8$S-&7'E"Q;525=LWJ2W54LR5+ED3W4^Z-AM_<5E>-7
M^D;ATS.8VY>MO5X-5!$O:%G[[(ZL_
MZ&J&-#+DD:3WG9'4'9FVY*BVWM7A=T=3,OPJ*B!8T61-WH7D:A%4'5'Z;:8(
ML+SJ@&!41I$]V*E91CY&X>TUB:<#F4$VHN="B7(
M3>[R-]V[ 3S:#E$!0Z+I=G64V$9+1@*,&I5+J&MWYYQR+Z
MN^U8W^B_FE4=&33)@9:?ZC*5F\DV8;I2/I0=:1>;Z!*(TOI:Z.1HG5'_64$U !Q
M.YT :-G1M6;H D<)2W=.,;@V(!,"+Q]?N]]6/LPWU K:.*BUK.K.X$]BB/FH
M9S,T@?.$00]V;0QZ-J3ZW_SBJ/+&&8SEF&=#:,+@L&+*<;
MX]F#]97P@FP[NET=%;0BO*!:1G79/8P'>0Y3X>61MJ.HH.>1-M6HT%;O)<+5
MG1N3'B;M8]H[V&[ZGFXX_(KN3;K/KCQ^/-\>D/BBPG]-.G.T[LH
MQHT]&_V&HE#TRSJ8PF\*?-50U15T)_0%AS(X'<<8]+KF4 *TFI*N:P.I!SI=
MTM2>HO8WO;O "G:UI
MZ$*\A"]U7='[(WTH:7*O#\@:VE+7&&F28HSTOC6T1XZ"42]9_:KC [email protected]>N<
M>10\&RB(IM,HO$HC[\\O;GP17Z68FDV_^(7$%'W/1("Y%P'#WRZ_@N/S]3C.
M48<@[L@YZG!D2'I/!G&U%%GJ#4#\NXIARCT3D0%""E(J=V1S!1&'H=J+AE<*
MSC;X98+[5<,L%CG_STZ #[#\YA<+D7
M@'4X7QUHK0- #.&9AB6O!Z0.14"W,;#,7F(02 >HZ%BZ=H"*2QC6H=T=&F89
M8DT>36UGWP0V#LU4(O\2;J !).&KJY44:PN>T-OAV/:4&-&WQQ?2!]WYWY
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M&X2])P=0 (T"?"QMLL_]U(/?>$CX_^: &2&FF :BE_,+N&" VF)8&RYFE)%:,:K9N
MK=\*KVUZ'1YPRM+8'9.5?!MF@:.NM&&NDVX_ *7D#=7!DR!]!E!MPVSL3A,:
M3F=!]$C(%8GO?8_LOGD G&"G%#*FEPS)=90=%1>?]Z,D_1RE?Y!T>2-4HRO=
MZX]&ENG@A<% E_2A/I!LV1A(AFKW#7G4=P96-PN9@^:U:/WS*F(J0\$ZID<^
M0$8^@GNV"8XMI8D]0+$^4P8W:PW.G7NO
M_AJM#N,,%@L\K8UZX!?U$$J:#FFSO.!YM;GXSM)FED?6ID^JE3-M5
M%%O--O5UN7T"A W.O7?] /\\BN(K,$=7!%!"SXW8ZF?Y&[/,#$2V39K)MLK+
MSX-J)3\SOZ*Y)&,RG6795[0+*(. @T=5!.^?W/H*='MBVCD:_B!NC('M*.MH
MQ^"]DP+,3H, "Z"?!]$VH7^-[DD<8M#@U]@-V59H*E#2;O5DR=& =V1]:,FF;.H#
M>YEMK%B::CIV"6E_^[!0+I*'WTCL^0DJKW\1;$0,AV$@KWM+\D_(EQC.SZ6C
M?H5;]^31J=NIKL9 &SJZ+V1+SL#L20-C: [DH>R8LK'LO65U5M.0
M:L+3#N+<''[IS9Z7+N(3ZRF@#/7Q$"
M*YD^AMGM]1UE(*F&CAJI9TE==="7%-F0S6Z_-] L9VF9C8YL5:"0#J*J7!*M
MB.<'.&SY8>)[]#5*E20YX$\?K[#P>L8J7.KJ<;+B@5?G 3 J'9:I6;:C:=+0
M .=55WNF9-O][email protected]]LT%412YHVJYGU\GIDHDT*E1!766VK&-DJA2
M"RD66K&%UEYQ@"Y=2Y-&#KQ9MWM#J3<":P)$T1S%DFW+&BZK2JV.8[Z6,B_$
M5GDRDQW@JY(4K&\T5$.COUNR7L?Q3\MOA(V.;9=Y9[AL.FXGE638^!^^L[-]Q] 'T];1PXM3V_%,NR=,TR1I*A
M(_8-RX(SN(S:RH8SN#/43=O,JBII0H1!NS]8NEK&^?"Y**J=,C4X !M$>Y&9
MZ?9M8]A7TYB0$-:9TE#*"B24BD:W:[FT:
M:3IHN6<+EN7@0!C% %H,1N"6V2.IV^T:DF6H>.ZW3+N[[*AB;M:B5%S;S2B2
M\7?#4:UOBFHJCO/\@OJCD*X5!?7GCG-+ 2?JV3@VNXIF#O&RQ]1D29?[ PE.
M'X9D#X>:I3MF5U7511Z=TE+&7KE_I0KK];@V+%UYPG,ZDK]'EM*%_P%_JX![
M#5YM=YV>I(RLH=4?J-V!/D!?247^-DS86AFZ_@!N&&=S%8MRG6>CNC>2NS+\
M(LG6< B.D:-)MJ%:V O%&!E#>:"LL/G9Z^\,R:_6WT,Y. F"UG5*N*/A)8(MH59X$:,#)T#J*R?))H-0>)8AI2[=-/',9
MLJ8_6SR.K>N2LDKQGH"X_%I$A88'$.JM;@F'"O*J@->T%*=2>,VO
M3@'O=K5I$Q#;EETMA;6O9@[QCD81#4"L:)KYL@9WQT)L?+5SB'=45MD@!L696Y=?Z'ZTLR>#@II .Z,##Z-TNU*
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M/Q1[^
M1=D#P1K!N@/G+:,8X%LQ0EHX#JP1FN UHZ96[C&>Q#RP1@B$1W>E.D5U8!Q8
M)2RQ-6&^%83 PZI3BNXZ$BLM,M#TM/-@=*5[*YE2OI([TFV/C"D
MKC(8.+V^K9O][DKBVV9-6J7FFR;$%WDL7V#Q\MCVB:*+_$6'KLYU961W![HB
M]E:WY/-O@
MEPBNRM)\GJHAQ9"*[ABVHZC-S>>I&DCC*""KG,^S7UY+ZEJC9O-Y=%4^--FE
MFOD\=0"(\WDLQ=Z0RAKG\]0!I$,;6F[WQV]F/D\-$-/Y/*:^[A'6.I^G#B!I
M0&FC\73-\WGJ !/;/-J:YFS%_8)TVE\WF4(P>:E#Z?IPYME,WG
MT>3US)0:Y_/4 21VFU75C4MB]N;SU,#/F%VF'>I0X'C?!Y3,3?ZA[,UGZ<&/-#Y/)KA;,Q)K'T^SVM /2J;5EG,YY$Q0FIJ
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MQM013P*/WG"TZDQRFI:##-38^KP*7%J3%XSU,:I
M,3F*ZID:4_2V4TS5-.R5K(S2L<#B8)*R4'W48)("U8YIVT;;!I-4TT;[,/XK
M&YI14$/3._;F4 8^-*-2^APU-&.AF+2.Z30W-(/)N0 5B=5<@%?KTHH;(.X@4G6MT-5%*W2%)OE;IK)I^WD#
MQ%*(5ED#1#7OCZO;':V,]J'LM4*O6^"J[#BJ+CJ.HJ\M*Y;%Y:T,>:NOX>BB
M3%#M&/6.C6BDX>@*IJMO.*JL2L<+:S'*RBVJK^&H4C0<1:BWTK\K;\VX ]YJ
M&XXJ1<-1"N]V^EP3$%?;<%0I&HXBQ#LRWQN N.*&HTK1J)6KE
M#4?5K/ ;+R8;IFKE#4FS#436[$M&LC>YQ1[:TZ<-AR@<+3'^YAM-3
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MJ^&,UF/.JMOJ=6B80ZUOZM)P.# EW9&[DM-3=*FG#D2!8<3*ZCO&E2L0F254[2_/.\G5)MJ-WAG?2'JFSU1I)MF' H'JH.
MSC53I9&E]+712-&ZH_Z*M./4@O5L\N? ^6+;OE+9]2%+J&H)SFC>JVH?;)/[
M#,!K4E.VN"&TT1E(CMU66]P0UFB[9%E>36-]G2U^
M];S'9?N4E[=-RS%J*.N7:X9BJ,\??^DX!ASES*$$F /CJVL#J0=60,(<8;7G
M.%VY/UP87W7S9%,A/IH6<_CP1(CCKK=B[ B*:\1DUO,_N"Z2'V1CBZ3/?O">R_
MR HW@R5M5X_S0Z#5YP3>^K.?"&Q'Y6FG%ZLJL&O_>+(@QP'QVUZ1]/F?N"'OH>%; EQ 6E7?DJ2
MRFP6KEY*V^8B&JS;&QV;GX2GKG2ZK#+L0_AL5I$=8W>6JF58NO)LQ]Z"\U 7
M_B?U9! M78.WV5VG)RDC:VCU!RJ@>; P_ ;>UM22Y+B.GMV=40J2#>8Q\/5S
M$:F9JWBL<"I=5ENBP7O6E/A34.R&M]!8R\#D4ED]P\;7!S@*G[[1N>@H8';#
M3\U:L*&EF00<7!E)475-V0GZ;CCJ4CS["RPNR=3ULL'YL=O'"1167S)M8RCI_9$M=4$B)' _
MU*X,_]5[1G;FILWIRHH/O0IA)RUQ11+]2R2.NDU?5)0XBTM^< /YO"W
MK1D42T-Y/-(=.0_1'IPTL2TGC@:F?#B0)3A5@K#HX!MW1UU5&ADX76%M/ 2:$/7E!/&74E
MU1SJ0[EGRMW1$%&"L^ID[ IB. >0L@^>C8Z/),7P(;VK'Y-Q[_&W!!GL8D:C
M'8!"+_7OL^XQ-#]G#G_+/WQ6SY1]N"E[?C.=:F%BUOZ:2+X.S'64%.4&V":63L%X5AU%;7!I6(N)J1?K
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M]8%DR\9 ,E2[;\BCOC.PNIF#IC@;5^ E0;MQ6^SZ(W\5D[3#)\N$8
M_;J-B2I'@;(1!*+(NI@,OWFT>O'23-47\Z*%>6-X8\O [,#>.QPAD7D\TY10RBQ,##SD9^T-- [!G%D_O^
M>;-Y!@6;E@#*MKQGVM+Z_K<:6GB$C&D@"J?O)L^?'5P?CQN+RI3U[A6[(3CJ
M=)9/#EA)@F<0<+ST5#1]>\;2<1 =0L3&(%H6$8!V6U-D1SN @0U0-KWZ),5)
MG+D\L'A" S@U58$SVH97O[[Q8T:F91D2FQABD+9T0K"JF<;&+/MG0+7)X%FH
M+L<6CH!AD-)8MJ-:F[=U6SO?YN"+"69ZTHFR)+[W/9)<14&YU[#E0(C:6K5E
M:YN7=X.PWS!EYY.VA)(<&H"P]AJI_=#L(O8E\:P%:8/8) B %WX%KHG= ,,QXZD?^DF*)_)[AO6_^>87
MRS&,C5:V1T%S5& F,Y*M#,S(:"D4U=:W;EU> >@3OA+>X^;9TL5,DUJ]PV/Q
M H)C8Y7F7C=I%R#/O'%E^UB/29I85_F\:]>M@SVM/KTD'HX%?+R8K(>X-H<%
M,H@&VO-K64Q]+"0EC1Y;E ]TDV0^+=AM1KR4C-$]?T8E_QK&MD8@X'=ET?FHH_(%^./$F:''82UI+*77>^Y]),_
M1S%9)-+@)4MIJ%TPYVP>KY5WZZ] NXZYP[*B*R44MAR+D7*'':Z7.958
M(S4
M0(*!CQY:.&:? !K56%438!4?Y>JKPLU;2" M\ /]&/MAXGO5*ZD#19&:,="&
MCFY+LH-SN^R1+3D#LR<-C*$YD(>R8\IY&3)-J"MZ?]6)GJJRQDL9G=&7G7[/
M&HRD$0[EU&U-D;JRXTA]U8#3I ,>HMY?J!+'WDA(K"F/O!1(AYIA:P/-D>RA
M#L=F8]B3''O8ES1GT.WWACU='0X6D.($&',=UB=3R\O/.BD%9ME2^XK3E26M
MU[LX"9L/:N)D_.@^E&IY^\>"0HWBZ&!RBPQ-F
MTTS]8E"/8NK%.!A%EQV9%:9^,2/0)%._?'+*44Q=3$Y1==-N
MF*=?#NE1/%U BLV/'498^N4@'\72!T"/D?V*/.Y:+J)\OSKN2;H':Z9I#31I9
M?WL=S<=>QB8X:KQ^E-](QFJ4_O;F3T1_"S(RE#
M>$PW^[KD:$/X297[ [N+(TB=;'L[(HSQEM6_F5-9C29"""8I
MSM,[;QZ%VP45W$  >7"%!S<1W 06F$1!$#TD[W#O;V'SZZ#@;_CC32R\+7[>
M^%9*;^K+!OE?'P;7_XF+R']_(W@D")*9BVD3M$<*_CYSQ^/\]]7-Q*N_C(MM
M_3Z\O/[0[WXLD)A&LS?"O1OXM^'/;VZB%+B5KO(?[G3V_O]^Z\H9H.GXJ-7R
M!@0O,%8W,<>?K^]B0H1/
M(-%WB3 ,QV1,09[O89OG(7=]!P&9I-L("J,'X/&?WV3_'D3_VW5>.0/&41MF
MG!BO5[;XYA,V318T162;73@53X&*7.C98!=TYMCF%$[ 0P0TV";@^8DZ6X[A
M#WXHI'?1/''#GGQV^>!U+_X>''Y3OB_GD?(
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ME!&+JXV$Y1LX+A9<+':(A>V]')/#_@;
M+DR[)HJ&5^-2]_/7#9^GC<'3]3E#MCF;,%LFM/PG=(! 2
MK(<5DKOH(10F45SDSF'9E$"^S:(XS;ZR\V8H_W59?OB*ZKAE&> P3/WTL4]P
MUE/P(1R3;_\DCS67 V*S)UA0-F7',+*BP)W;VJZLS'K7#,/QX'D-ET@=4;#F1)4;H#20Z-!=S30 '(%.Q)IBJ(;!^:!'X9KHT#8NR/C.;8TWSE3O0L(S5:L
MIM93[@_-7G?0E8 5L1K8ZDO=(8 /;-#31D/=<#3G1&L]L= S)H!'SP_RN4S1
M1$CAKR&E)/Z6<9 PQR:P- $;)6XZFZ?T^[ (?.<&Z22@3AOG,]VQ7-2GG0Z$
M&:X3 P.X\6.VFN#S4M$G73I>&\"+1E_"0OC@+BYJ S^Q6974DBI$3L53H.+Y
M%9BQR2Z\EK3]!.2UI,QR2JFW1J%<,KADK$N&81E@:\NHR656,AI,I&SMR1%/B]M7I+!&)>?%U^:?
M5>8UEY]4Q,A6F3\"&*:HZJJHE%+_61L9V4O-9(3?N&B4>#I61!O$0].M4Q:-
M VF3V_F&+\S.VI?B]3FB\ZGS]+!\1O5C-9E=NCF0]5%O)*E]LROI0T>5'&LX
ME#2GI]/)AW)O<,*975EV%0:I\S2I^73JQOY?L#!F<4VC>SHS$+.ZPBB4,K)D
MS@>F=>5A!'19\.LI3:R99HDU!!-KA,6UNH!$V)/%52?4&XS/6JX8:(=X3.(7
MIXTMWF88?S\B_^G4*QJDZ#%5=(K=7%W#,G2WF:K@:!SW"3-QF?T#^<''IX]+'I6]_^HO6,=GLC-AX$NH!/[JR!"[email protected]]A
MGP"QCA,^\X/S".<1SB/M2?ML50SIU]@-4\('7#8A,HWZKJ8B6DX9G?.8/1DR
MP ?G<*IK%]];2L?A U?Z*BZGY!:/
M[N9)7OG[1E$\(7XY?B&_*Z][J^P?#7\P1$.O<(!-/;?8K?!.N?BUQM:?FI2K
M2H?1(9X\48Q+WZE+G].ILME"\\+'\\3..D+*!$YX6(7S".<1SB.M#U1M]^9J
M1Z!J;S7B$GL;G72JYF7# 8X;6F9S*S*'^Z
MU7'JT>U<^IC%*9>^INY]C8[,.WON[NQY3%/.]8:> S_Q@BB9Q_!T/YK.2)C0
M><"7)'!AG7Z4I$G1))2,O[B/V&DR*;W#I]I5!GU;D:6!,Y E?3#L2[8JJ])0
M'AF:I9FF/APUU>%SJ_>4V8!\ZE[^^N'S0K84=0%,Q8U#+T+AO^;!HZ#2$YAL
MTXZGR-=N^"BXXVB&IS?\VW Z"Z)'0M9@%[X$+D["ID_^@%_+Y10XM_^>_G7Q
M''YU^>G@_8_";!XG+QX2K@#+J;'5B%Q S?V\30[F?@>P>]F#])FL@]^>K>Z'U@#%Q.NYC>)
M/_:QO7W1418 ]^Y %'8TRN\@1? [B4O;XX]!J8CK1 F2:(TR?0!D'L#I.DV>
M2YS51[?H(VX3"%8KME(O@;S%1D6 _=Y/Z-0 6 3[]Y)OQ,OF "V(%I/4]4- 
MT,WC&O(R\J[0Y+N_'4451J5WZ(+09*C*\ 80S\,QR0#:EC\A6GY"!6V=_, E
MT2V!+V3?VF*7%;Y*UE@%UGKP@T"X(8#>A30!>M#B9?NCH@7F5OKW'-3KY!%%
MZHI^GJM1S#Q9+FJ__WQULNH%P2>Y).$<.&)-.AK"_?;1%!0#P!C7(!"%\JW'$:X&U@C( GVO@: L5]S(9@3; ,Y=>,_
M28H^V)P42%GC?B$*DB7)D#)YDP1#A8BT_2>9H*.#1"%8!BN9_656I
MA8[;([DKT@E+9"_,OI(92U<(?%"T")8NRR+ZXOG;W=DL\%%K+>.LHWF,TSHK*$(7Q/*:6E!I'SPU(
M.'9CX9&X\:8AQEUDDE" 5NP/GBQT\A(ZD*0840P,#^("C.>/01;T
MZZBT=Y@*;?OKE;A^F0OA1?-@G%'GN[^M>@Z9GP9^!:X44;M6,%BRX9R@J/I4
MT)+"-_!)UP\BZV\'61HEKF-Y!N.UL?FX)[??;@E!WQOI,=:*([[>I/OC?-@XF.
M^PW/,%ELH_F!)8L<##Z=Y 3XNI@DT30W+7'+W$B+8F!*TSOB\UJXE)V:E+5F
M7 SS(S3JHMP3\\J:YO(GML8,XQ^UQTLR=?V0S:%TRUWVET=$IO?YT9^PKEU>
M7=34ML->ZP<#<D<_\,
MG&VJ5M:.8MP%N$L\@P7YGAX2W506MXEGC=&47C&G"'
MBPQ\/J^0L7!@Y4KR!]T6;5UN0$T^X\!:.1;XN,+3=4&:!%C5.@KCHT!;%9'C
M3-\"IG13Z[-.)^J
M:LN\):4"U];A*\Y
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M@V"!ZXWOPAJ+;Q>0++ KC.]O!(\$F!;M 4['$H)2OJ(VL 3?\20G<^Z][V%J[+W R+3YHH^D\ 4=
M"OY\ECD?H[/^.SB3CG/7JQ+%3=1B8G5_,,<EH9324X,$JSO7MX7I%Z\AJ
M>[F>)WGE[^.33'D*5Z7>IR$:>AF*@D\RY>+'!$?S5)4= 2"E8Y]TJ@J7/D8X
MC4O?KEFFNG7*PL?SQ,XZ0LH$3GA8A?,(YQ'.(ZT/5&UWHVM'H&IO->(2>[S)
M\ZEU]&/2V]8LT71XJTLN&*T^[;96_G2KXYST?"LN?8QP&I>^'?>^1D>N,-C4
MO/0=[FA+5PAJ;U.9+73]QT=8R4\!2.^)6]VU_JM7:>3]6;3D$[I),I\^U9ZO
M([email protected].$\T&.VZ+-9M+;=[& *JSS1=)/V4UWO64J;FGINX,T#%Q><)UG_5ERQ
M%[C>G]*5=Q<%V+8VZX2+35KQE=-H3(+.RJEDU^YAH=5^N[2=ZY(N\#+XZ@.)
M"?PU;T":[&D,>@2UFF_9^:(C;.GVJ<0%G^YR9%9]2#[04M(C( /QZB;F^/,U
M[3W[*1.#(8H!!7F^AVU>&R%I+/;17L9AJH?K@F\6BI%M=N%4/ 4J,ZB7NI=U"F*$EL(JN$:SC+9B?;LCRS\:_\QO):H$ ]L
MGD!@D\%!7665,#,;U^3"QPBG<>';OE1P3ESX7IW!NL\YX!FLM6>>[9$?UE'"
MDQ,YBS"3FUC&D:>(:M#PQLJEYKM2@Q[M[W=4,Y.SCA+>$HNSR EX=PV$?H;?
M9L3#T,]]%+BI'_CI8^4*EG63R9874?E!39,KN$=H4Q>IOW..YQS/.9ZA8T!M
MYF_@W_MC$HZ%1Y\$O*,U6WYCY6+0A!I@J4%-]8:/,SQG^%8Q_)D<^R[]Y$]I
M@IG#/F85DR058C%?-8QUI)FPG=G&FXDS5CBKH
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MS:[/8^I/WB*RB+AB[CGK_#>Z_!#H!&1'A\%_SX%%0:2&^;%.J]:,I:/I'P1T#_9#WX6_TP^%T%D2/
M!-ZX1  LL@13^!*XH? #/I K/%56^N_IPY=7O]&/EQ\,WO\HS.9Q,D(O@/N"^YB&H#?K@#/"R
MVL6@"U^YO8W)+Q\V%F1BU\B)T/,3.L<9"=GV9F6&&3G8%HGV"G
M2M'M8T&>@A%I_P]WFG4+ 03!&AC[I+U ?,KPN'8$/WLQ 4M'5PCGTQOX,R D
MEP-JQ3U8[08W@>Q/5H5L\;(;T'<=8R%.V=-KXN=Y5,9N@T<1Y7]#&O6.\DQ9
MS+>S+HWK*-AL8I*OA\Q($8R(0>K,W*(1"S(2.@R%[X2O0WIFIKHC=/&Q9,?[
M'FZ8L67GE?.%WO,>[email protected];]#_LG1!!#F
MIAA_ *[Q2)RZ -V?!'Q4<%SN_3&XEPD E!N;7V/PC3+?*NO_0KO99(UG3&WXVCB"\+8UC!3?5L0&SZIC
M?XHUFMX]C2=YN%E%J>D/8@K#I/?Q>4EN"-DMPBTP^FU:U:0D_RE@U+/1'[?&2
M3.'(PZ9+LMQE'TY+,9REX#C&]#X_EG/AS%4;/\U<,JEW^6F&GV:XPN *@SMJ
M]>R1]HSG)Z96:0DNB,_<&KOBQ\])YW5.XLUO6>GMRA'$$<01Q!'$$<0P@DJO
M,E*WVMJJ-CM5V/M39B[6AM\* ^(1&G\JYE:5X.LKS'<#
M<&1%M*P*A]Z63\/:ZJC.3"XJY[4*&V2W5?PLM6/4H]FY\#&+4VZ4-F"^6@,HT>U.*4U#N?"U7/BX65IOI53A
MA)_FA>+5S0#W11_YA)\6=")C B5\P@]G$H5EBS*ML4U%LOLR,TT-]-GQ_3LZ& F4,),=*&)
M^47[HPM9&Q#:H[>&& /K(2BVHG*5:W&I 0W.X\.<$SDG.N*%P8?1E$\(7XY
M@0=>8E+W5ID/4O^@:V8MG%5AB+(5;AR7O=:X@B3/<#>-BQ\3+,W=M.T6&%9'/NEJ?RY\[&V5NVG,)#;Q@#D/
MF/,[%K >GGR;NC;6'A;
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M?(25?!!RWSL@+*'DNCA!JSTI%2F&59_OL;P2-!D,Q<
M#R3@YS=R]OL,&3K[_44W?Z4[924NN&M[0'_$ ?S!K/IND3[WK^&'7__S&H$+
M-OPFCX"*B%?KRD+?LI8<(@L2$&>[V&;UUXL-W9EW%[&41MF''H,V>*;
MA99BFUTX%4^!BESHV6"7138*LYS""7B(@ ;;!#P_46?+,?S!QY-J-$_@4)R4
M44O+#(6R4XH=?\Y )[email protected],7E[H,)?5B>C< >C@G,HQ2X9&D0DR\
MZ#;T_\(\Q_2[K73(+'46/DPCX7O+7":-KV;>8BKQ T&&I1F5[CV)W5M29 ?3
M?.&'.Q^63>_\1(#_XB:\?-4;LKH'^%#M:!:L@DG6]"9N$H7I#AR:LW23A.O$
MQ.?P"YT<*ZG[#9:](2&9^&MP^ZMYO\+,]>F?/'>&:;3PQ<#-MYHE/2^PNQ.O
M:PC3.^HBR3Y/0H4%GLK3S]/1UW['A'REX\"33R69%[_^X^T\D6Y==_9NX"=>
M$"7SF%Q,^BM[OQV!6Y
MQ8\OR2R*4S^\72Z^>  0 I!_@^],?GY#HN#KEZ&MJ88B29)BFM(_)9!KY>O5
M]>"KHWQ%.&5-4[[*;P1__/,;?_S5L'7%,LROFFJ:EBRKDFY8NJ3+3E=R+$V5
M5*LW&%AZ=V0[\E=\\)=J-5Q#"0*K47>K(_3FB1^2)!%R"@@?0F"E*:7D;H7#
MH%H"!8$B<7\HY$?NJ'G
M@XSG'] -99]=+':S>.CA+D+AC6X)K [?C0DR? *OC/&E2Q"7%0_.^T3PZ'H+
MZ&"),?'\!(&8NG_BPJA_/"^*Q[ ;4*1^>B>,NE<]H7O5%U1;EA19>$(/EETU
ML$R(* 0<"'43S=." 1,LI'!#88BHG\5^DE,R5ROPZ":'+C1Q&_D5F,REFBUV
M/30;":&Z.8IO73 ?%$C,XUD2O?^^?WFQ_'7P_D
MP(C3S=&K/A"R1]P,$!^@N8W=:9))83*?H4W @@E8#9ZAW\E$U@O\$'>T!BL\
M[J%"D[)2'#2C8#/!420!> 54NB/ARQT(/_*2].'WY3)).A\C,+N,_BK1L(H#
MH4.K#.8JH?5,N!]WYM[X@9\^XCN JN,Y)OT4RP.FW("B9@K&$5#POYG1!G>1
M8AV=FYBX&976:80X*MZ:"SMU)R8!^>8O7@D+Y&IJ/_4%VII,N;&6,2$FPBIXKN-J6>RRGJT/BU?;I4'T9>>I^M^VQKJ8-55Y 'B7.J9@'X>
M1Z"NX4V@8\%UB>:W=PNU*]S&T4-Z)ZXJ1JK 7"&<3V_@-V"%)8NYWK_GH/IP
M'Y2K27A'=9Z?8AG=&K&6I/(S9@4=G+JH*C,"4 Y;4"[C^$T.:ZN^R:_8 =_N
M@QMG5(C^%V2C,(GS&3 *J"+X![4OY:N8_'M.P*.CCB9\'[: O Q^+@'K-U[*
M&JBMA?@C/QZK5;9U"O+E0Q3_":N ]2(QL@U:6]PA, \0?QZO4!_Y%P!+[OP9
M4#%VPTR]K$HSY<),U289(WGPKFB*:Z/!76*&9E%2YQT%F> S\&0;\_'&_H\;U6'NP@N!(S6'W%
MCYG?@'?@N_$C=5Z*)5=/3I? M.$7Y$6G=1\D5V(B-7C+"U,)D0Y$8?J]* +&,2M$8H*=/D-!,H
M0^;J_181ATB-"6C'D "3+XBR5*//0(EP"Q(:HA84XB@@2]E 
MMQD1_73]==%#(6C47OQ)'JG*#M# (D>@?@!]FLEW(6+941=U,SR8B'0_^"3N
M*>-@?".(C'^;.>&P!W#__@25XZ(_<_.X@AY<.%/KN9XJC""JIRDH*F*%AH@)R)]D"J [Q;%TKFK,4'/9N[2$F<@*B9$"[-@
MCA70H!6 LD4U;>&T9)K@L= 6^ KBHH=,L>[' BHE8'T2 S&B>-U]HZ8/WX&6
M:/,M=!FZ5;I_:AO!Q+DW@9_<95J.A'A"H8XH>A#Y>]=%-QPO85X@@KJNJ#3]
M\#X*[C,=ESNMN5N(KDOAF.%V%J9(I-J8UHO/4)+ :TQ!^\;31 I(>$N58TS2
M.7SGSKU'_,?D%@QYX
MQ I>4;3\[%&2KD+<&C%!'-P2/+/,P,K"*0@4$55>F?45QME1-V_S0+$,!*,:
M#DYKX*PO_0'$1+J&TF(1-P6?Z&:>%7IGA ;:%/S6R;$
MX&)_2%WTM*^ %4-1R,Z.G^G9#Q>'%:Y GQ#\: XJ [[Y)<(/1*'_%QPLP.>=
MS4&#>Z+PT4WO?1$_YR%H3'Q9$KL$CB440_B5*_ ^
M_\I>!2N"0S2F*WR"8[87B4(O=O_RX?M].+],;_"!;GR+8A2Z-.X7P.)?2#R'
ME<%!SOX6TA6N %%WPC\CP* H_!>W62[:3J%< !G
M37KH+RXN"G-V1(.BY2KK=Q\T_I;019YJP<%29RCVJ.C^2)EUC*GZJ!-SO;RB
M9=$2+$TDIO>#&&![HV.0?P3 O/_)69>YXB9X_Y-6, Z;E?0MZ9S!J7@*5.1"
MSP:[\/XG[2<@[W_"&*>PY1CR_B<-UG=OWB;D5YZO)P(#Y46\$01C ,,A7;0U
MWO^$L_UYL;VBB[)SEAU0F.]OLF'_+K$1.C8)GV-V1.5FD/7ILN5NA/EZ)LL0
M35UM0$[Y_&?.CMOL:(/9L,N8@<1$]=PI'YM^ZUSMK,1G=X0U7MU=LN]
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M\88A2K0O&977\+4L2-FJ-$/#$0VCC @DOTKF7-\:KM/$>KU*J35NHU:8!-E^DQ*6"O:VV0"ITLXQ^
M*6.V098JR4D:[*F9+A[CT
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M<4SB*LGQUV5LVP61K#6@9^>V\47Y=FW]#%HNZ(MEW&Q6*Y1&^T
M7H6+Q%F+A"&+JE*A%U^32!Q91+*^0@M&*XUW%YJ,R2PFGD\G*M$J$W<:Q:G_
M5_8'7F*RVW_A$Y;XA*72W.'VIC.SF?C.*Y8X%;G0GQF[\'*E]A.0ERLQQBEL
M.8:\7(F=5 E>KM2RD%*KDJH,T9%YBA]G^K-B>EUTE#+:\[3N,K"M:8*\5.D<
MBT,4T5)XJ1+G1C:X41754OI-GU%>7#-&@Y*!,HX8<4SB*LGQSX<)^:D_J9\P2:+_)@#B6*(2JE-$)A=KP(ESY&6(U+
MW[;T::)32@=%9J6OC<-]R.Z:JQ2-O> F"4D3X>9Q;X$5K'"N)5;MS9EE,[NZ
M)=44G(I/4I%/\>$J]\]=D?&B
M'_8O39HYSO"BGY8%.5J5GV1INF@J960=\*LHSO:M87O3U$39/,L.XFU-N^.%
M/^=8:J$9IFC95@."RDM_.#_NFCRAB9;61,5HB[/-FC$D_&YG[#L
M9S5;7\!L6Z'G!F[H$>'JCI!4N',3X8:04(A)&D?)C'BI?T\"'+D4DR1U4S+&
M*4LQ^?? GR9P(7I2DR79%;?.4EF>&$"7SF%R3;VDOB+P_?X&'A7\4#_P:1>,'/PAV?!'>&Z;PRR69_/R&1,'7
M+T-;4PU%DB3%-*5_2L!ORM>KZ\%71_F*J>RRIBE?Y3>"/_[YC3_^:MBZ8AGF
M5[6G.%UG9$MV;^1(>E>W)-NP+4FU3=GIJ_ U>_05'_RE6NFKE/OV9\QN,)_:
M$0J<[Z!H6\K& ,YX3.)7#.DJW')U_T2\"M*G-2;K0+)96M-LEA:I?)96O3,J
M#Q=;-$F>+5K\0=RX931X?4R0"V%=19CUR%X;\5];^207/=9(7WD=))>ZQ@9[
MG;.T6>=5K'?.I-9>MW@[%!>SH)7!+OM$NLFK6:D!8:XMXX%S
M9\NY4]$T45'/NIKT^0>T+Z#QX\.*G_N(]O(1]3>T6(ZFMIU82QZ+O^(.FMGY8
M7.5(*B,&P.61@:VV0!X55=2U,EJ/G+M(LG='?(P+7J^?7;9D7R0#7J=@7E$P616>7DF/CO\JR"$7S'#;!B:!B.!VY*
MRBJ9'!G]$?SL2,H0'M/-OBXYVA!^4N7^P.YJFF,X7Y6OVIM?8&%5TI1_O'UJ
M6^LEG\/I+(@>";DB\;WOD:L[-R8]-R'C?C2=D3"A):B?H_">)"D9=Q_<>)S0
MYA>KG_>C)/T_/)%_4/_I&B#)4WKA7C))H/(FT\7!"F^
M[,V3LI#2'6G6H*\8DMI7AI)N.8[4-8>:-++ZFJTY U4V$2GZFU_^OYQ%]FYI
MG4>NO#LRG@?D8E+(0^EEP5;[email protected]+ZO>$ ".K(4J]KCR1=MBREIRE=>6C4
M51;,"VI/JZJ%%]3R@MJS+#YA20AY02TOJ.6BQPMJSTOJ>$%MA=+&"VK/AM0M
MJ#H]8=!X06TY4GPR^;>MB,^?:_2=V>LN+@I<%'A!+2^HY26+9U>RR MJ.7>R
MRYV\H)87U/)R15Y0RSGT'#B4%]3R@EI>P->.K;+O._*"6EY0R^61(7GD!;6\
MH)978;)Q<3*DY 6U1]H'7KW7BBO1DZO>XP6U7"2Y2+*$$UY0NV,DZ?Y2
MPO6:PW\1I"\9=^])[-Z2SW,L7KB8T&K-Y&*>)JD;8KE,NI)J#O6AW#/E[FB(
M1:?.FU\,0U8467&6@#\+GGWEEUB!&H4X1?9B\B'THBFY=K\-OV%5*NF1D$S\
M]!I)4'IY9L\:6J.!HDHCS1E(NB8/)<=09#(WZ+\5QC/8_0P<7YONE)R"&O0@C=A40*%$X9-
MP*[VBI&M@1IP_E:?^W+ &^3@U)Y(2-;
MU*[6XRPUGM^*(+[Y@DS2?:>PAQ)%%A63!^6Y0'*!9 ,E()"V
M7&%V4/,"^8J0_+/#R^MQZMX\\4.2)+#,C1_2-HD[^F:6%9(>ZLK(-LRA-.@K
MMJ1;EBGU9,N2-'N@6HK2U^WAH*F0]%8+-*TC%-@15M"3[([Y5N/_7UW_\1%6
M\E/@+V]GR/N]\*E[^>N'S]+UQ1?PY#K&;'$6[*X6^$C"ET^_OCA<77=+AU!8
M]+[2:>C=H"%Z9'8W?,Q*EV(R1IA$(2;)/$@QC ^G(#>$YWULY.D&0DA2P7.3
M.R&:IY,@>A"BB?"]J74,8>H' >!%1-KZ^/C,?<2$]$28NF,B
M@(][0^[<8()/PPO!N49RP!/?.QVG6*FSE&_Z)1_O$-P0UD_);>RFL%G8S4,4
M_XG+Z+;@P1*^!YN$[1,:^@)2 =8 AL]1G-[!XWTW!K44NJ)P!0#S-0X14/=U$0/ K10PB[FKB>'P"ZX.^X
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MH!G^B]=V :%0  W@__=$(+TN;1B750Q[#/+N,ET;=JY[0O>H+MFQ0X";@ ]1@Y0K@]MM>W A^
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M^IA0JD_*[Y>8+'(H\) 9X=6_X.6-QS,;W(1 ]8:&_@Y"J7"@QV3"8DQX2IUORU$[;$$=.M4&-1<,;5,W/JV1%M4SX+S7STR+Q7GS#^M5'U
M[(XQ9LCN++NZO?=7C%UB9*O,'S04T50JC 263\$6Z0'FTFJNL?'(6D.3,K)H
M^) ^!K;*?*Y.U1&->D;TE="$JR;17^V,\%-1 "+$9(:]># 5)]UN_N&&V#<"
M]NTG=V1,^YM,HMC#'D"TI0?MK>,3;/'AAQO=;>B)-&^CA"E[,;F=!VX:Q8]"
M,I_-HCB%5;"-"+YW3.Y)$,V*3AKC>'X+4!3=:N!3;"F3M1/RW=LP BWFP1=P
M$["**R0SXOD3WX,%O7F"[5F2%'LDW3YFW7(\[ Y$!+ ?OH?[?YBWUT>JGW:U(PD53JJ*U!V(N(3,7 <$NIE@#:(I/7$E16)E/(;?;USOSR"Z%6E[*T7NF-\M.@RM=R;QD]4>*/#;
M/,3GL[8W=$'*93>XB8D?@CSAC(R\78^BYL,QBNXCXQR(M=8].[%/12\XU&D$
M?]OH6?8)6 K_YPI?[MQXZ@I749#U-&I-DYZ+4!B1FWB.S:54ZZEF9IO PL,+
M<*GH>5N1HYSB>L9I->_B2Y
M6/6S#1%\:=Y0"Q[N9QVTO*P54>>)-5#.0"NXM*]:S]S[^CZE1OL
MM;Y?S^GZE4/-7M\OBIE%=ZV\V]9ZAZU,7+=[;*T:W_4&8/N::J$]WMU6Z]UQ
M)JWPC'EKJ]PO/\X@3LZV[015[3%YFUGAS9NWAHS;S]8^DGW=VJ=D2DL3+1(
MD.(VY;QLR@^ZJ-@FVV:ED^QLL5IU65PK"J9Y;7>9+99%W6Y]SJRAL#&
M.RV<4$]'M@Q:-0T<*U?49:3OGEB?2$4Q15DN(SF*-XHL3>H8.#6?S/&="90P
MP[+,G63W]*(\]ZAX*TQANPR=;(N6OI\_E5'_\MI(6#W'-=Y\
MK%8W6509C81QE^.YI7)QA&U(2FYBV'Z?XXQNXA55AE/O628PGYXST' 3Y%88
M6.X+E'@KIHF.8[?=%SB=6['*XOUU*C&\5ZBIKS*_56 OE,)O%9IFE]8
M<&]SQR<4!44;[>3G!6Z2_/QFV@87G]S2"%1[N
M?."['7LYJD$L=E^-_83VY=Z]]:(_=P)TPR:QV.5JO4_L"E#E=HJE/6O7N\7Z
MX1BH%#]V2A!^+MB5"W8+)'M1 Y)U9$_7Q*AH9K[6=SIK: W\"8I@1CQL@0]?
M*=I>1R&14MC>6B0^Q(>Y.0?\_AE<$C;NBKN_NHHX25;3R125$APM$WI]9
M^^T-P(4?ENV!^^_IA\L_#-[_* JNP2>!6WW7=88>'WJ
MP9J* X"R20A>L4EL)$Q<[+)"&UJ[8Q=?239F,3S=[5W7.D;!H.)W14]S&H+9
M[,>>-<;>;LB>XX;N*0HS;;W=@1WD72]>]$3+[N_^MMZO^[@NW:L-YRE98P]M
MCVID'?+%->)FG2Y@_>_5CKP0SJ5*UZWWE<^!WMQ;-OE@=2^4!ZB<
M3T@,A)@'@933\>B)&6A#LYD9%"''C1+D&_$FR\*P '"R:-/R#(,+B[^RJQQGJ#@S\5I'VMJ2\/4_R>,"S2GQ
M[L(HB&XI.<@ME8@#TT$^=2]__?!Y<=Q1U(4>JTBQO1?R5UY??,G>5ZBZ'=]N\M[)M'']GFG6&AKE_?##=PISV0.YL),?_>WM2;NK>"(I8?*MB_*
MVT%7U0XZ\WTJN#;C?<+;S1CH#7.VX&S!V\\/$V\1E6
M3=0;F:/$[6H+QD]PZ\H$7RR<8$.4'<9;)G+SBJ]<3+V(5Z9><*MZ-E85CJN*
MPL:/N,_0O'IHU&=0
M%%&3R^A(RGV&2N,8;LLG:Z)QGE6=+TZ$,9<))WIB2&,#*=GY_A;3CBLV6"]Z)AE
M7.751L*3BX:]W+'AHWS/YLY=T171T$QNY$_!R'<71IWV+-YN9LW$Y1.'591C*KX[F]TC@"^=W6J KSWN/D58C$^:CG"8FN Q>/:^(HG
M1U4@"#OF6ZR.ZEA!6T"'5L#BV5" WZX$!&EE\$EO6TCV:+?+W#_ ^$[ W0W1(=%%K=,=P!*E#+!3<>^MC.#>5\,FBQ9G*9(
M#1<[ZE__3I':)=NRQ*4HU6 ZB6RQ6&<_=>HLL$0^&NFUN4;"Q/&]7>B;?_SU
M0Y:(CXXS^3B?^[ R]L'V$S>(DBPF=^1'V@TB]X]/\+SPZ_R9OA.'L.?DFL2W
M(V?E:Q0/*7RX(:-G^"J_J9>YIP.,$HV) /I$B&)@&(?J"8K[W3*2J]^ I4E172'#_(9V^ "*XO,P)\TDE!\&P^
M88A0>Y_/\0-9B9U'(H39^(&^?;CQ9$*GS8)"#W.)]+(X'W,RRO?J1]XE+&'[
M0;ZQUP'QDS40BGCZ;#%J'&9;.GA#5#7G6RHFS8#&G8#F )T!_Z08H\.T0"^\
MLAC5(IOPY09DN=<5$/.WA%,!G.WP$1;*9V7-?@>_ F5![2/HJN#;9*@1 %Y,6LWRPU&+'F]O,Y\P42 PC (;.?9K;T.6>8(4LF8W:>Y#G!;O"GLS0>3LQ >RY8#"<5>NY9)@9:7-=^,D'
M4B6Y^T%G_20O3.39 U\G.AVG#7,OM(9MF O"3>+5363TWW>CF!#A=W 31HG0
M#[U9SE_V @.U=A[&BR?'75S4!GYB:H[*@IWR*86"@CIL(418DM!!V= Z1K[-P9OQP'^^=A,9-%>& ]
M?+17'(W7&9QPPP!5[4@(P7]E)"8T5-? 6?*D6%*3.K(!+*FVF"5KR+A[R5XU
MGZ&R:J_ZPR%QB]O:>3B^"*Y&DWQ6V:J5*H')6WMRI*?%[2O2XK:]_//BWGAF
M) $=MR=7_H6M,G\$4+6.C.4.JK(ZKGPRUF:TN6B"BXXL3H9D5C
MS[SH9?[FB[F8ZRF;WTA*>T-$.]+>#7),A/(BPC_?[[K7TA>,3UQTZ0_'8A*ENYGQ@CW!O@
MOJA(W9Z(<=\0+76@B$@=X)[>-P8F0O?P%GSQ236Q8L"KE]@X#LQUE-VZ(^)E
M ;D:YHCM.K!4+QI/2)CD7[]- 69(QE$1 @B5CM
M2Z(EZZ:H#GJ:9FAJ5U7K3(>EGVAJ6I$>EN<0%GE>V7CLQ/Z?- 2?HT5PYKGC
M\T3VE*;_P$KC(@&(T 0@87']+U ;\C8\<,&?;R]=DD/OS$1N2V6'$9:Z,)FL=M91QK(WV;VLVBXP1?CM2-"KGM@K;@;6U
M?:*"+XT*K[RY\''AX\+WAENB$)B)5O%D\
M&\WB7SHIL(Z3NBL<6<='E3Q2M[1R%N$LPEGD'2[,_O"6ZJ"TKAZI56':S[$3
M[KY(Y[7[57L_C9X4-=31353M;35O)G$&(916!4AT=&F61Z%/OMTXD$4#XE?
M3J2:N101GC?<>(SD)ZUC*&RVGFS7T&S.;,<>%C
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M$>NF*5I:7Q$'>D\Q%-.6)MG10;G -\0V!CKA_X.7A7
M0RM)2)H,XFA\2Q[I(W=1#V"E5'12XBW + N>7A=A139ML:MC7<0:T@&>@2TJ
M2M^0%5LR46]P3Q_\5*TDU''^_W>6I/YP.G\E^5FX&Q'!\Y,T]A\RBG\ZMCN-
M4B<0G)P.PL-4>"31(_#ZR'?ICV/B",]. K^'%891$$3/R<<=(CS[1/_Y$ L?
MYO_>^%8N$*7#/!=M2?KKA>"2@":1NG[X^-N%5'R>.)XW^WQ0-*ATQ5YNCNV;
MB;05\MN[9G'"'C+Z[T7T*0X%9C@TQ5N[BG#D55Z?&L4W(0Z/ 7.[+Y9A%
MK)E93JF1@'O#4,$U4-VW$B]/HE]A#77)&K\TQ1N-X&"=MJ]!?7Z*3&M8D;EP
M)"'QHA&-'PKI*,H2)_22,MJM,&/J%EZTKK$3-GCU./,E)@&0H00B\+;<;+8'
M;/3N4L$=#94QJ);9^"QG>\[VFP!KFM*1M"8:+;.2#?V2_7LE,ZH9^W=#DI3&
M[_I9'$U(Y6:0]O552MHYL4,!>EM-?DQQG.CR7P(T8=76MBZ$3CYXR]&TVV[B3R
[email protected]&@!7YE'5G[/2T:VRKQ[J>D=L\K>!N63D+T.M8SP&A>+$L7"Z&BXC"  
MLV+1Q+&,^Z&L^*%,H(0?53B+L'YZV"ZJ..KT0#_=T;S@ZDS+WF4@=?L"1U01
M-.D*,%J#U21*4$_@8_+%:AB^8E1_# !#[#EYUY&9)''E+!3Y*,"&Z4I,G.*ZJM^KE#
MR\G6B]*^1N'C5X#6*Q[O3C\O:J"LF#C)>L5=6:5HQ@#WX9>&:.B2)N*^J8M=
M!9FB8?4'W:X&#]KRB9:BN;M+T28TDR5.IQUA JR9"D[H"92O)I22'> I^..!
M1LWR*VIV/06LSVO(:K(C/(:V:88(E%C7%'
MELNXFV3VYI$!)N#>SZ&)UV\QEX16N7 JCRF?9)8)7;_$R%=:VRKQKJ744H\*IT,U7J7"I8&^K+9 *339.62IX[=8Y
M.Z%,H(2?4SB+L'YVV%F[Q6:!%FM%(.V]43RNTJ.ABT5L=@RCGFFA[R%ZHR53
M7"3.6B14J2.C"KWXFD3BW8.KWE2--377*E5V\/I^I34UQS7O1K!GRAH>"1/B
MT7\MZL"$X9RQA&3!61WA&;AW)(R<)Y*7PL$BDYA,'%KNYH>"X[I17!2T/?OI
M2/@>^G2IG#43X9&$)':"8$J_1R;P&WB_#R3SZLLN\;.H=,,UK].@202 X'D72&K0 
M74?(4V*)$$W\<%:*!1AW'LF\[LHE2>+$M/(JC>:5>X(C#!T_7KYL7ME':[B<
M'&;X8A; )F@=UV)W%*M1XN4DL)3_\Y"-^>+G*@4Q:NR
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M%PVKUQ.EOH1[V.@KQJ#.HF'Z"5\*!>0"@$Z2-BFB21P]^@[VG"BX:\EKDPT_$K]<5Z4S5%=%-Y$5G
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MA%' DXS"1G=3W*[.L/O?_[6,=2AGI>?J'K!*^$
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M<"A0[EQ-.5BY7=_K;O.UN[SU6[^^$X? %U?1]EGJVJFG]@:B8
MNB'B?E<535,RQ8&M6[IA(!E9_3:GF;VA69\)]25IRLP3Z,='[email protected][C!0,,QWOFL3)3PYGB<14[ NVL@]-.?-U9XB@(GS=,/*U>PK)M,MKR(
MR@]J2A/M[]_AK52.@+]RCN<H6- ;>;/]I]\CX2>,/5)*3,C&'#73L9O
MK%P,&)_[PH :X S/&?ZL&/Y,CGTW?O*'.*29PXLRJ=A)^=S6,W.$T:5B8
M\_QY\3PNH[KZM'F^RM0X1GRB/6*B@3^L)P&N#H>U=.K4F"O]8F*T6M3AUD*D
M;8EG.[&+,Q5GJN-&8Y1;=;Q>T3S/.;:*E.-O&6T-<36T_2"#G^;O2ZZR-$F=
MHK/WT67HVV7GVP7->Y:=R]+%)U63L8RTE=+S=T+T>NW]["FVJ^_UO/I>?KGZ
M?@;%5G-Q.E>%V*3X^TMXE8Y(?$--P8F0A16]>*3HBM4?-=:*[P!R3KDM%%$3$8D3/PG
M4O1E^$;2J^&=\Z-.D W3QJ9I*&)/IM-AL*J(QD#NBKIAZZ9D2EV[U[U7)4F_
M1[F^,B\^:<#NZ["_ LLZT#.%D=Q%EINW!+F.Z5R-='H=.*!'0J\//YWD,RO8
M([NL77S2-=58 WU_B-YB_._A@Q\$Q&.<]S$P %;A5:\S_PYH-KI84'OQ!>P#
M\>R\$_UUWL"%F@ZRM#"4LX"MBN8H[(H%0A>?\!I&W@_>KJD+7Z,D&<31N!?1
M$2 9+#,;NP$&M4MHXYU%1Q>2_.Z'4>RGTR^S*!XPW_HJE!73Z>\D'47PFRH:\>'9WK.Q$^=("?JPR91
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M&2P!9RQF<4)#(A@I;Z!D)SAO')MO1U&1Q \<5=S;S,?\4
M%.'LQ;FG#:C&H'YT:7\GYG L;$8VPS2&!^?G Q;=WHM/*I958UTW;V[\_4$ 
MP$4_'Z%+0POMBV(!QV 9O_^LOP?8Z[A')D70W[/]R1$SZ2&R3Z\Q&[UAC\@=GX708U!_7I5+1Q__$*""_#RB!AJ<6 %Z$7@=MRS"AE\X%(
M'O&ZT^\@]%_"Q8'0 N/QE%OI7;%:!N%7@+IJSMCK#MP14&[8D!7.N!I^"5,0
M%?\A(,R>852P"*:Z'H9_'8@7AD?/3GK=8L8"@X)-HW^4^=4=5PY;^W_KB#H_
MWWZ=C?'PF;S+D_. IZR\=4+= LSXQ6;/#!IM1%E=+1IM+>VOBW 5T/*(U0:9E?1R6T4U'K_L">(X(+)
ML@$OVA+EW2!LA([CR"7$RW,=B@-J6V+')CUI;02/]P)F%ZUOB#]^R.*$7M;.
MV()!4LOTPD"6-@Y@+T*P>;8L3-9*]@N-VSD_>O!#GTD:4^D5M0V5]18<^^8:
M7#M31A,-9 HV4HRW_.X-2#9B2#] WA- R^Q(\G+H;<=)E4&D*+N"CT!V JL.&[0;Q2 /?*=<\\3#S]
M3*+'V)F,?!J/6Z Q%K Q.TISV C[*)-$O2)62=Z-!-
M[^=\[J9'S:#_D.7.7#0$KEFY8)S[0N="/*Z2A8WT=X=G)ASZ?ZQS.
MOPG7EFU_^?99_-H?W'T4S,GV/)WY6FV8,<2G<_+I72&'KB54:#, 7FM:K6K=DP)-]!GD$_(88<'SH[I<<=$2GN9_H2;/V_8OAO:
MFB :"OV,EJY4;@)Y"UPF6&+1 K>CSPXJS/; Y5,LSX8;Y8ZLE3$H^"P'9M9I
M-+Y?WE[RTU+]PMFD1Z=U--S$B !^C.'&ZO;%WMX8,V[C^[;*O&-IJ'(MC,7L,8C+!)>)K:._)&NG+!5-
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MI[+# V?']$I'4:OKW!'D4XZLXY+!7M;95XJY(Y>2D4XLU+!\TUY,F'+D@DYBW 6J?LX44J^
M*<]LXYEM;72"S(YJHMK1TH:C 1<^+GP5HT3K2+C"$TCSPG=H5NF[TC]7$DAG
M\S+"QV(BSS+U=%I-QJBM#W2$;%/$RD 7<1=U1:NO2J)I*UW%M%18LG\J&:,;
M1?(/NP<>^#GBA6$,,0)5J0L,LG3?#,Q?K2
M=>
M=44@'S;!"YWJ+G22E0IS?)LO=.)2P=Y66R 5N)39?LQ*!2__.VMN: \LM(B(^;X-+'I:^)JR"MH^F\,'!1&+AO6=]J
M)6 Z(C$M'8S)B(2)_T2*9P=13&#CO2R.2>A.[V(G3!QW-KTB_Q04LRP\&J<;
MDS#MDB$\<^?\^!J%CWU"5+;J# W3QJ9I*&)/-DT18U41C8'<%77#UDW)E+IVKWNO2I)^CW(*JQ>?
MD&3"#Z0Y!BM'Q\XQ'K:A4G#7G&OIL2+R_P_ [X2*Y)#.N"7+AD
M^4/KV8D]"[;SY*<557 .NLBT+%46>[T!$K%J:Z*%U+[85>'?^@#K [UW*A6<
MJ[WH:.UF479)67E6/YF-QT[L_PFKWMQ^S[O37=._9P18GP$":ZQ. =F8 ?)"
M*6=MX&WHGI.H%FUOFC=;A2*OL4;3FP-Y8W!72Y1=96F2.KG"9W"?W[+Q XF%
M:,C@WI8XS(UB&0VRVUQ9]F(\JU&UP8 8SK?P3T*Q079="=>ZCR5YK2?PPA]W
M9%[&:N&A7ZO/=Z0L>.';+HD
MRUWVX+04PUDJVWDUP,X^O_I#KMI:H]J8/LW<,*EW^6F&GV:XPN *@SMJ]>R1
M'MCXB:E=6H(+XCNWQJ[X\7/2>9V3SJ^+D/R";],T)3B".((X@CB".((81E -
MM:BRP4X%\SBTWB_BS>B
MCY65IS/0[/=DN@XS@1+>F)JS"&<1SB*<13B+%C .?!C*\+IK6)['5V:34Q3XDS?0B7,!$HX
MB[#,(M4K+*DC&3K76"RS(S?3W$R?'=.SHX.90 DST84F&E2_'%THVH (3R2I
M(\; >@B*K:A;&BA28!EM9QT>:[KST#7,X$2WKKBP.##((J'Q"\G\,!+3.K>*O-!
MZI^PHM7"616&*%OAQG'9:XTK>&(BKB!>\L^%KV6&KR5HY:S*6;5Z'TV1.R8N
M(W^&NVE<_)A@:>ZF;;? T"^EDZ[VY\+'WE:YF\9,8A,/F/. .;]3X2S"682S
M"&<1SB*<13B+,((2SB*<15C/[\ MS>_8&$WRNQ.[H_EGHP7IX\D/J/ 1D]0T9?>D1]I
M-X#??X)7"[_FK[M*1R2FZ\=D!*_PG\B7T(W&9!#%!(#N97%,0G=Z%SOP?I=N
MP J]_%.0;\?R_ITEZ9B$Z='X$9A"N^\(]U[59+T>Y3SA7;Q28$?2](,[57B807=ENO&&?&^ %YB(.15>#N*XI1^
MO>N$?]@$I 1(5R?B,$:X-\!]49&Z/4!O_@D
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M:GD8WH&%^KXE6'X.OTK4DV[!MU526^B=OC_L.X2@/627IIET.P(V?_#&(
M"5EUL,JGS014P"HE\!'^$(B*="DAQ2Q!3^V+D9((D/]!S3T
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M/L=1T@)FKSRNG..A!EZW_2??(Z''/J0"G:DY?Q4>Y6GWF9M%DASW-2F51
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M1ZE2D5@S89'DW4=*[HZ$%5,_4%5UT43E@>M: PLP^QCS8 OT9()
M20*B*;*Y=85?#X+JHDS]=VGU2=T!*7)UX;$N\KY?V9<1(B](O$DTPS MU ,/
M7T>FB >]GFAT>RJX^98BF4IOH/34>YR;._0O_+N\%1=D!4%UT6[=:VJ#Q@3_
M4=45N18SMXZ=9M1E&VA"E: $/G[]2K 9.3DM$T;3F]1R;F'+QF,SY,UO#.JA
MY1M7*5:OBS5;[XD:$%+$O8$A6GK7%DW)EBT)_H^[ZB*A&:EE7:4'/\[&QU-&P7!P?N7&=Y=BU$VD2 I209;L@8AE8R!:
MEJ6*NBK3)$)=,ZS>2G8#*H,@>R"CE"#O!ID7"12K^>W'8UU7=8Q6HA>2KDO;
MQ1'Z0$<6_ =XEB41*["V89E=$0WTOMX#_K>Q3:,74@Q1MVCTM(MZHB7+BMCO]BRIIVA8DJREFM].(ZD$-2<9D)-U0]:.
M#G;OXU?EM[+Y4$\>D"OK*+-%O1*/,D"O64 .T\L)'HYKI#BNU'#<@?I2 _(,;-.BI5#4'3$QN(0]7>SK [O7,PUS(.N+$H8&
MSILM#<358+WH24A1- 4W'8F[@C?=.3_^19SX"+QIIJ13EQJ^OZU<>O9 UTP#
MB3U#![S Z48T;#B,2RKXS,"EJJ9+"RZ%=5=LPLKN*MPVPK*Q; IV-#HU11)06_FYOW[297,#1"V]'^]\/:8/UDG;B2RB^B
MW/U\[L[4A*GR^Q2B_,Z"8DM9CY:^%]AU7"W;%"9WD>5Y/OVR$UP[/MBMGC/Q
M4R=8>07]DW:5[$7)P9WY:D8;DM>L_3$ KZ-N1W/(;R2]&A[>Z'(5,QKXGI5B
M1KNGW2XE\^*3)ILT5K."I%= 6\JU2O*O38S]'A_=;R'F=\+[SN#IS<$/-_$3\DMB9]\EQ0OIKU)
M'\-\E6/#(G7CEJ:TJR9:0V_5Z&G>D:@+NS0DCQ2I;E\"+$A_."1N.HBC<>O%
MGX9=9?Q^%MT#"TS9GQKPV4XW#2F*IE>*&?7>F+EILJ9JAWEI+_4RIWZ.#2+^
M!!SW1)+_RYS 'TY![JTD;]RV'3=]Q%=X2%Q1JZI/$BL$*A8^K^K6%6-;A&&KLA^1CL;(_*[^_-7\+,0\F
M!^G2_OQ].%)8LD!UH+=T"U3R'(DN&<(S0)B-@1+MP&[.O"JM)#;5*J9LO(0=
MMD>;-$&$^B>=,*%#9 EKVC[YK(&48@ 3'AW6#M0W-QLG;"4AR0YY(
MF%&?MDE0^XIJ*+9BBD8?2R)6^UW1-/H]43%MJ]?M=['@ J#FQJ%Z'91U
M.&T"4N?ZSDRJ5L>I- FSI,L]9%J2J'1[NHA-U ?H!UC4K*ZLZ5U5'G3-!@ZI8H+\,L+2AX.\%TO/0394F2&.
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MZ=^$V2OOKJZ+]\UW=C.Y\T^KVXFWFLR*"N[8'$D]Q$-+BCDJ'
M7\^>^V?_R^>_WU'@@EUCN^=[^-V9"GJGA"'9FR.P2QYNS1FC9L8 HX,Y6W"V
MV&"+G_P0S%Z4)6#_DI]/B4$6-LLP_OHWH6OU_O?SS=7W;[;8N_IZ=?-1^!_7
M)60XW$GV"HFSPY[/7WD=1W &3:<=81(X89J[)#0Y;4+O"4H@S=R&OQL=QXC5
M-D<$-L$-\]61K'8T66] 1E^ FAD99=E5O6,V
M(J7E[6%0ZMDHFX>65"@;XJK-_#!S\(B ?"FB<$<:MZ7E85CJM(
MY6:5#?7YQOT0F10-S9+<'XYH?8[@YF4XZ2REA=O9\[*SN(,,?HIE0Z.^*KS?
MHE"L652YH66"+1:&MF.B)CQB;F5GU_.SJ3^9'553V3:JE2/A[5RP
M\['=>2'\:F8X-]WG9;I_DLV.;LAL&^]35@G,^0C7\X-X% I.X2]P-^',W 0%
M=22SB<@9]Q/8]!-6S_@1]QF:5P^-^@P(=11)X3Y#9>JA>W5C]V\6A9?_DS>_
MDP1Y\D-(HL#WVN=5?(V<$,B4DD7LX9UT?"T]=<<^F.\GA(Y?&L[==OZ%W;#C"^RQ_Z.=5%81F!]MPZL1/M;N:XNHWCSG2AAWLXC
M9':04D;U6'W,PLS-9&6ZF8'S\\D<*,P\;V\OUX4\CAY
M6XQANRP=5CKJ>59T'1T(8RZ2_L\H_B.?8%"T0A><1;]T!L)A]1S92@FE,++5
M%@3K.Z96QE5>;20\N6C8X8Y-E;YX&WR),[IS1QAU5$7C1OX4C/S*$!0 L2CO
M7CLI,''YQ8@)Y=:^S'0^N:.8)C?WK%Q^51?6KS7]AZ3")(O=D9.0TD,>_!:A
M18$3?HO0/+,RG(X'\F,"[2.@2P0\%-_!#WW4"(8U]
M^).JK"R@(U#R\N*8/&:!DT;Q5$BRR22*4U@%5LO?ZY$G$D1Y9UKZ7B_.'@&0
M,?'R]>"WODN**F7/=Q[#"*!QX0MT$["*(R03XOI#WX4%W2S/HDY2T)7D<4I=
M03]T8T*U*)A"WZ7[G=*UX,E)''F9F_I/?CJE(,P^K^[GO$A(?_)X*%@*CP0 H1R?&\7^N8?5\9WE#N:@^VY'PJ2
ML*YOS?U  TE')NJ* ZT_$+$E]T036[9HRH.^(>M(UZ5^ W,_ZE!U>PSTH&-=
MG' ZDW- J_FWA.H]?TS9L!!GJJM>FONQ/O5CA?VI:EJ9^?$0"Q]RL[%3ZE?M
M'I^Y,3.ZY]A#?T >XLP!,RGSR1N:/Q
MF.S93=Y '0F7$8+F&6Q\\@:_;*Y"0DVY(S72<+CQN^;#[?=B!$;@)[,69V=G
M*]G)C:Y<1&2YHZN,]T7A5HR^DL^Z.&-+)G=4F3?C9D-U,MV[/3M6>XHS0RM93;LS:VK.<&C@E&F:^N->**MMB\
M[>Q'S+RW0Z!Z6)LK!S*==H6[C3
M)D,2TPP_FL [S_";\K@G4X:T>K4@=Y#.>."SU6KA](I2JYCUP$M0Z]XJ^PZ+
MVL%&&05JO>U7ZRFCW+?]:MV[8<8-*:O]:DL1V'C;"5RNA:>?:N^^RJ3M
MQ978WLH5=<55TVTT\0AI'4DJ(SFJ-E9I0S2<=WMBY?C.!$J885GF3K(-=%YM
M0U2\%::P789.,CHZ*J,[2.O,V.F-(-J*?\TKXIEHQE;/<:V4, HC6V4^1H]0
M1V8T$L9=CO>6RL51DA3]9Z(L'0;1,\_N:L!G;]09D"4X]9YE O/I.0-,MV%G
MQ,!R7Z#,D8\)J=[>#J(LM.UD:;;9R*;6++EU@$D=/L$#Q^*R3K>_2@@T2
MBU0<:(-4VK]V[,1_T'MN$!4X*8.<9?2E">V="GRW8R^TUV5 4OKNOQ,G2$>N
M$^<=,,<9[=U;/.W"EV(_R3ON[M[ZO/-N G2C?7=IERMW=9%5H)YG;G\.[+RG
MKS.D_323#BQ"'R2Q2WL&TZ*NASCO\[O2$3@ESCC)'Y_A)_"'1$CR3KX4$C_T
M@$KQ]+($X>>"7;E@MT"R%S4@8\NR+(DJ^I65V15ZO/D2G&WVAU]J?O9UO*\T6I5C59MXI+Q XD%S+LS<^[8
MY [>G9FSQ0ZVX-V9V0G@TD2VDBFP'N9K\4M86UCM&(U+;8[GT)4R=\
MI&,!9S&SU^/DW-J=IK5#4D'VN/5OK;<&#K)]V9^@2+4Z)0G'NP7E4]:X\I@3CI I8ZM\J^[<4=6:FP$+^>PI)6
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MU+HC/)#2>:(SK9Y(O!/T=.'WI?_O?A$WR1IDJFJOWY8/K9<*B&/%/^??OWQ$ >>_Q'$
M,@ ^3W\OFE]XP&/]Z 4G!B
M=_0E=*,8A)7V,"N6^_7#SK=\^O7#?!LS@#^L0?PKU121M[+IU(E3&];]1)$G
M2@C^#VLL?KKX(@F]E:\IHH+HTM[*EW[]L++XKQ]FA"N)BDC"NMY&*OX.VM.Y
M'CGQV+F=-YL[2Q(BS9 5U$826A,P3>=*/,4TE1_T;_@^F\2CRG%,;E/ !'WR
M:U3T4RP(./]2#YR5J^&M$Y!S)2 R%-QB MX2<'S"Q\\D)+$3@/M@>6-PO7('
MTW\B??"!P^3QGM(?%
M>1(/RZ;$J%U\BWCY35&/UI# ^?-,94_23$5N'?GRPI]X^O%+_^SHA3&KAG /
M>GV_/1]Z80/H)4M8TQCU/!?TZL.Q(9W2Z% 4TBC>BHKL%9>(-\0CXPEU:^B9
M/GXZ.UN7$Y,>(S1&C_%O$'/^-?G1WPFN'=_[$LY$]TS)J>G(;#4Y;PAM)$^\OA.'<'(\._=T1D=5
M8M[=>9V.=-1&%-ZFD?O'F9%0,R6=&DTL&XR>,.Z<']G=B[FT[(ZATAB8=1
M/'9"E]R.G)A\#^!-&4D-S,70=.
M>/<,BT[_'XFC/LTAHC]Z@[![O__&"1_)NN3_[H?^.!N?)>L@7=4Q6F$=I.&6
MZH"NDQ#O<^R #U4ELS@_.+.T5,_4SRSGK%D4#*JD/R[*?%R:E+',+FY_7ZFY-,U56JEA5^0[?0>RM[D= M0D"\AR^TR,NS^$[ >+Q'+Y6
MDX_G\+6,7CR'KQWTXD>J5I*.K2,5 ]A1-#5'#Y+Y?7$5E$-RW93C(=TVTJ^E
MBJDZ]  ;O\#?^45E*_C[\(O)8WA;88!X,\I)F'J(B)O
M.W'B=<]<1:K,:$QGE_W;
MY=P5Z1=W(S].":GX_ DJ@8/&UJBB()572
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M(Y"_7=_K
M%I&'YWBQ2!3>H_K?VO9
M3Y7#S-N%')Z:-NL"4AUQ=G8!64DVA;\51N]W2^\*4FVFZ57LD?@JOHXC+W/I
M=KJ.^T<0/5;)/44'DN:XI[6IRLQQ3UUYRLVPS)FP",.$>:&;T*HET!19:2.A
MWM5=J!XIOB%!/K0C&?F3ZIAFT<:H0:9IJ_O $-/4[C@TQ3UDB0#5LOI
M,GWWV_MK25FO_L(O]MCI81F
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M2MRR#\C]ROZM+5+Y9^?C-RK5M]EA.6%VB\LWBXS>+:]NL>OQF
MU=HVJQV_6:VVS>K';U:O:[/'*X/:=($L';]7J;;-'F\2Y-I,@EP"%]3'!L>;
M!+DVDR ?;Q+DVDR"?+R6E6O3LO+Q6E:N3\L:QV_6J&VSYO&;->O:[/'*H#9=
MH!QOOY3:[)=RO$E0:C,)RO%:5JE-RRK'.]Y*;8ZWJU-NUZO'(]7KQ)"-ZE]4W1ZFJJB+2NCL$@-&WZ%)PY8Y. -Z[;9UR13$W5#ED6LZ%W1L) NZK(T,/JX
M-^A;W8+_7L'P 8L[:EJ.) !;V$>^9 M ::(9JR@2T,GTT%O2F !RQ2QX9?
M8>A#5CEXRW;/[@\T!8N29.@BMKN6:/21+.HJEG3)!A&2K.*Z\Q6./F"1:C]XOL>L$BU&U;R"^4C-[R^2+4;QO1=KXC= 8N\NN%Y8L'Z"^<_O<<*UDUL
M+F,!^V0=S)]>WT!,DBB+7?K3,2#*"1]_NR"A^/WVXM/G*/*>_2 08C*!K]%F
M04(Z(H*SS'<2HJ'@A ))4N>2!!-:*:7
MD!)GG.0/S_ 2^$,B).X<5UX&N)E>%BEC2XXXA$\P:AN?N/#F')]I3#'H O&R
M(*78IFB,R2-MRQ?%4R'))I,H3@58*7_G*H;AG5Z\\
MAE&2^BY\(=^"(R03XE*ZPW)NE@BP[QE_3H4T@GVY,7$2(I A?(?N=9JO-)GE
M7S[YZ91N?O9Y=2_ED+%:<;>\?P/+C0OR18+K)*,<\;Y'$[XH$1?T%5P2TRYN
M@"$BIOZ8,J_SX = :\#N3X"H(/,HM8((J$YWD?PL+)(N/<%)MQB$"CV5;7"18"H\$ )H=7RO%#RJU8K#M3,MD#AV/$)!W0(3&/,O"%TJ
MPABDAO[TF<0YV\.JP($YY[Z*X5?QY/F).W+B1U(2MJKENE^X]JA'>VC5,#WTVI*DIS/PR^$)."
M))2-P7\.J(JB>)G]O-!V@)\0,/N8@?\VD\,5=58X?KEX.W.1]L@#I4R2$1!1
MH.V>.+7BN3,_C*/Q\=FLT6N$<6+W#=K,OO%AZ+BIN*11SJ._7:#+C2,5?/TE
M9_]8P-;27D\)*ODDH3I-#L0G"95ZDE!I)PF5?HI0G:0*7,D?/B6H3M((RZ?)
M@2=IA.63-,+R29HK^33-E7&24)FG"-5)JD#E)%T+Y22-L'*2YDHYR3.C$@EQ ZX,&OT.KQ4H@UJ\9"*
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MFI$^?0A%.)Z2&V_$QO0-N:6*^204Y+>3WA4YV&L3,M)Z;]W<+#W-O6F%T;"/R*'J4>GDE$-I8D/2AR1@_WV^^;^
MN^;^VWY[_^[email protected][W]/EPXG4\F'(TV^]WZ PE 2* Y);Z^WE[+J'^0F% I*
MCR=43$DG"$@/J13I,<7D'?/W8J;*&$O @T(=-U+VW1_NA7+8 A'MUF^?KZQ3
M&M_]C=BR1P^W,N +%/@DH3EL<:$T%1Y+D015I(CB16J_WAPX>6
M>9LJ':GFD-+)K/R JEM3.GX!8MK@V7;SL+U(I:<3I@K)S)MB.NX%O%$Q";Y9@I:X8TH74]EWQ98)RCU53&9>(54[1Z6X5TP#+Y90Z(E<0@)O
MLC2:RB'37^B8J0GU6(4PA-9NS(3^%,KQ&1O0* "?_!G1@ \X\QN$:BWY;:39
M0H%(S(O\A%P^4B%";=HM;Y,F2QC*\LARSR"ON):_&2NP1PO"@SA%=S'Q'$)%^%$0NLL] J4<\V6
MT\5/$T@VB-0-J&S"ZGKPB0MH]3D-NJ$R^IP&5*DXNA"S'A#\49+ #2'THF3&
MB&#?*'PFL,^&*Q4&''M4GYS0 /LA7PN>2>;H8OWPQ-W[O5\$/A1 CI<:O+'XW(VBX1F'@
MP\CQ_,\(LH^.\*^A(9,XA(-7X'6H;K;^I;#U>'-E+F[H?UP%^K0"_R16!9-1
M+<@G5H$Z.IS1\2743/7#63\Z]_2U'%+!_S(6S<& &T"[F[(VU0G/B<^X\H)0
M19+UV8,^"4+O6RJ>GE"H._S^A3GYC IN3JCB)L;2PNH06C&$+L+0O^=!L&HT
MN.C=P'[( INPJK%<$@'&8#Q;!JVM6QSCV5?EWU5XV.&S;$_WML$DH-M7C5-KT,
M'S?*;Y?VVC'O>CI\NWEWG]X&3*V;?<=/]HRM;KV'>6MI> >/'>+@!SDV2.5/X&O%GSN4K
MQ,5F)+FC)S<3E\_KZY!Y@@2_0EB4Y^:$_F#Y%%U!LE\'0GS%->;VQH302!=FSZOB^T8P&^?UD*Q"ZL6O$DD6\6W5,:
MD%@%LX#Z^:(.J^<*JX*=<]L6X@ZXW+S?E@)N<6=>'8#/$H"?F<_Q'^U"JC^F
M-V$0F?YG*X&X5)@[('.3DYL/R)EFQ*I&9KK5<;E3<;G]UK*<9'?$YN95GS9B
MZY9U!R*X,]'\;KOM:4:$.R9S<[^;CTFC3]UTKAYXLPE^IGK,"X>"_\7\LTAR
M,>PRR4,_&T:/$[B#(C=?O+ @,&=)+$]BF=; K@%LJ]":GW%H(YG_A6F+
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M;.=?!\:J+4'OYBM^/0=_'VO1\R7=$+LF48&7 1*XU52/33:;W
MZIP_X&4NN2]/Z(8X/^N8JL78BB/ON/-.MH-J-#03^/!
M!Q-,J*[email protected]<09*;&9S'#<7'DP!& /89E1[2NX\S
M;4ULD\R9:B5L$P8YZL7S4TT<9?P7:Y5P&$DV.&[@R:7-Y%3(/S >'\9!4D1S
MC5).YWP(,E)O" V"1FMW+5^$L83A0%!@^-F,S0NQ.Z"W+"AI,I0M,/D*.;P0
M:[/5O(310%)@=/H*)IQ_!=.CZB"@\@W7)4&9SBP5:
MS7@UY[RJNZ/PD.527DE3?K&$Z)8/Z);V^W4T64V+U50H/ *Z;%0D!"CT7>5 
MR![!O48+&>\,QAY^6D)T3F:HG\^.!SH\!QH^-Y,L)]-)I!'J"OQW]HCCXX8GF<^AK18\"/"#S..&!HW 0Q$P
MY=J,S"YD&$T2\1S$+K$^-6J_'EQ0+JY%8EF/:O9OY@]9VOARY5^&[0O;:#\S
MW,^4-K7PM;7,_GC#D1^.P0-%AEFE7'9MP(#D"T*S1]>>K=V-I#>"-*T+"0'K
M!$%<6SK^?R.ED;0?_AK*;UP,3^F$ZV0OO3%X,^RV![W/;C>$?,$WG7B2*??C
MR?&^I$(-&'2D/G!4JL!)Y4E?1%TH,&N^"_C2AX)\P%%&B0WJR2$$UP*:2DR,
MW.[;I)RU?6T'6OJEN/JK@ 7!6/VZ.+\(Y)@<\OH&)J
MA2OM)D%.!V6)LB\AL&(S>LQG=EM._ M/>4L+BKQD W-=]V,%=ZD3+W^HRWP6
M_@JJ-BJ<[IC6Y)/&'^?WQ?!%><0<3+*F-V(>3^P)7Q^-@%)ZT:W!HM@GR:\2
M=0I^WZ@3*Y4ROUSQ'<+\?#P)PBG+5^7LBUVJNHEN9FL5+IOW[^'E]'!"LR&3*PYK-FAC%UABJUY@SOS5NIK/4IT-*!YOR(*FU^S2
MFB_/3TUWE#G\UQA4GF0A"G7R_/E06O8+-)]"R?A0G,93UV8,#6K9?2SF+LC,
M.YPPZ,_P0\FK4 QQ[NU3)/!77M-N>@)A+V)LOSE'9.P'CVS%WT5B7L*T4NP!
M7 J"P7.NORA^O4L]19=)DR:"7TR.;,?!.4/$=5WR^-]I\N5XTW*U,N4.#G7*Z9X>T
ME:AVQXKC_B4C.6'_^5)WD9ALY&Z14LS='LDJGS;] 7
M#E$VRW;7AC$+'^Z=.C[<*^&?BAQVUQ7SF=7%N==\M4CG6[.'YKR(Y"/4$G[;
MIKC==7+FT^]D:B,^6<4>Q'(=:9R>P)%34>*T"68[E$NM;$XVO5J7T4YF7,6U
MI",A9QJ:S97QFGF*SK#(85L],'TJY\2JEQ986:
M.HE_.N,9*^JJAD,O<&>.VHC/V'C,$>#ZAS%WJ_+9@]5.'>6G1:X;X)A=M-F:\/5_IN5J8*M)?10-C
M[;8S1MO)8!Z3\!J".(Z>.$!0BR=)#E<2^_K\_<0I^1K"7U&38>NR6F*\+;.Q
M9KJRR-?DZ*<,ZA?8?MP^;NWMJM8N2ZN?1N9K2*N+K>XQG.+';V1"89D[07]/)Y02E?3K\#Z//N"WNJY"S
MCS[Z].&$"3;@6MF].!IU@Z?=T'[LE9XEKDJX]NKK$WP^L/BE6I_*H?GP9<29
M/?0V%RAE"=+&)_ ]&>8?6_;#6+C\'U!+ P04    " !L?Z1(Q;5TZ4P3  !G
M0P$ %0   &EC;'(M,C Q-C S,S%?8V%L+GAM;.U=ZV_;.!+_?L#^#[XL<+@#
MSGFUV[T&VUTXCV8#)+7/3KN+^[)@)-KF5:9\I)3$^]??4 _+#U&B;KW6]<^I=CS\*SUNX,]S%" 6X_HU:?^9-:Z0IX3>BB UEKW
MA'Y]0AS_LR7^=UOPI]\O^_>M\^.S5FLM=\?GY\=O%[[I^R%U+UIO%OYTQ7#M4]_:)^^?3P[
MO3C_\>+MN_\LEO:G,T9&XZ#U=^U>*N/.6;/V#U.&O42N"W@*.4?CA80OCXQ[]AGHQ/HYLU)6O#HN[^T
MXL(7KYPL57AYDQ8_._G]X7[@C/$$M0GE :+.4D716%[5L_?OWY]$W\:E.;G@
M42OWOA-Q28' EK2$^-1.B[7%G]IGY^TW9\>OW#WZ673X$_,]W,?#5D3#13";
MX@]'G$RF'CY*_C9F>/CAB#@>$YQ_=_HFKO_]M>^$$TP!JGM# Q+,[NC09Y.(
MZJ.6:/=S_VZ)?.+XU($VB8.\2(2"1!Y/1.F3P@9/=B6W#S7_& 0@I\X>HCA[89B@_:#,0Y$*]4CNP,%-\$=
M+\",@A \XUVAK#=8.OX+OZ,N8=@)=J5YO<%J:'9(>Z&7P1B&$K3#GP*V;@KI VZVQGN->$.Y[/0X9O?=]](9ZW
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M%AXP$(MGS- (9[H>)D&DT./.Q539%>=6?=8QGOW!9^BI!_]7+)#K#=
M#NSX(_$7V@NVPM'\O7D5O^ZJ,]7[J1 <_!8P\A0F:AH'??R,:8@O9[?8'S$T
M'0NZ.PRC'=%MT%%M\.(EY2/S)]VI\+D+8:\9J&*7M4'N,1_Z#68]#]$ YHAP
MZ4R%LH,1J!GZAEW7QH)K/&78B2T1H>@F/@O(G]''FCFP6<^U,>#1#Z"+: -1
M,^#BGJKQC7[R87/TZ,\]WW/?)>^R$:()?Z]@GOD><5/>]\#L%-&+F,ZK=BS1[)JYN?J2NU?M84]:01Y2-Z\O!V9N8N_=6-.,?-7/\0*W9J
M!O9:!GZCKNOFP]Q)4?_(%W:E$V+V\$^]J"(>^7S@$>$70H_4P_-HEIUC?JNU!C.K5HDJ!J:
MZN;< (_$SSZ>BGT*'=6_-*CT: #J6F1"O=^$ TZ6%BBR I7N$
MT/0$Q.:'$^P%//V+$*0?VJ=G25;>]\F?_^@XCA_"&,),%4-T%3(1J$Q[\M 3
M]CX83"!/9W@"C$V XLNBJU*I$"MKA94F8XJ!+!:3 >MUWB(
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MX47\>6ZJ; 6W:#NQ%?A'%P,UTEP)S!WV93:^SIJ>4K%@V@=?T:
M:"TYT'-O96382,+<:\7TY&MS8)N(>4:6.2@NXF ^ )F74BVMH(_^/B:3IY!Q
M83G/K],J(#^OO"[J!1L3&F1G:]:*Z^DM7<#X0&JGF.PH:!7.1_+#<2KPL/.!@[,,WSU D.IY;F-6['PJT
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MNW@U[ERA)D_Z$&EL;;55C,*WD]FTQ5I(6S$"8+D@+N8[*V/+JFH6J.$.E
MO)X9:.(4M#BI=)MQDM4W"%UV!*#0V%6M;22RK8?#E
M>1J[-&H0'^(@0\5\4&W4(#[,O=E5\D&UT28=27H96_*PBZ*'45I<+^U13OT=
MYR&0A-7HSZFB$\.CWW%@H\SP9?(D&^:W3"XXI=6,P"*]XDL5E;P!(_#-@P7E
M2;IJ=35=Q^A@[$;1\7LA0R4WPOF#F$8]E)
MBO)ZE<2!P.@4%PS,NL.5P,[*M0-YH2#ENEI22'.]M+*4T?S">I,%MP@#+5T5
MM*/Y9N7E$C4Q3=GVM_)09TU,4]XX9O):^!4X99*#EQ1343;,0W^8/BUG$9JY4&7ZIE2EM-MY3GHZMBTH0M79(M_(:\JIE2>T4C>2T^3J9Y1:#KWD./@W-_<4*68!BQYC:OAGRRI7W+;
M>\.P]1,K5MX2OS?1RCL-8^4=\QHFHX1I]D>;:S'%Y@?^K'RX:4^8U#/,8A
M2;"5#>)'GX& TG@E=F:/#%&.G&BFPFY??$KFK?O?, ZXQ7>DB;>?DJ?A/H;4
MA>MR67]_6FXA+GA?XQHSV*N*:U/YOT/DD:%X#+C#(Z[XMU[#'O2;<\7P>,BP>,G@AGKZ'P#)2TCQ9
M&(LG0F/'0_9(X1T%%1F/O0&T#H0&QX0H$IDUW]$A$7/1L+O<6P@26MU
M06,MOJ;+08JQVQWV'FYU. UR^"R2E494:(H[%S0I&1(T3^
MQCW;SM$T>"$V8=F768!Q#ZPM)<%V'F>9XOM0L8N]V?D
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MJ/YMA'W-XUSN3;KIC3K7^&D?HE[,TUFRXFMG0(-LJ":I(_FN0/XT9AK[EHR_D?#?/W[4>W\VGA
M0QJ(Y;"1G6\76SH>DI2T;;;/6K.T%MY=S'BQ^$:% 9EDBT_!&_I,@> ==4!$
MHHZZPT_AY FSY&%#'C\!"6(W#8.DP"7BQ ')NB9>&$02&Z,$IG>9"]+)9E%=
M'2EOOT7R"X+_C!D:X1A+0F@,J!L&'.1?/'62/0LC\2YOVYH.1WDNK=VAC-I-
M$!>T8A#2->(B.=T,IZ0-K:O,E@.[N'ILR#$KG?]UL4E%>>P6 ]";ZBQP/2'0
M\IT7Q%QC5ZEY2O8@\)VOW8B#R7O$,Y/(>_"?HX>![RB8O5\P3T4GIIB;0*HS
MQF[HX>YP1=ZS#'=8W"-;,:99F  FT)VRN#_X# 3VX'^#QG_.5+';07P>)G]@ 6N&W@)&G,#'W<)#$$BYGM]@?,30=BR8Z#"/CB$V>_0/%G[T[
M;@'9TD [,-\"\J_QE&$GWA\(U3#Q64#^C#Y:0/VC'P!ET;;8(&H_^0'FC_Y'
MV"[!Y@MY\Q?E>9>-$$W8>P7R[7O$35G? QL$RB0;L9S*&1,>@<)+L,*_&@@Q
M]8!83^UC'/XVC^87R#&(4-&.]A%IG6)C-8
M2JNQW,TDH3M/
M5W=W;_[CW__YGW[['V_?GLWG9]>![R//0[NSO]G(0]B*T-F3]1+XP7IW=HT6
MKN]&9+"S>]?_X]D*T?\^H_]USL@__>UR?G]V\>[#V=DJBC:?S\]__OSY#F-G
M/^([.UB?G[U]NY_M>TK7Y[-?WUUQ+[S^>QCX9^N,+*2B1U"T>>S
MB_W[S\]?7C_^>+?/G_Z];^*K8/-#KO+573VK_;_(HU)2]+CX]G\
MW?Q=@<7_>?88^"%IO=Y8_NYLXGEG<]HK/)NC$.$M;C^;[AFW_^I[.T\>>7T"UU^/EQW_S#^=^^WC_:*[2VWKI^
M&%F^7>I(!ZOJ^N$O?_G+>?)KL36APXD.S8MD_7*>_IBV#MW/83+G?6 G,N5@
MYXS9@O[M[;[96_I/;S][#?K]3>BN
M-QYZD_W;"J/%[V]%H;MPD=.*>LZAA^1C9F'4;BD$QH]6***CR.?LCFC#-9IX
M$<(^V01;U)65TP&ETWQEA:M;[email protected]$==:7Y=$ Y--ONV\(LCRNRE*O 
M],R=)BJG_)3\@/B;Q2 79E26RRSNQ>NZ'M!6&,T9<@<'ZZ
MGM=..YT.(Y&TRSAT?12&1 +/KI^HO'#B.,D'9WF=-6N+>20R]QBOUQ;>3122X5%(U(KEXN^6%],_3\(01>'$)GL!(X=LAGO7>G8]0A0*R6_D4'"FB]G7
M+QUYET8&0-&453$,.4D^'B03^!4Y+OU_:T;4T=IZ#+PX^1H@"(])FRY"!+<=
M^0B%)M[)AE@IH';F$442!98>]\2=1>$STLAGXYNA#M3U&
M@?W'=$/'G]A$+Q!+7I:.JAJZ#Q:^!MO$*[GS'P+_.PK)QDCDF4XM3>4V32.3
M-7N%G-A#T\5?$8V7D6VQ1=A:HES7DX\@4>CIY/13ZO- _=M69_/-(9([\*<+N@HA,D3@0/3-]O4CIK.B5J(9D+R^Y;D/I?8OFKJ9%'+Y9#U[J)V9
MV66^OCFN"#/WO\2%%YJZ;SD<@A3]KWSM5"KY[&65.2;LF^<;"_NN
MOPQG""=^;%\+RYY'&8>]+&G3;'USF^^DZ:+H#LZ11YHX5T$8A0EAES3.-+-V
M2:^^5KTK-<"EUP)_GDS"5C8
MYA4"(^=LG\U&D\U^261CT7R+;. B9X=>KA^=.^[Z/&MS;N69%7W00Z:B^26!
M_]9!"ROV(C'J3KL/0VNPMER_-:EI[SXI369XNT;T$D:0S%+7'FE31\-
M<*6D$OY"9+];!MMS![E$6A\^T3]0I?;I[?L/68;HOY!_^C$A4SMT^EO/6NZ'
M\ZQGY/W^YO3W\][IN8HQO;&_):K,\OZ.+'SC.]=$X560QFS:/Y7[-4OG3N^7
M;\F_A15DLML.32>5$1^5>_*-H3MRR-416ME<";7)&!44E7\_T)/;'!-_)_I&-BF7VFS@AR?G\3X1CE_QCX$3&9;KS$AR$F7^K$O#G;$!6$
MR:+\_N;BS5D<$I:"39KGTI=(CHQ:&<))%=I>(._>?Z#BT)JS(P,Q9^U">]88
MIV3.XL?1L'AB .9,?AH9DR5K/&?S%^W9/#I&1[;KG7/Y%#9>5H2$.7DNNW9[/$Q,S9^^]HD4\B2,>\\8PB\N[<^]A
MB/+SVWDY/-9[R(RS%K>U8;^PPN=$T''X=FE9&VK=_W*.O"C<_PLU\W\IF/G9
M/_^8V'80^U$XLW9TZV2?Q)'-W]"XO4/2G>XYLI&[I=0\H(B/^LHNBG@@CH93
M*)YH9(#1'@;U-(=7D(%"%T4\Q.LXN9!DU?O>!V%(]LET0>AELR4TBA).#T48
M,\NEE2C6QHTLCY"Z#OPDZYK%7'-')?PD&9:9FHC;P(O#38WMS=%?-6?^I7-(1!+[_T
M(?AME>G8-8V4X]R=%3!S^'6\9Z1GES34"F]
M50G*C$9JZ.2TF('8R,)6,3 [^)M/U+9':P;]A(AF3[:NQ_!Y*?5W0S2EH>&^
MXY#?\!%>@I\H.Z6"LRQ1G_AYSY)LRS\!T8Y*0X
M<>YK,VN49\;)9+7V8#EP^D%5DIQ$3NL<[)Q1>,G_PHQR>58YQ_!J H0Y9D3X
ME,N3\0C>*^/AMNI@_\'OQ.NL'5*R?Z$5G<3WK+N9R
M;Q6N#I;$>WWH :YN[L)^7>N<=[AJ6M+2,_(<<@G 5=S-M^I5WOMQ/4^NLN$Z
M>6*^/
MBKRH$\2@YD2(LJE<3C\8(4J0F$".KSSS!89K0_)QQN]5Y#PKLB8;D2#JLV< 
M8T#P+*:(NW=:U 49UJH=CSQEW) 1K\2X;BB=A(Q[U7)Y1?$((*-BM1,!3Q(F
M9)"L=ES7!J$-+HM'#^=8D-U3-*N;,+)1:GTM-+HQ 3+T*8/NBY16INC8*'XFOSZ2:V4$=_7/DKI]C'-+]G"77UY)?U5XE
M]J>#L[,)W8\'A>>OR%VNB!DXV9(E7Z*'F :?
MIHO,..2]FQ,=!1"G)\0UZ"/A82#S6N?GB(VA+B9:&YLHAT79(20=POC
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MY?]QC3:TD._XJDJDIXK;@XGSWW%FB#P%1_4T0NUAYL[*8ZZYA)=Z&)DBS7Q8*"R\.R7&
M6;$C#'ZR%Z;VBJ[RI2EN'KD&@\'W_K&T-DM9U==4Z1RNX*K"A!7.1-7%+6,)
M.@ZJGQP:3G1)@P.22WKG+GE_\ ZJGQS:[0_1P0')I>*:H?O^X!U4/SFTVQ^B
M@YLJ4!:5Q*=/[M(X;Z"8S=72GB 745@F0A+BH[^BBTH>GH*)_8_8Q>@R#ET?
M$0,T_(+9&Z>Q&PA>F.]K\G+%'@ $?X<+^&:\!KZ^2KC"@8V0DR07WM,]E+\4
M4\T)L[UJZM/ N4'8=D,F9DMS/REY C3Q8HOP;KHX
MNO@_>I&F*E6 NZ^2*NS*&R:&L!F-3;6[7D"U'(^X]IC?5'JBF?,&48L!$\S'8HL!A$9;QJK#B4;0WV/+-M"A^J/8385
M7_:I#I4D:G3\<0Q'>=T)($DU9V'FTH);^SN4M$1R.72 -!#/3:F71E7.F ZX
M![+E4'D[K1PG08$@3M,M="@"DRT%OB0-'9Z*[V5_G"93Z?"4O&Q1G.0XZO#$
M?"_[H2IU4(>7Z'O^.!CR@&O#]F5=''*V=7C"O@'!M\F&^O')20T$P
M<"WT(;XX9FSQ(URCO3^Y=,T>SZ4'U\J7F_E;M:MX,L5R2<&U_P>4U$E^8"X?
MN*[!@/*I3O_*A0378>A12)Q):MTS6YT$T_*2=
M+2Y!&/W)L$JY=
M!1ZA.$QQWO>9$S1\2WZBX$Y(GLN=".4O727*D?JOBS3
MO5\',=K[M&!EN;^)(H8%1P5RIR&ARH"^U9#8%>Q+IP[BX!E=2E5C-M\<.6B]
M2;=F2/9DM4[CZ:$$43=8KP,_V4*UFNNTG6)J4[CX=-LWTUQJK8CRX[.+>!O3
M!=FM;.J9/8!QT #+P=/3H.*F)AR55> 3!5=):'U;+:G^<6$PQJJ#XI4R[((!
MPSC'6+;U;8"1N_33K%-[]X0M^A9@4FG2/R3C5___.IV-4LAN@&OB;&^S9Y-#K\?['EN0L:8YB$2>5>
MV' ^=A\7FC3$E[B#B#I,!DENWWR,R +_B9S_##RZS0N@",B.<7HIAHG'Z"^O
MR5_]9>HPMI16O&47>-)A %X7K!%6[J7$M.^S)P=:@2%Q398-ZW#K7E:F57Y9OK4'@V;C#&3H4+K>4CJU%QPZ5*G71K*/.#V^,M,!DXN;OX;$!AWP
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ME^=6';D9V.\3O6]2?&_HB-^1.QAZ4
MD3B SZZ?@<[email protected],E9J>T"A =R=MM$R5M+HF*^!_2(VS\:%^X/
M>7[N> :34H98-7=V5L^P:Z.)EXQ6.L>>@K\&^(_\!8&JKU[*N"I7MJ!$KXC>
M;E?D-QW;SP4
MH5PQL/81OV#[F'PLT!)0XD.,$^HKKE?.ZK4\"; -$67_>'4=U!27DX/NAJ?)O]=&77U%>^%
M%N I[ 27(R.:7^$PA)>[PM_XPORRI.%EXBZ9RL7;1-;K?+B4*2G
MNF G=ZSD4/30H'#R? NX@7MQINML$QUJ=\0YKH[ZJ:_=X4J:;XB9%0/Y'))1
M'OMFWC;R1-BJ+QYYM?"(;R1%A2=F'NIP@2DJ@:[A)!UN.WEE(N)^Z7#KV8KO
MW*53?]\IF45>FT^')'4AQN5<%.B0O2Y!_?42Z]0AX[VM[$3OT73(:._Q&/T 
M((%], GT3(TG XB[1/0GJEBOIBO H21S4>)2]#( JM.;[8BIAA
MD:.CZXS\,U)DN+?(_A*+,TI+"].3]<; B6@)CMYB*'SM&>,?-4@+?(S7:POO
MIHN;,'*))4J?E;^U7)P4!Y(_3\(0Y;;5Q"\ZZ>2W>(T3LV=R
M]DSNFLE=,[EK''+("K__1,Z=0[:DNW#I0<:AWK/7&4MO;O+*2>:DVLLQ 0:-
MTI8SC#:6Z]R\T*ISM']",?UM"/%RTS(JJ9-1$-E/I.?@0BY./1*9%G](HY;A
MS-K5)&(,2\/XI)Q\ETIDF\ZLNT2O47I*4[3J_,>'(#VI?=9+L\E_X+9KS,V=C,YXT#RB2'2_=F'@3RF)-%3ZVE,J:"]^YQC2BH=-B ZIJQ4Q0'\5Y+)VF<$>!7DCTK)Z:F/EL63K+UJ.WV=E5;JI(_@5>XZ%7V6[M5FJ.6P N 
M]4NH-YG-FF4VCR#!=V91XVB%(CJCR?8UV;YJLGWAW=N_KHR'*V+;!&N$[]TP
MJD9:JVMI[L1OJ<9']^ZVN)3INE_NOEK_'> KSPK#&ET@,@(P#G/J'JQUO=86
M'>75<-H)BPM*OH3),3 Y!LTY!LJNNTR.@,)@)NDC=8"88
MS 2-I6PP$_K(EKU2#)AP9= 2!LT=X+?MVE=W96F$4S]32IR&H,0)==]-8T"0
M&&"G??/)/WC(F:,M\N/C@[?WZ33:9:-!U##Y3@!S9$R^DV;Y3J\'SV6,K\U.
MZ3W'%).#VHEM2LRE9?_A!Y3Q@16TW^"";W+Q*P-
MKU;TCW?^9$W3T*8+1I?] ;(36UCYLP.1K-27;7D%*G-2[>5HH(]42]U 'QGH
M(XVE;*"/7@$B
MYV\P*ZMZ7G#P20:HRP!U&: N6+O, '4=,K'GR$L8"5?NA@^PJZK'6+)R#'"7
M >YZ3]7K!HP8%>1LW?E0O
M=[:O!'FJSZR",0%5]7XE-"9(JW89W&-"K^H%U$M_D[\SW-NH3?5^\N>! S]U
MN.$TD&C\D&B5%_'YO0I<>WI(:+0+4UP\CJK:D;/>>.%HH-'& (UVYY-?T9/U
M@L+1;:*$DH]H:AM]#?'I>AS*''F57\JZ4ER_PWQ?)G&4
M9+ZFA_6,)N@XKF_A7=)W+#?;4"*RC&A GGWQ5^0N5V1%)EN$K27:+V2V3NEZ
M3N,HC"R?+-.2%;N4-:I:[I@7RQU'5!$+J22416:>A\R(@[0=#0SG["42X;AF
M%$"5KW$#CHJNI&&,/J0=0MOS?($:VAI<1S\D".
M:@V_J]CGE?((%E]RCQPS; SY/@F'SQ;1J).?%G;@)/WD7U_X%.14S2R7.G!I
M)1K-+ELLD!W=DJ5-.+FDG%#WCBQ]2GJU:2%K=!6F5;)03V26FFO[;M8;+]@AQ'YT[*B%BKV[
M)^$1X:UKH^JOZB'PMRB,]BKI*2 ?8_%W*M6'(/H[BO(:!%8Z8&_SC4IZ:5#P
M-L#9/]%VK'>.!B9"J9RCP/YCFIS5]4FGS/92O^QD> J4]_23:)'=?R$8TGJA1*0E?/M?+5>W'6\KOU>RFV44$E,XT8J
M2VVD?!M$Q25&M6^G*O,+MH@YP/X::MO+IBC1Y-^(WN6BY[BUBE6DRH#66=<8
MPJ4F*FFLS0D]:J0)G8I25^*+9102 PS[-HTO$$/6?H-
MA_/';_4TU_:15&!Y.D5Z^#^M7!PA5&,U[$G4U,_.0_WPEOATIPEO\@=0JM9$3A>:/=G4\V0)SBXE%5Y:<^0Y@>
M[W=^5DHO67ZBTX]+MM\3=U29;(^F'[-L$V?_UG+Q=\L[>91),3'*Y/[M%+&UVI7[J]J\NA]>ELSB:-5@[email protected]*4$AY+;J*2UM5R/
M!N]O YREH;:E+=6UJ,"3_O;8BQ-+YO4ZEE4;/CJB;%X1M-Z3K
M>><3;\ /73OAIM9F[F="K;[!4W;2ST3VQ\><1W-I'64[9+^DT*_]R[!V=LV_
MXR/>YH@&R"AF;D"^-\N.8LNC*-0#?.#*;7ZEDMX]Q2N?+T._#3=(&55]B?;/"'(
M/1C6QN&3W$+?X;HU[&4JI=6OE2F8)12/7J0+M'A$2F;HH6ZD0T[F6$M&I EX
M".4)OK2D'VG*#<""KS>!(T0NFTAY78H^\JR\R5>.QJ*/BCR]M8.,# %,>%T<
M;<@/T?9@)_5V=P/Y%5IX>3#3(;^D"$V?'=%/(;_;J+6G8
M#__J)MOC9'_(+PH#DVUC*J;Z!X8U<6'Y+N7SUVA?B\_5(TX%Y!>.-1,F [9"
M_>/)0TM8&EA2+CI%WA0??E=GW!Z-@=;E"8"1S: <6UV!" HUY:*O,8^!_3*0
M0B:!3T AZ/7#7.5\+* *SJ)JE2#R59,L)<:6+@\%5&>^'4SR8S2V_&!5%?_A
M6JL3;(T3)7GZ) #<-:K XBCR.KK>6]#? "
MN87,@*.$MYX185I,#[+"DL7?R56/K%K>^Y:O)X#"?C"H+Z\6]:4GO PVL8- 
M6XG-KU6M_2O$R>EWCZHZS:4U#SR/J"7Z8_\B*TZFN=P46-F\LX]8LG0#+8;:
MK;R$Z&BC&VR[SCM%B4DN^_2NDTV'16TD<_(<)DO*E-$@DT/<1ZQ=WRBQ 4D 
M><+H@F"GAO *.QI*:W# "-"\UZE0G4VK,3
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M#D+IQVG-3/I+S("!]%?WXSY-R4X9LR?%.&#Z:>;L@(Q>LKR1_ZGN:5U^D/[-=!KM-7J1_V+WNLAF-&3+PGP)VH'N;H:P!S5")9$C0M7=\1;TJ:^\.-R!'RW]8]9!(8Q*&\3K=
M+M^(T$PAGBG$,X5X4BYC32%>@IQP./AR14/4SE<4K0(G\(+ECB>WK>>9M9?H
MSK=+C]
M>#2S]A*=N^$?MQBA.S]"F)CX0\FS6._[@ +Q^3/6ZRQ\>:/=YG+JAXB$+*%9>(
MYS3J)X8 RK\<1]$FST=SZ5=[N=JD_2B2?D]1+^79/Z9@:$P;O5[VRM)$7DWU
MT*"::A2E0T,F$_#E7$  \IT_?J-LD__:$3&2HMW8,P;,G;L P!]1P(L KRW?
M1LFW\XULS,HLB:;6*J*6:0,FW2JD)R7:OS?*H[V/R&$:3QW#SCYA\
M*7<^6>XXX6T:K1!^6EE^9H-,',=-M76N-<.^/Z12I<3%'8X
M(D8J9WCJ10?H3<6,@_@XA*@=NOL+41 !):R8QT20FFL1$V1?YJV+V0&03>-4T#&OJ' ,<11(86->4;%LG7PY%966F3J/,7U ];(?V#0U
M91Y@%. H2D* +45#^ _RDS)#5>$T5B6,HK):4JE20P&$:!DT".Q3HJYL*UPE
M#!6E1ZM=_1"IJ%ZZ"L*(6!^6A\+:VI+3=F.I8FHONSN?+#MZC,@Y0S?Y/9V)
[email protected]"Z'H XJ+THK^\S"BZ*F$O:5L69"JX!I(,\,N;R"_*)V>E1!&MG34X$
M:O1$[A9E>KU>LXJ- 2<+1RB/!A#=P+*IE&"Z<9Q<15NL0<$JSP;ARX>2R30,
M!+9F:YWK:"QR76$/ZN M"_,IJ+G5NZ\FJ4HH_[OU"J/A:HRO[YQ]W-$3V%'_3WPQGH-$G\_"IAU&5XB.QV4BB@
M$=;IXB;&P0:QYZ]HI<27HQ9I]O60[XCEF!VU4APQ297V'&T"'!%C\\Y/(O]4
M&1"%F/[(&1OA'DE-%"0AH*C2ZDMMF.T54E\EV\8X $]7)3SMK;?2,<..2[/;
M#WL2?'MDG 3D!^-8]>9$B.JI<;E0;;CG^-"4NTH\AGN3YJ:\%LVT?($!OS;,
MPQ33 M(B34=DV:A.U2&$Q[]LU::S\A =.S0A8&$P@@_\.FK,88:V6 -O/S$3V5P01,TE#D+1'*E!SKR4*')G3R>D(GPHBPG(8HDAJ_59[KR*EA>%"9#^:Z):);IGHEHENC2RZ9:)#)CIDHD,F
M.F2B0R8Z9*)#4)DRT2$3'1*6X]ZKA10(,NE"Z/PAB%#X%-RZON7;KN4=& ^G
M>&GY60#O*O##P'.=?7!OAE%(VEAI"*6B2(47A)#]8^Q%6^ICA1(0J"1
MOTG\
M;G#E9RK-OP=D4GP) N>GZWDCM@[::^LZX52K[KH>QKXQ9[8YL\V9W>.97:NP
MS/&KU?&;\!Z.Y1 >V1%V"$'N%[#),*CK80YA,4&WV<7,_
M*-RP\W59K8V)(]?$87PK7Y'C6K.5A=<6QQ=3TUH*-;/U2B-GQ\.B3>BC-=I_^4I^'VPG&U=93S
M^@ODA-(&VZ+*9:B1C'(WT;B]QNWE"TM+,B;&X!\WZ@+EGT'/00#N.BQ 08#T
M59DGZ\4DK568EK72J38T:[OH[ZX:%T.UBV%,$V.:U BD7F6-P^([UZX71\(Y.6*CF8/;'-SFX![-P=U:
MJ9AC'=ZQGH?*TP )D4J2P#Y''LV-NPK"*-RO+7)FUB[II=3G[DIRM6[M.JKQ
MWT$:0,8,,&: ,0/Z, ,ZJV%C#HS.'#"Q@ $KFW([_"'PKZQP]1B1)2BN6G:Y
M5>O<=QI*;4R#T+I%(=F6R8ZF;$H*E?XW
M\O%3SRK!S?9ME/_CY*>%'2YVAYM7\>L]E8PEE$\371NVW!VM!X8BCTQ%)TM7
M)/N[Y<4I<"K-HT__K;5L.DQBG +C%!BG8#1.@0R5K-POZ$$:?*:*%N_9M-X'
M78XB'6ISZR4SH FH0UFOD+ $_1OEI;XFL' 26#A^#VC$57)0P@:2C$^.A6-8
MI!P]C?EOS']C_H_'_.=1%LKM>W,\MSF>36P?[B%]'_C+>W>[1\RXW.5O#$XP
MLO@B>X*#2(F)3\F7:*7O0]*"G'Q.CK@V=U\5*T+A3,@WYKG9MD_
M 1KD[U
M&+JH43>Z&+F,HU;_6'AWB]+$P]D.]V_G=(IG*T3D+_\?4$L#!!0    ( &Q_
MI$A(PX8,B%H  (.#!0 5    :6-L&UL[;U[<^0V
MLB?Z_T;L=\!Z(^ZV(ZK=1=;;]\S9T*L]BBNWM)+:<^9T;#BH*I3$<1590[+4
MTGSZ"X!O$B!!$@3 \MG'N"61B'CVK3?7MXFI_;1V]Y_ QX_Q2+^%//T,YC^9YD_3S%_NW:.S^1E,,K^Z
M\* 5H*?!!G'S,S#'QOSC>/9Q/'TTQC^;BY^G\__,/NT>WCW[^24 ']8_HH?1
MD^B-";C_Z?ZGC'C_#WAP'1\]O3]8SCLXV^W /7[+!_?0A]XKW/P4$=U%X@*D
M3,?_RP\9"=^>O-U/KO?\"0TS^10_^,-__V\@?/CG-]_.O?!]$C]N?/J/7V\>
MUB]P;WVT'3^PG'7N14R,]JJQ6JT^D;^&3_OVSSZA'AY^#] /_R@V_O#SOX0_2[%P]N
MZ5SL/.\3?O^3 Y_17&[P""L\@C''(_S/Z-?$SGX ^,FO]]=,@58Y6N%+GT(F
M=_@';*>
MM0[BT8B,?_F!XX5/"?_XE9P$'O3=H[>&C5023D]#+G[?/>&7]COT"G8_T/GX
M]>$'8&_^\H.]^7VVG!J+V?QWPS"FT[GYN_&[\<._I\1 3 U\B^G]WW\+&1$K
M6X <$[R1(*#93L S+V^!EK>.&47_K)$P>N+3VD7.YA!\S$WDUG/W7-84C^]R
M*^63.OSX=]:[];2#%T?/@TX-=HH/R\=-@0->DS+',V.1PXP/(DHC$-%2"I=.
MF- **H"5RZ2YD'C9>1TH%4X62#I\H&:1!BJD01D+PCW%RCCZD]1-]'T*]%
M$>-YN1"B,\&=N2P, WK*FYJL)-2E(7Z+05DJ 'O?PQ>AO8VB.I;(K58"JH
MIAF>[/7.PRB9CR<11O!OTE'05$$_N'4>7EPO>(3>_MQR_KB$!]>W [\P>TW>
M%(R8C;L^[I$&R(I3>[8X;B!UATVWE%O\2&2!6\;Y_2 KK8M335F:*(
M?=P?=WC:;X,7Z.%U<@^^0,>W7V'H#&]I^.T6>45V7&E$16Y<;\(:=Q1<
M3<)@?R<J0*6[KG4SF\<+J[<4U. L"SWXZ!CB+
M!8$+[BR2Y'X+J:K;DNA#ZA)FV4Y,<\SF#;DA6C.J4X+3S<;&2;:UN[-LE"Y<
M6 <[L':(T;WK/ 3N^@^65=2_*!.9M=QP&^=R,8D7H1*B %-% 01$=$<@I P(
M:46P%"RR61#Y@*A^1"*O0[I*,F%ZY](D=3(R'NF8^A(/E!M6*XUEC=Y)6 H!SZ,"M
M'0!LV\QT2=]$2+@J2;Z#%?,4*8:D.-!;VS[$>R7N =/4WO$TP%Q3'\2KX$RV3O/?;4W<'/^_M7'.Z*W!WSNR':>S]:!_8K$KC_[
MT,=0JAR5(/ZYUS]FB]F"ZK421LC>9&Z[$O\9\P-BAL#3._B >4*^[4>0L 52
MOM2?W%"N9).B9"]1L@/3:BF7_$0^\PX9#;N)7JV$E9^U<7^",<[TA2+GKKUC
M].'ZIV?W]=,&VM@G3O$_L"N<9EPA^M7O9XCK#>;\\\YZ+IAF^>\2G$YI4.Y%
M"&.VBLL8X_8/^+9!*WV\^V@SYS
M$)HJ5QBJ7I$95"OXX,Y#C?DR/C&2(8>3SX1@'U_^W#%-F(PF3<9M(J/Z+WP.
M0\Q%C#K-B*G;S8WRBV4[MTYKCCM:F*.37,6
M%>UF[>IV"S!E7,6:5+1BXH!0EURS*U[@LK.0*3!OQ6X/[29AR10H@+4"R V';
M@"<24G7[+?F'I$.L<D&W;3%BS&9SK/VW'/K#3YWW$J(C%>.6P98FGCGJA8;)8&5&S:7RRX^
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MEE(RH5,KI4(NPL+^&5:$!
MA;AN (D:Q/-J5$CU'6U\9#8OE@_O/'L-SW:[Z!JS],37H_LWU_L#U^Z'9UX+
MQB*.KNSJ/A%,\S95GBRFBWE8#?CX L'WD$C<.PY8R0#@NQ5?%T(. ^
M00^02_1>W._P%?U@!^@9W#:1G&$,$,5#Q#D&T(7G^OAJO:,3>._@K]#:!2]K
MW##BVEGC8G!C!C[#)^]HH;][email protected]@L'VQL?[US\2E2"S>+]TA'7'P2,MP2
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MQJNINWO7R<U%PMS8ID%*2DP3=,'!#JBFLS1(INLD17
M>J"PF]3L'9GZS7V+V27&5]=L8,!
M3!TY*S/FMY\^!E?K#'J0B/]K;1QW/Z0GB1G>0(8YW-23VZAAJ?V=<<:N)SHQMK_@4WUQO$LKVUK:1W
M5ES%<^9D5QC.PL46;%7H#U?HD5=KAQ-!?ER('%2MCQ4H"?\9NK%1Z5M3GD"6
MJ>@,;%*91TIGLLN($6>CL#\[_FN&.VU\JC*-)[ZT%U6\0N_)'8XRC#2R8$,A
MG]"PVEH41H\>G%Q-U! ],8./%M$Y=O+DG0?Q%;17X9USZ'FRHE_9DDT-+T.-
M+;P"\K=!,Y;%PTV"0TZNAPG^/B!<@XAM\F*VD\,)A*-^)BFL2L?DWL,%3JPY
MEVA.GRY)2CU+;YZ[T82>E$._)U7?^$WI_CL[]"FXZXP\#;8V5I6%0\*]9DFO.Z![:B!NQRZ[U#S[ZW9K9.
MSPF37%T)&L*13\;A$G'X=ZRFJV)'" ENEO!XFKZUC?JGU K;TW6I.:S+W6H,9OD#OJ<5^VE>:D:
MORIR+HAW3;06(*W%3I9:V#Q$%\OE#_IRM/5S=9KN-NT4K0P0&19.RNFFUA-"G"]Z^V.\$;;Y$SKBLJ>0ZXL+LS=T=YQ>-REC
MYRL[VD"=;$8$[MS)G/2'Z&WQW<\2##K>AX&&C!J
M!>// HWJMD^=PTCF J7<8@CF]B.YZ03S>PJ9N>A)(:GYC6LYP'%Q:\@3V\GC
M=A!]>5R^^3I)/RQK,Z]B\%/RO WWE":E)M)R7.[)[.H)FX32ZH=[JIM\]6Y 
MJIL]G:T^(DGF4D)9!S;HXP[4JU*%X?\27?6G8BYRT$Z-TLNM#3
M6@&HA'=?+I,]+7TU9FW-ZEUTI.;6B4]957IN<_@TKN>&W;3UT'=)"_/*L9B*T95DUOQ+K.J(Z[@
MJ1AZUGWGN0?H!>]WR)R"Z&CX82^GU(,]]D"S;Z9 _*=LEXM^#X/$+*)_829'
M22>.@_C;1U0DXH*F(#KH'.OJ@*D15<$J50TQ+Z]U 'WEYM4SI5U^_M5!O]C!
MS3U\A':N]^&&G)L79.%-8:;3L3GO-3./&0,19\--RSNIN,]X(T7%C:^1
M4*-G$E02A7ALA0PN$VRIGZRN7%JOD<"F[?#_F)_R[Y$;.'AO)Q]IR VNG
MO;;F#&T-\ N#U[D)^*;@F@--XH)_]N0'GK5NX-S35]1ZZ(0/_DOIE[.*)0P?
M?(LIZM/=O:60[)[N-4(J1'')%&N@F%>-D*_RZ$+37]Q7Z#GX(_07SW("]BDS
MSI=D?R'7 +ZZV]JX7D(P%
M9R)>FL#8#H"6Y]C.LP\P 7(7-GD?'*!GNQO)MU,+5I81]H<--902!2'5W@ZJ
M<7UN"A:U5!90,@AE7Y#<0$Z^ _ET(]++W,,-W!_"I,*'WBMUX8[YK"*?4F*$
M-RY-5Z8Q#5U)C(Z4%HB(*4%^1Y$,!2)QP;RC7&96+B^5RV/+)1/:3/04$4U7
M0Z] _A7NGTJUUSQOZ +JD!WN#?WI?#X;!K3;"%8#.\J%?[-VI9V[9N]*_!CG8JC!2I,Y
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M<$/"*\(F46?]O#'?5(,*%COL2(
MG<>33_ T @16RZD,211SK(1343N*,56Y=59\3 UV&FT+
M&,N%0?V )51ZS0R:(*6%3#5?IV .X-%SP9IL^Z!P'C[R_P)C/!Z-P_]?3KQ'
M8#8;C>?H_R_'^7 57@&<&BO>2?H5 >4%3(P1P.4J;:.1Y0*2-G.
M(QX.K'.*L E1Q=]Q=?99^*2K5(EF$*LY8,SSIAZ0:WP2=VZ:2R'04WXP6;A6
M3)96?M84B%5GDWFUHP:8#F' IS<'8SXF%7+YL?FOEITND\PU(J&FEY,820@F
M?O&04U#9@*G.H/=JKZ'_X.[8!03,%Z1:/HL+
M_I:0XUF2WODDCA!R9.TZ)@@P156($",AP<:E[<%U@-(W7W$Q=:VUY4%2J0)U
M<+F']O[IZ/DXU[AZP]]T[.C >EXZ6"A,\%N2L1SGL9*E!B)RJB[/$24?J;G)
M"09#.AI@IL+DRI!AJ4(E8DB8J_VBH3VK "DY!OCK&)83LX@20DF#KY#.XO.7K7-TXRH:/(ET=M;O _7/SV[KY\VT,;&/L7_P#8^S=@X^M7O
M%V&;J\^VO[9V?X>6=^5L+E'26IB@RD?5%_O !P/:&PK@0&&#
M.W&>3Y+V1+$-Y!\ID7#2$4#:C$!2Y!(7=3?($!LXL]YTL*<$+GA-_]3N/4+<$+CBTA
MR:3P"I^+"DMZSW8[]SL^TCU2UJ>]#PV4^K1O,L$HO-I%!Y!5VRH-;!7*40RZ
MS+TO36!'?TT-\*B\\-?<)C=:Y:"7(4KPIQ70!$A<#;5=-,"[)G"KM%(&X-A*
[email protected]@P?7-NUH$?41J5!*Q^7VUX:Q3&"3OJX*&6T%,(L"Q'LO:NV^;"IY&R^(
MJ]J>T1?667B)#J]Y%]]09.T%-OBK8%<+BO&/ /II!XD9X=6!+&D2/@Z>NSFN
M]&Q !M?=Y8A0&?$Y646<
M?;>\C=K-"3&8:>4]*E0JI+O'9=0' Y=V.8$=O%\[6]?;AQD2/
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MQ E6 0MUS?AX3*P"#2(:Z35%PEU\70CC-!C].
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M)NIJT]C/*\1%X^(H?)/CBIU-*:\1$R0@+:%R6P&\=2XL_^7,V>#_7/WS:+]:.UQJQIKF)B1DXJL!7PW./XSC
M8$3(X_+-> " 1\ 'PC%QT)V=65^>$YC<><&ZN5&=91Q@3Z71>C
MN8G._!OR^*^N?^PB!$'PM;.Q7^W-T=J!F):RDD:ZR2?%BQ19E83-B(VH2WY:
MEITMW/[B.J_01WEQ6*Y.VGQF_XXKNK^XP=]A< _7[K.#+PEFN?#>QI,9D/L2
M@K_GZF2Y*. V8B9WSB(['CFY&7(4'3L8Y<]KD*[+B"/PCE+4E"=%H5X/%:?=
M!7 "Y.-+GJ.XA*1K>N!#+,GYFL%S =QP%^=U*V&3CB:"YHK
M'H'OT'Y^P5-BO4+/>B8++5C9']ZAY?D_GJ1CKO0L4KPU>[*5NG!L+;<'S$QU
MH0;S>16.L<@$/V;FLY(/(TE+2$UUT888^4RF?%I FV5Q5!12-2%TR84,<8?T
M^O@=.L'[?T+/O<+^$?^J?CF&XVU52S7UK/&N("RFD_&JL(P3FA6F-0*(N27Y
MI^+%'=$2TQR%5(GYEH-$BTWS'P6QE:\:\:.VM*+$J:Z^GA&V=C+%MS5R
M,@76>&/79#J?SJN=S$13)]-)XDHG(T/BUDZFD]B53F:BK9-AH);'R=#4U?\9
M@O#D_P7$]R+OKIT-?/O_X'MAHMG/23I50!V\P0F3:;S8&S9OB @!0@D@4O)/
M&@B0R&PJD8S3!Y7F%!]#8 LOR]XOW;UE%P-7Z<]2K3LY>8-(V^P&0EEV>D]?+9QJ;43?+'VM#->U,>DVFU^[ :W>T[R
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MA()$+]& +?Y@MEQ%:PSL1Y4
MPKV%G6?!W52+FD$YY1"G\Y5I=%,J>D":QAK_/O@T;FA;;/H%@?G&]?U;Y\':P=OMG><>H!>\XYVX *\!
M'/!&-V...5^6B"\^COA/]\WC,_>8,/B 2?^(S_%=VO[!]4F5(O[(BX(^@@L4H$L
ME#8S[BQ:&RA0"6I==_/=WC&G/_ZS3.1%8_+?/+@PHR0T?K670'6(.Q-6XJ45
M\P00%SOD!YQG\&3M\$W$/(%Z*&9;B]@"=OJ6H31G:\6_6F9 T;U, 
M97!S>?30?(=5]S7307U%@6>A\<&?1YJ32=[;C$!,$(04
MHU,U:FV_NY $#]%]]O'9%0M3#=,5'WSXX@803)2>9.$Q1QI^F.I1BBFGE-*G
MEUC5M#-L1D,%ZG@8X[_';&868$BRQ?)":N9F.-7]$'O4A"E2$]*QV\3LJ6#F
M5JA*=*[OT.R^
M6#X\6Z_=HQ/@>H?-/XY^L*_H&L?WK@)\5#+$_T6R,%;%SZZ8,DA)@PQMM3@2
M*#;!UAWZ0O&T_PSCLEP:^.K5I1*0CY[E^+OP1D]N)#)>4@!!.B?<1CB=QF/7>,:@F\0\8
M3Y,,GJ)?_WY]59C!S!\DX"(=C?_K>C6)BEFO[Z]NSKY1,\J
MZ0!6GG!LEP5I5'CT:]+S&._(X2K3"Q>'FB.*-K9'(@,=9(%(O[RV2Q'$BW(*W)$LZD\>8)94!EX%
M/B,;Q65/H#JW_!!8 4FS:O8Z6$]+=WK"0,S,3VE!T:$R4C \[!^
M@9OCCIS]:M )]&RWBW6!7DS[(L:M/G'/1)2B/.&CU0?70ZJS':47?G"8= 4B
M2TK6")65IT6JWU&/S(:GE/>J0A7):
M[CJ8JC>DHXK*!O_UEV,S'^_P&6&-ZEF$R6BVE5$NFBK-L(PEMF(T05)=&4KE
M*VJQU/SJL\G4,"K!I+P419R8!3SIL'I2;7@UX%%?D9)96T$I-;1?K:==L8]4
M];,J\))E@'_+>3Z?%8$"?9!2&H&H*%@Q3-I+E\4'65W$]Z5$E+2 "LW*J!@I
MZ4 ;<. U\-!,FLQCYBW5@$E9X>_F,C9+,:8 G92J1NAI*VIZ+5%T2L >"*;*
MQEF+KH*.E.+L*KQB)&J74S?3A:=5X"K/ O^QK.E\5K67C/_4KYAYFS873KI3H".)Z@PHNE#D!#QH^? 2AO^]=J*2.?_.
M>J_.2FO>D^L8JIEIT$!MO$Q&^B"BK,Q;B!28^(U4SD]V
M+#L2V(H%/K %EH@S/F,M((Y#5WIAC^>CL/Y5+1#8_*/*6"[F4SX0WE?FA))B
MFVC!2:"+Z>4@J$T*S&VV?$#4XZ.SS)QWA)M,]MXB(C(HJ$8FG2W^RF9CLJH$
M:.Y[5;](*4)\,R<^DCGWL:IKL*RVZ%JT5BA.#]!>PBU$7]6;&]MZLG=579;Y
MWE4*5 I#_-],,].LA&A,'&2HZP+1SH*'O2;"LQ9(UDTL*P(GV$5$E5S&TLIR
MJV')4I9>@+R'K] Y\L?.XGM: #%BIL%EZ_%)ISH01I1U V K@;ZP#G9@[>I+7'@)*$4ABRO^XI#YI#HF
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M>=32A5  (0DE7W0=,4
M-N5D.9^ZUV0Z]QI>^.^#':]B3Y^2),M$(2$U'7/%BD?:W#[B,4%12-+%+R+]
MORI$EA8/.$TS%QQXE*4CSFJ*++E?UPAWC5NU3B?Q]>]T_"DOI^Q'XC!R79^=
M7]]%5]0
M"HCF[<%G\SD;&#I%G$X2YFY/SA!56J)?;W75<-$I;F0J%KF10WE'#7C*C'![
MXC'ZOQ3\9 K\-()05SD)BL(Z"@TQQ#9!!HP8ZE"")-=YOK%?X28L0SA__P6Z
MSYYU>+'79WAW]!'OAM9UB&U(1";6&G'&W_Y[E2Q-HP$^[O (\?W:3^\@'020
M4< W,@Y0WENV3W6$QT=M9,_VTS&^>.#.3$'>"@:C
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MU2J^7TB*VF7T#0E/AC7TKC<9S4?"WJ0FM#0G(Z."4U+L(GS/KHF-$D;
M5Y$)#2]1]5Z'DU/^LJC%:L+E;=+>R,-*:'I1&'N5QDW4I'52TQ!%'&ZEB9Z'
MYT[:)35-B0_&O32O83;BXPOBW(RN24VO.J0F-32GHV-2TQ)LXKR/#DE-V/KA
MQO4KAT+[<5"^T1HJT)H*?6%C>":E!KR
M*TRH3[E#,,4M?*OF,'E&E:>(&>"T%S3"8C$K.H68B!KPMQ/!D"@"'Y[;R5& 
M+ODVAN 0T0*OM@7@#JX#ST6V#_9P$P%[[7H;C1!=!$L)O#GMJ,B6T0>V$_5S
M8R1NV2U ,3V,>_ON-&A?WSZ!S)T_ D.
MWZR][1#GAU?>]M8_7(_M'X;=G>M+R
MO?+@P(QV0)>?,,KPNYZY; 3D)IHWTJ"C(9AFL6$"F/2DWZ!:'YS^!;([G#.B%
M2\K*PG WD>*;Q!+\N(IWRSM+-&\FD<3D@8620A)!%5\)L+T-RN*].\_='$GV
M=6ZM_]BYSY6'[6I>D@GW2DZXC6JZG$1G4PE!@++2E"2(:"H^HB=25#,5-:*B
M%#9<-IA#4+TNU(#IV7+L?Q%'=(%\D;NS-^2',V=SA]?LHGSY=AL5]EN[!_0;
M2&Z40@G/>N?Z1Z^V4Y'P8:0"5BSOW':/OK@2B*7;?M@L*1U/K5/I!XMY-]2#WI4XKO0.M[2'$,O8
MJ,_*="$T!OC/A(SC6TNS5QJJ[YTD0*I2\Z3P?D+U]Q)6FE<.4$PEB%EHP^0O
MW/W!@R_0\>U7&&;@GUT/VL].N(N]?G_T+,>WUA&0R4^[$-:;?QS#*W3.X1:]
M\VB]Q6V=/A^=#W] ?.*_[)+N:MN0$V [@4L>0K\@LB0MH]?O
MA!;ZDPH07(KA^Q52,WF(^-?
MWA<9 =3!#>^ QA!T2)BP_BM$J9^;GH)3.1[A,"7[$EC=
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ME::XX:B_8NM$!7KNK'>2MRN73N_7/BX1.2P>^.UJ''>UBDEEZI#1
MMQ^A)GMG4;!T9&,P%6G-$DD64.KL+ N32A6H!IR7)6!@PA"&**NJ"FLY@$.0\OE@>!'%&ZA!(W)5B6E0Y=35"3%QR^F0Z,K2PCG=>;B)0O!^AV8M
M.',V5^BWASU[E:H! 96.BO?5#?58E;&D,-&H]/
M5FS($M+A 8KKZL( )5 5('DYU<?5HC\ BN\![@62W,^+N,^7'C&Y-2COI-D)GKW9S.PZ^XC,)#HS+O_-7BLS*F7"KP/\
M/OB&*2AJ9M5>"#,GA-+DEF(CN1RV**-*0[YT]Y9=#"*,AQ080,5TN
M2^8;.A67=&8#')V/XYOB($U[)[!Q>?T]Q4Y&.5+TA/
MR:JX:7 OS"RZY^/NUU_2VV^R%%4E9N+D,Q3*5Y.>B1/2C(14EX?QX"E-Q6HE
M5Q+$/'BP[,W5VP$Z/CQS-ID6QP[_=/DGNU(ZH@(DL^]?-]
M#Y46JPL7VDR$CI9]L#MMLG&'M_+
MBE#&YHC?S1O&C 8Y3)H4_4K8W&N#0%&B$SC&PFJXK=?(>%E K%&6FO;9U?PU;ZG"HLT9O@;3L\G8RH,2W?0N
M(;BINPRL-3F9^&C)(_^MT\OXYL[\4#@M#P>+OD["X7 Q<'9 Y9?IRE44]7[=
M\-QCI"Q=;M45A9F<#^BB8R'[V$4.4&[X:OODGV&/MD?K#?IX,?(Z@/MB& Y/H1ZJ]\Y[
M588I6AE2MN!;NH)D4[Z-2B7Z,!)6VYM"^+J>OHOPQEN2.YDLY\L6?HL,HJ7+
M:B%^T>)7>9VA]OM+_BW
M#@9^>%*$->U<[ZIP23R,<1\1,&>+^-;$PAT8*Z+Z$37Q/9@T^2JL
M$UO)Q4T]"3^E3?0S4TQICJ4)3G->A5M'@ER*']QNKXYX"9]=;$QY2KZ;*++ 
MFT//%Z8QCA,4/P"W6Q"2451+W%420[8D=?E$-W',LC@*@ZS4:OQ>)8"(J07U6D0BN##/3X.
MJ @?/;]\<7V @B=ZMC']:Z*B,C#
M&&]"-3-FIIG&28J!A=1!3%YA_!0O=Y43D2IW?;05+WR55T%HFB@-R$V FPO3
MW'KJV[9&N'^N,,K-I=P
M:Z^9IYDX7I3ZU5#'#7\WL>4JB?HA41!3!1\R=$%$F)I8R_AV$"NQF9,81E35
M?C3PFF;^RX%++SI@K>:#G/JP0DPU_"R=+XP5"T>J/[N["V92!=,)+E4?UTSY
MU<#B%3I'B*N1KM[0Y#G6[N+H!^X>S>/Y>UJ3A0NRPIVS^OK ]A2E JPUF]S&
M.ETLDRI!,EI8%!B/!Y(!\_5OI/K-UZA&4)*FJ&6"N%%WK#W]J@0[@R?O&KHI
M6J'_\,^>T+19:W;"6GA,/M*3L?GKS.SP7[$#?OL7_$IB09>&)K;)I;SU31GWPK/\G62(;G1(2+0CPBX
M7KTW$>:Q"!Y;!%GH9!A\%IPT695@<_T"-T=\=C^^\H+TZ/9MANR!MWSK6<3Z-USW@(G&_%@X#L*".<>F5^H:924HY&3.$:D8;;EF#(
M ;N-;M4B_\+='UPGO-LO*?.,FE:=0P=N[8#KP[4+127^H#&;_%4-B_AX6Q8(
MZ7CYJN&DV=N':-0?M?EVE:8LXC5RA=2X;/#9L?^%%ZN/'KYR]@YZMDOM3"+?
M0[0&#=U9M-.ND"W>E(E+>/#@.BS^/G,VV6K-F)7W[/H!_HZN] SBZ*!;)
M/"\@)LO9=!7N)2?>XW8+L@P Q$&^(CIV(>>4)1[)!>'J=&:(TYER#ZQ8E=2U
MQ)PZK:(Z=5E=[,VK)3OCPJ=%;0(8;Z6@^$KN;#BW?'N-I+FT=T=\H+I9\M>,
MFI+$KQ&+_%MKD[%13OJ2;4,T6'BEQPB0\0B HA&5>QNI.F*\BQP+]#L)A,RO"/:>FRXM-!MM+"#H]L\I%&-3QP
M\5>QLD6#'O50\C,<>E#N@N2IIQ3@T5@?U]7JT> #OY6OH'S+-]>LVFP!\8N[
MK,,-^0HX6P?VJQV\-_Q:YR*B)*?@X8S_NW,ZHZ09R1#179OQ(,HQ+T,;(=J/
M^[T5-MCXU7V%I)T&^N+&P/\MJYFHJ[@>"4L3PZ?G,-S:5(OP= OL>H-FQM[:
M*F2ZVOBWJYWL,#WD)QGJ\=?AKO#D=BG$HJ.]-7XCVY,\T?F&=6K8,H?GS#I
M_'I E@&"HE[ 7T/#$Z
MIM79VR-;;B:T)JQ1(EW/+7?F-U[23H&P,K]1_BK6D3Y.2Y7JBLN"6?TH]5#B
M(=4D[^54LRX^)IN.9UG'2[IA'H]7),/?M?8W'091['O:<\X-INF45F/%_+ L
M.:*$%9#A16NO)$NIQ$/]#>)6>'C/YQ5ZUC/,[5B04Q(9K7UEW*VMTF5U1VB=
M^^HX'X*_W>,)B^8KK#N_W4;UTV'Q^>TQ\ ,T>;;S?%-UKYL JNJ^N]NRS'V4
M:#*-+RG(>IX28-+*_[BB/SH!D!E.UDI+K/UH3?+7
M;U=?1?FV[30=:ETQ\WJZCA0'XX(;W6!FS(WE4IC[57&UG4P]B?*ZRN[ DZDL
M4,,]W/7/GE,.;X9G?7$QGY?Y+N)Y
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[email protected]]1U^. UTL1!?9_\'F!7[V4ZZ'M0ONGJGT<[>+]V4*Y%RDS\V^ %>H\O
MEA-7A6\VY(81:Y>N1];=,*>*FR%XO&XB\J_039(3U]V=8\@SR# -"-<@0&QG
M#IDDG&=V']3?TS>(J:)7?]]#O$F-_?"%ZQ"J1Z3<&WNK808GS=D(<=X"YO:T
M_/QGU]M"&QG?M1,&,^EH*G-P$OZ\)!9W4K8PDD:#TGQXPBUNW=='&KP*Y\*!
MS_@F>C5^N^N43/&<)$1.TQ4S_8$<]TN?HI-TN3BP%&H\?T'$@TL$$'S\BYS^
M4H41/N9.R5%S2,KYT_S:>.8'7^UU=0
M(]#R)\--")+:TD\GPZ#C_P=/!F;L%VEZDH526'2>KI'3;M9*_30DN64RW8H_M).9&*,D&G
M'(0>W<#:J=O^JF3F! -47D+N9F[CY6JI.ER-3KC 6MPDA0="L:)>R2HB^O#P
MN<+:J7EMNF-1X<,ITWG*'EV_&H>F_)V@WQ>WI3M=KJ37MI5#P9_S'$ZO2I7@-/)0V\'6R//%R_""6$OFQG+H)I_KU.PQ"XC)1P
MH7Z!2+X6L^X/IIK09-5>)-1*GDR8L@>5UB9.],SWC_NHS:*S^14&+^[&W;G/
M[WWUE6TP\A!247YQ^!.2E2&NI#934Y/AD-Q:D>%QN/4V?>F?>,0,S9^5>T$Y
M,!>2Z36I:DR#)TZ[E"])DT8_BM?%S-Q'^9T
MGTER1,(AB%D$F,<3<)C=54_<9:*6=QONU*>-,M#=F[MD3LF@/GBK),-U)I67
MK_0SX! ^B6NEX#_A.:V[.DJD7\2\#>R[6;"JB1],]+'3X7: 7G$KY'.:;PY.
M)DO\S=TA,CL[>)>=)Q9&'GJFF!>'__MN)O#(:JU/3)D\M6RQB_KS?O(UH:3<
M6\H!>^]I(V5N!N\_[VW_C\\>A-<.LG?H![*\)W7G<&$]^GZ0W&Y_S^VJ/+).'[email protected] RC^
MS'=*> C9>\(M_XUX2V&W<(-O>'A QA]:24!+Q9ER%*=]2EZ"GY"<.S\I:I/J
MI T'ZX+#@E.]>H/>VO;AG6>OQ>;7W3@93*K=24Q>%,\FL\526-:=L%QY'VLY
M^XM9!X3W@23@$N='5"ZN\?STE)9+G*2A9^A"''SW9+W[C.D5)Z-[:I1'R29\
M##9&-A"2$]SF;+HYN;'J.C'G,C*3;V-D&J[^M2[M#%1\6F
MRSSE>'DXAF(G(
M1"?3V=SL\S,NZU1/\P.NEQGI\>--]8Q4WG4S@*DAO1NO0OT]6>B-7O7$O,9F
M )HB]]6<)Q?45"AKL%F!FL_<)K.E5XY0V99'7IK0@(W!9@K\,O*B>CY9];LK
M6FQ/=J(90U\STV/2H,7,2/I0[FMZR"?S;\H:PJEVY.+#8,.)&E3A8GAQ[NWV
M;+.Q\2O6CCSGGQV#%]>S_P6%WSK ,>(02AWKQ> OY9N,Q5UOEMZ$G'(67RN=
M\C:P\DC1RB8N,M64E6K*#S5E)83!UO6 [?M'5=\4$B$NI&J2\2VT#0FR\6\!S]X*LZOFU[#BZX\]"UO>>^QF_O^8J]?P(OU"L$3A Y OX/>
MZRDY/2FN[N0C;ITG #='=%&?@3$F,IKB5PV>O%?!%(
M$\Z&[?ZZZ;ET;53@(L\'GM551\F";A\.CSH7:A>"PT]VPHW?\T'SFJ$&LZ!;
M+0?WVM-X83;9X:TJFAE%"X*AOXH+00=Z4ERD>L74)"E4;T]+JR)U'";*4:U6
M%!C -KF@:7A+JGPNL?NR*<L+375[(
MT< 6 <0H-NK@F=  'X&3+)B$2Z*]Z.45>D^NUIHQ2JJQ H#;XB/%:'*C4A].
M2\BB2.4,#-S'-ZBE]3Q0@LKW6'E6I#P8
M*^_0F_+DQAB!9OQGB3R\M6LJ9DN'-?L*AJ4LY#<;?V"K^XV$XVZ-:2Q7*V%U
MVIQQ:/A; 3W.A:C*;.WFHM=]@QXG1,O@ILQ;B]IC:#YA ]]X* AY#_>6C<^Z
M7;@..:5]M':]7$W6@9-A;E7PBL=_T^!J8U#N#33HU[[FF/J=$LZO3)I^JJD/9<#/3S3_S]".9T;"Z;
M? 16-DN*RVX2=L$U^R3HZ7P)]C8M@GI8:3HM4CX*>YN;;' *2?E?_JX<>WJ9O)Z&DC#O9@A4$&Y+SRG',#:S:?]7 $(60FF]1]@0%.5C(&.O@]KNGVEBHO!^CYAY5F&N5P9,ORBCOLC@YB;.JBW-J*?B:B+9[AH,-K/&VRY1%/?+*Q(HM&4#;%X,9&EXU4S<$(1X-[=[3Z['GY0KBEG!QY^7,A(TV2=0MS-%CPA
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MX4IYG $=$B@QS[UR.Y^.>SB8GN&GUPM7^%-]=.9.5[UZOWUJ4=1K.3A
MU*#T!MZ>')XVM29BQ%%PXQ3OZ,/TBR*NZC&F8Z.'6N]KA:MTD(TV/A
M7./9H2^]B![RQ0RCWW:R]P';LJ3\G"HQCN+W$QN
M.\-##(B_R>N00!UJ0"&-QC\_LF>3'NI+?Y/2&$'>,2P!*B;K8"&=(;O"*ER*
M]'5,C0_7F:FJM><=?7 N3UBI\GBZ,GKT@J=\^*F7F3!/R5"2L
M[Z7L8-TANVA[,$ORX$J"MPS)>+O5FDO#R 9Q0=\U>IR^JH[G^DV#\,]+/::!
MHW^S?G.AX\$W-9XY'[ZDS92.WYRL393:8":1A8%_C];)QXOB\=R8FQ("&WMW
M76UTTW5&^H]QZF:DWXL*>IT6>KBCJ_+&WBH.?_(]>E_?<%RSJ#@4!B_0>WRQ
MG$B"J[<#7",)\ (R8IQZ2:^,$8<3Z'C$X;Y>9&),YX)670'A#DHY\,7,@
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MT"WO/?2/7/HQV\1Y_)WT(RNAXJ[ETC9B.-:)/"=0!5H]2M
MK?Z'Y8F2S_;P"#/KIELA_83$,C$([]5&,OY;ZLQI@]8,/N\N5\)LY57<$MH,
M]>A#^Y^7T+M&[ZL_."#=.8CQM:WG:9!>.+KKY>BI]<--V1B2)VXH&S_FC5F#
MHCIN7YQA]_2]<:]SH]E]50KF@4G?<@(,A>6)^L?CO$YV:
M?23$(:>G[W_[FA'B>@GQ@3O>YKY J,]M.#]*W*W][-A;>XT8O7C!N[]M/.WAC._ Z@'MF;Q5!U&6Z
M23$L<^WWI$/S#3/P&4!^.O"+O\R<$R:2TK"&AD_$&ZJ1::
M$^JBV)H;AG?*05"<9TJG18E7"JR 9(;A+AU.&UT')XIG;S8S1ZI\1Z8GJ6*$
MV](7T^4\MW>;T@'?,"55:!QX
M$%1Z7@5ZBDSPV]8LOO8T2T(/T'03RBP*I05(6-9%!0A5 4K!4?OM77Y0!1P:
M?\YA'QL71<9$=/BH[2B0V4P@Z6BH_EJD"Z_4_F^W%Y;_\GGG?O?K+O*N>D4%
M)BA\\+>#-9)OL,28<*DO(@@(1?6W;P@3TVPOIG3\5)@C%4DLY2C&U&?;L9RU
M;>W0!Y5-EKNYL<5^50W&F/SP5UVN9C2L)81!3%DGS D2NXR]QF(KP&"M^3*P
M6*TTQ9@DM?,O[FZ#K"#\4.,'9<6[:E#)9HC_2NG9JI0@XA[Q&QBX!CSD_I0:E67AR=VT)6Z/_$ED[QG6=!X-E/QP#/ @A<
M<&=Y?9V[?6"X?H+M;CL -K%V?$LRQ!(]XE+"2
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M_Y@*T\C]D>[T(M*C*D+JW5\%=]PFO)BN)O7)$1EIP+F1,$TU38TT] 8L+;(>EPE7!@]--L[BIA@)*1#24K]Z*$0XLXUP
MTA!68W(Y(%6I0P5>'JVW$,L5E?KY9R0B(S1?J7O^^?W.)LE/\N
MP9I+@W*[M^DTWG*)W@[?#*P'A
MQ5C^/5Q#^[6B%J_J#8F^NH(-7GLQIU,CJM*+J24WL.&SXC$]-1Y&*M)>+$@$T@C$ T"\"CD3\DX$5W/(I?PL?R/DH7K#HA/[MEKH4*-(ONULW;WD'QA
M.M8NL*%_YFRN'60UT _.UFOOR-R7ZD)1?8; PR;_OHRY7-8"/QPQA'P\)K"<
M#8A'!=&P6B4_XVG+64?F#Q(PFX[68&UD$JU1?OUR_7AU"1X>SQZO
M'N1BJ"W?T2JIN.I"5!2
ME!,65VRW<$TJR#:8/+Y'.E]'JLG=J!WQD0U3792KC6NXW;(X;F)2%514NP(V
M:_QW7$XG-2X MPLHH7\4>P:-L"]*&P3SO8I7=V:T5_'FNNKH4K3$9]8Z/R1M_
M"<#2-+MX/N7U;?UJQJQQ$[7;ZXYF%-+0
M$/F$L0;WU<05JPUA3X;1&^DM-&&+Z$@TQ_.0J$\ZH'NU#:C,K]3J2
M.HBDMC)2'YA22]D6;8;99#NT@UV5W'OG2Z"2:%O3
MLN269"?N7[^D)%N2+5*D1(D4=2YP.TD57PX?4N0YA^<\_.T_?JR]BQT*(S?P
M?W_U_LV[5Q?(MP/']9>_O_KR]'KR='U__^H__OV?_^FW__'Z]<5\?G$3^#[R
M/+2_^+N-/!1:,;IXMGX$?K#>7\Q"%"$_MF+W;[]___XF#)U#FV_L8/WVXO7K0W]?4\E^O?CYS>7E
MFX^%W\R#K>_\>O&A\*/K$*4=.UBF7R\NW[W_^?6[GUZ_^_C\_MVOE__VZ\>?
M_ZM8.MCL0W>YBB_^E_V_<6%<$M?X<#%_,W]3&.3_O'@*_ B77F\L?W\Q\;R+
M.:D57'LH^.J?_^DB
M+?SKC\@M5?C^X5#\_=N_?WYXLE=H;;UV_2BV?+M4D3165?7]+[_\\C;Y;5HZ
M CM!B4/ "VH)\J_7AV*OR8]>O[]\_>']FQ^1\^K?28>_A8&'YFAQ
MDYZXZ%7V<]6(5K\_LJUO9 @__.[#VG]?[D)[.V:K"+?N?5C
M-][?^XL@7"=2O[H@[7Z9WY?$=^W MW&;KFUYR1**LP7YEI1^RVSP;5MQY[CF
MMR>\YA'I8[JXU84N0L7.8VDYVRZSW',K! UFPJ!]N,5
MBDDK\D=VCW>X-9IX,0I]O AVJ.U0SAN4+O.U%:WNO.![=.\[;HCLN*W,YPW*
MD=EV7Q=Z>5KAJ5P%GH,W\ML_M_C;F_C.%$]M2'94_"OD1QBO%,"V0Q+KK/5P
M;]S(]H)H&Z)/0>!\=SVOV>YTWHQ$T:ZVD>NC*,((O+A^LN5%$\=)/CC+:[VS
M-NA'XN">MNNU%>ZGB]LH=G'S*,+;BN6&7RUO2_X^B2(41Q,;KX40.7@Q/+C6
MB^MAH5"$?XZF'W^U'+LTL30$)KR5JP'3I*/!\D"?D:.2_YOS?!VM+:>
M F^;? TZ@$>5;2@@:K<<^035#=[)!FLI6JW,$XDD I8>]]A$1=$),#PLMBAT%JB?*_''T&RH:>=
MDT^E[3@;]=G%?,Z?ON">9OB_DA?D><.=S!E>'C:V^)/E3W8O; HGW^_M#_+7
MMGLF?S\2!X?_%H?NRS;;IE$\1SOD;]'5_A,*EJ&U61&Y)R&R6HY.H*/.AI<>
M*7=AL)YNB-.=+/:.!\K996=#GH4![C?>SSS+C_$W0EPZ&[+9X1GH>.B"77<&
MP0W:A,A.-1&RT:V#,';_2O[9,0)B/7<&P',0XRX2 Z+C ;-[DN,;?0RPXV_L\!SG0/VQ4NU@ML\KYP/Z1G]B*\\O/4V@J9'\;K&
M\^!*[1X:5D\*1_ELO7BHF9K9IK^N1USA9NY^BCD[U6/LG4R\4-==XW!T4G0_
M\\RN5(ZSDUGFZ+#K,=]:H>_ZRVB&PL2.[6IBZ?TH&V$G4UK76]>CS5?2=%$T
M!^?(PT6T)+\.4<;8J?X
MR^Z/!IX>-1AU)VN"O]\,@4W!1B!A@24HY]%NOT+_M&W">[:
M(=W?>=;RT)QGO2#O]U?GOW_;N3S7VY#;YLR4^^':9E4C$MDQ=L>ELDB*DD%'^][G$\B)&BD][DW>&?115 TLOV+2>9
M13XI\Y+]R5B82;P+H'N\G; $K2RN1-ID-^.3-"W:GY3I:J-_Y-7E^I/O&3?+
M$"OY=??2I#O)->XP)->7#OKQ?]&^0JSJGBI7]NB]IYFA)/*26
M'S]:ZZHYK"S6O70/:&EY:=^3'V[5!G):HGN9GD.+Y$P\[=M$D+,MFA?:A(?S7,Z6H')"?E7B[2<*.7MLKUSOJ4XLP6(N_S-J>.ANI1RA7\: 4,D5<$#G
MS"09F6I<"0I[>1T0>O?.1(PH-FIYLSF8^_TMEM_>GGKB>_#/\^9&9WVZ,6G^
M/5'SWEV\OCC6+OT]6%P1J^7EK4A=O]/;Y$7
M1X>?$ ? 3P4'0/;C;Q/;#K9^',VL/?D>LBWSQ!M04[BYJZ*]W'-D(W='I'E$
M,9_TE544C2' _JIQ%E)IFQSY* TZRMC
M8F*(=%Y6Q7H@E"L3WR%_D(22'9Y,#,\DOK;"<._ZRR2AC;(*^.HJ&55^>C$'
M<%I,A:PWF665)7"Q/SQ*895R8XTGV^%07*LAUE12/(X""8#(2*JKF7)!WQQ9
M; V[,7K 2C+6*V/+7[KXQ#A..P77FDHJQI%3*55*?$*1U*]L9::'S.ZE"%I=
M5ANI:S^YNEIFA7DT1[?(9>([R?%68B"CP%M;3<>QU.C>W-45CXU]ZE<4U$->
M?O1UL-LJSVG^(6ABP3T$_O(9A6MR;S%=7&,5Q*4*7U54A?:U'V4HZ**\1RO'A\HB0N,
M@DKEK;ATK3F&N:HJ'5-5.@:ED!HY.:T 3?1^84U?,]W^BX^/(H_DHOJ)$/76
M.:N&BI"1\O5%521^S2W.,83D@UGAPZ+ 5-D:.39F10Z+8E-$HDF ,"%(&@(2
M%'NY" CG38RIL;'"> G?9)H:-BN.'#.VRM3866&8F$?X$:7W9@6*"J/$C,@<,.,54+[5Q:8UR.$RTQ\C#%=]=ERNI)OIC:!'69[?R509
M?F8JY7RH\)N'.5YFJN$HP;),PT1L)SF,#\\ 'KJE<_10:RJF
M&$J$B";;>(47R%_Y7-)'Q;+ZM+ C5^7EOOG'<"**#0F&^6=P(GI+6
M8K[M"PYP<( ;Z !7;?:GCK2)AX7V<6?(7;]LPXA\35DZ*E/\
MJO(JI4_FO\::JBZK2FHR^1ER- /VK)@:'F2\8^%3.=GR#L+8_2M]L;Y:
M;%8-%2,X.,H/IDO-,J$6UT'V*RMR;4[!T[(Z2'WC>MN8ZD*DE3;%_=:6#YE<
MAMUA[8<<=ZZ_Q5!--RA,OJ?H"BV"$!6BUCZ[?J*7W/OXX$<1278NMY)>@'Q&
MV$K%O]GA(N2\IVU!?4J@#N&CVE.S-=!**^7*SDZ'*^2C!96JD%9:C>3IPLA$
M(;0\5*G/2ZJ1^+!*4QP/ULE:5
M5,-DFNBV=>]0G153>A@N-')8D]+*9$4>;C-Y2>\98:61S1:9XTM<((=
ML:O9YA)G9;A(,X=3]6_(7:ZP CO9X2E?HL?M^@6%TT6FUO+>3(NVHM%(SX2K
MV8^$F]%YK"P+3:P-E?Y5IE^E?'M!=W^9?D/(#1+O"6+Z?2$W8$RGD^G7AD+?
M7MF-V.ZV4/_<59VT "=^3[:<=CI?V[S14*=0VVG9D]:9\3_1K"]-IZGGQJ;B(:D9./Z03BA><'N^>
MVW'XYP.%;O";SFO/AX_X)87IS/<02SZP6'(U
MN#2]W6OR\9TZ9PWEK.T04OKU7=>\#VZQT,/40&_+.?A)P(!
M*^>!M'"1-"&6]T (8,C-\<_O/F3WQ@DES)%5,%6(I_[3*@AC0O9Y9?E_W* -
MR70Z#;L0J:GB)GSB_/CQ#95Z=^]3*AC$&H"A76./'*F"Y*3R<>WTVD#)>SLJ)\F=(F>N^?
M/)Q"&5)]/;U&4WP:57! A:K:C.F$E+W!7%%:T&.$A^.QP(C-/;:JNGJ-BIV^
M7U]/C]$<;)7[L\*8J(K@H$Q!RT:'AT/-B2ZI<8UP28-O)*\/WD:'AT.S]2':N$:X
M5%R?M%\?O(T.#X=FZT.T<6!JH$F);?KDCI#S9HU:7*WL"04HX4;%(B$^^2NJ
MJ!S#VFA9C*?DP2;9EC0]4H $MQG<,+*AG
M@^*KJV1486 CY"11Q@]D#>4/J5:/A%I>M?2IXUQD4O@J*Q\7V:JF2;Q0=/L#
MA;8;41GAZNM)B7\@ 24[%.ZGBY. AI.'4ZM"(+CK*F%*J;QAHH!-*0R,-$)/
M.QQ#S_B?=#BO,CA6'04AE%U&GQ7#+'GO09NEF@TI-Z,OQ,M1&::GJ/6%:EU$
M7+-\-\#Y@+.@)M$LTPVVBQ/ >0.KS<^F4[9+P8/\0B<1NEM 'J[GN
M5#SU&IJ> -B?1E<7,YPC;2;!1U](BT0MF4Y1)![!Q4:R*K+2?!XCV2A61H T
MXST:,XSG 5'-F1QQR6'$ SC9\. *2E ^50@DTCK26ZT='&E<41\','] . *@LL,%>D.P<91&C
MU( [email protected]'\.;HB%BN@*Q!XGT,L8LD"Q")Q]#G&9AFZW2/<-I_TB/Q',Q\Z
MD9M'R,-]_M',L,[email protected])".?CU&9@'(6=JL4Y!SY)G:B_EL*]],(4N;']#=;
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MCC^/A\!?DIOVNVWV[N3Y>=A#KYJA^0[:?7\J5C5M0&0!WV %?H?%WJ'H
M_VTMSUT0S]@D2B@NHIISIGV[NJ$A/L4M(&K1F4ZX??%#A"?X+^3\9^"195[@
M:D/V-DROYD-L-?K+&_Q/?YD:C0V1:]V="NSF*,92(N?P.CQ3V:<45DI'>*(V
M1!5G.%\=(+(4(K),C)"REY&;T9)1=W#4EKW*>0H;5=:S@@.35Y%%6W"9%7?H
MU-868\MMT))^(Q;@8F[0D$;C39S#,B:8U9!VXVT_O8QV5%X2"OAU>&)GA^YR@='K-;#I1-##<*)*]C"=(IF_M7$
M'W1G.MDR-V8TY[BIS,A @$4+-F;=,I22;JJ7UFAP.KO'H!SVY5BG5LF$AN6&
M5#G-6Z4'&H8/ESH.&8!-??N0!]C0:]XN&=!PX-@7:*U2 TV'CGDSU2H_T!CD
MVN57Y!B:2J0D$<56&3_-GL 7+5D9%*7NZR9.50\N>%C0JRO@T
M-BN&@P]/Q!JDF7/E55<[0\8+$"L/_W)\<+"V)N/S\&_5 :QW^08K8-[16V++(GATA\1VZ=U(R 75?EJ"KCL.J&0ZD$
M^:?986ZOD+,E5,E'P%C)$I32*A661OM029^A06"ZYDO=VXKHY ?I.&ZKA$"I
M/K]-OZ42@JCF*#+]7DH(*]H!9_H=E!!(9?[$QJ23VGJX(%CGU"/!5E'&RYA8
MCPOC QN1Q^8J>\;F.EB_N'[&*GV\H+GW%T&X3N]>9)"'3/#8=T^!MTWZH9.#
M599380(+J.A4P?02FLB>9W7@5E%DS%@K=@F'_D2
M;U1? Z( 8C,-X2\_C@[J,__H>!J30@%4U7>FRHWW+=?)>/H3W34]0-[7S"=7$YJ/L?!P\GWZ.GK=*F[8
MJ#XXD*\-K\:2\),P)&\0)';*=?(= SWBD*Y&='%G4\[AS\AQK=G*
MPBN30Z=FE%:Q#CYCXV2]73.YM\IEI&#VN"5MX2TP,XY(ZAPV*U=/;HQH.I= 
M1:DRSO#V47&+4UU&Q1PR'D5-\A.2-S_8>JQ0$U+0G:V7A[DC6W>X"4(2SDK_
M<-@5E!#8D>.<8;GEOUAT+_^*[\>-L1LKZ+=L[SU:X
M1,3 6[EHEVA[E9$2(C55^NVX_2W'9.B:S[E5O.< ')WB@+&T!M-Y",31JO98
MFLY#4.,H++K/.2 U_;*!QSG)^99\A=ID^CN9HNBU=429'H' BZ>(.61Z)$(C
MS'+SS/08!"%X>/53TS-@A4"3FJLA*.B$X]RLW1:\W$7O>DT/5FV0U7G
MO?FYL7+0Z^"FKE7.[0" EQA%SNMO,]5DA #&D[5UYLHN<=$5/H6M[("7L9M51ZNMH,^-
M* ;[:;M>6^%^NKB-8A<;I"B:+NXL-TPHA/#?4U7K8"9A+:S@U\2_VZZ1,UW,
M/G]2\:X]!$A#@#0$"D.@, 0*<^"0T\W+(8A3IN!>'U
MA&OV#G*Q:T,P+?XBO;R(9M:>$;/6KPSFH9Q\ETJP37L>.J(WF1%''F7+?_D8
MI">U3XOX[U6$H6.<.^G[V&*+O0T=N5D8;% 8[V>>A0^-5/?9K/M9EO2^!X1J
MX:KH?(2/2#*.M;U!NE7W/(2Z)$EUGM+R*4Q>R*W$L;8:I*X,*?5"TEBW+Q'Z
MV.+(Z:K$9J<MOEK( ^#?PN[9+4@ABRS,>:*[<&K +I29A&QJ^SHMG%\F?X^'N8"[1
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M/T08I57,WI3Q5UFUF!?3HL2$HD[V@"S'L#
MFH>XS2SV!%'4N_=+ 44>4.2-8QJ (D_)CE-QYP+,>%TN]YK;5*#%ZW>O.66#
M%*+( ]A;L1$VL1J!C1#8\[IA(QRW =DP4-=4'KU6\,DBW+\
M&MAJ@V#SA_3N@:5WOQ%6]V-= ZAB"VJ/X20(0\YR5KF) -/:Z>< N_A
M X8<>;(P]TN) PSVW%#I .=\ )RWH%S$,@,P3'0G!LI\&QXXFN@^!8
M_6Z,#(MZ!9<4D#;J 1[X\\!_ OZ3@?M/)GA(NX;,@A23I=PDW5BI+*>)BP!<
M-7I(WJ.K!K@-@=O05&[#&*\9O'Y*XDY"+.\2)2$[URORUWM_LB:QY=,%I C\Y3,*US?HI0\NP'H9C$2YKX^>T?G0<4U&D8^O-RVK
MNE_MF"N!(Q4X4H$C5:]5!ARI9B#W[5(7[.J"?)A55'+DSI&72K-R-WQ3:!G]:5^SG\*(9X0XBDAQ!/X3X'_U(P%
M"?RG?9&%5=REMV(^'02YB%+$.1AGQ\V#VB?C+%"=*HPJ:49Y"M/0XHJI&>\I
M0"Z;Y!>83_L,4 'FT\[.5A:WLA#YJ8EH]QV3T8PX%9"7%G/4C&D5)J 5Q7(3
M5E:@6&Y"P&J>'M@)IZV(46GBM]^:9QG,P5ZSD9H1D)JXL2)^A
MY*AK1SD,U-=JJ:\K0[_R+UK$NS J_+@IL"_-NF4&OB&@S-&2,@*VV&L.Q.<^YE4X+$CQ#EJ-7D#;!J
M*!U!=@M^A7RT<&NE/RD]_,!I2CH76?B^C4WEY&.;+K".N,.; OEKX?,XL]:+
M*5JB3?0H=U70LW!UE?L]Q_=W=/D)06*JI@LJ?P9$FZ^[J"U0]T]30Y.;;B]U
M-M*85]@94,U6YSAUTXGCN*EH]_XB"-=)URJ>!;FU0L]%48RE^@>R0F:R5'59
MR+H(%WJC\^'"I^<4/
MCW8R%BU3!:)[;#Y;$=Z@7KS]+(@BXJ&A60RR6Q\>,LQ$3 DMJT $"Y9Z3!C9
MXN4R2J5DYGN?EE(A*672*1+32DLQM"F-9\&^9'/Z>G9'>)>LL%:I5T;CZ.0I_,2SB\N#"G6D_EA
M(=W *&VG,/\5JTI[O7))CD4UI?@&BIA0W-^F\T9P(%/I$NZ/Y4'Q5Z3
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M:[>R6E>AW2<3]8Q[841'EUZXP5[A"ICB:M*J$#_(,(3"G>N
MC:IWE\? WZ$H/FS-ST0)*OZ>P/D8Q/] <9YO2G.L=M:?4>BE-Q-W09C]B)2C
M/?#>LQ!*<8X#^X]IHK>PLS2HY:5^V4GSY'6+Y^]X^]C_%PJ#6Z+JD1_5?_4<
MM;N6]AE71(VE/:T-=R-R[T;D?#N?K1_N>KMF?B_E,DJDQ"9"K92E,E*^#;S%
M)<:%;Z=;YJ?0PGH _6M@EI*DD HYYR34AP%D_GMETC&_UF())1)B=2=T;>)A(4<7^3*B^=,7MLS,.I((
M'LZ[2(_4YY4;Q@@QSF+NNAU+>E15FHAZ6EE)IENECES@.[W:GQG+B>*<_.FE4OM8E 8D5>?XOV]CQ? -B7Q)S3RSRO+3S7Q*#TT[_V,C$@R?J+=
MFX7MU\3(4X;M2?6&WZUO+,WWA4+HPSWE_JAOIP-]M
ME/8'M2H/MT7YW4!Z8339QJL@9'C:NNQQD CVA9M1:.TLUR-7 W=!F)R;'8-V
MUIV<>,NFTJ5[;:HP)/^]L6)$V_,[[6I0.WIV1-W^0*'M1F0^[WUL#?B1:R>C
M8>K,W70XJ&_P?#CI9R+[XZ/V,W"T3@(NLM^DKZYTCR&S]X%_QR=CFR/B'B//
MU01^RR@JZ??E/:W;AFR=F.F$7)5[0DD-/[HKDZG%0NR"6V28AA_A3
M6A260.))SJXJ9>]^/%T.ZELN/367!$&M S^]Q$^'*ON3K>]0RS48,?WP2>2B
M[W#=&7;2EJQ34J'UU7Y$^!@RG5_?#2ZI\FGR*QGAK7_1MB7E/FT
[email protected]=ZY=S%JF0SP38X+U](#4WG_F<@"W>@V.*%7N83P68YAU.1MG1QJ]6@X[V.GG_&!UE(X?(=J&!ALE',K8YVSD
M(U>@LCB@!M%=M:B5R50.P!GW")4\X&0<4.:_D22';[$5WD!C?SL*&GL6+535
M3CA^9+*4/CLV;EL-LUDU27S#7DCSF )L52:@*X*29,J]G#K%9=PJ]
M0BQ"@GP$_(.9Y[9JP,]XG'/ S;HAZ/LP9!"/YQ";Y>;O=4T+<(SF>)OEW]<$
M[U/VV1SNKHT+U0\/;==K*]Q/%X5O?&+'[@[+K.2]H8Y?U8%76TQXF0)>3^AG
M?O-7W)KOSU4/-KF#T-$3$NGWEPX"W/'CH#&J_8552#!'I KU*I]KB>3^ ED _WT0Y7+7#
M:QYX'M[&R2^[!ZW8VYZ&LGX!5DB/8B<)*W
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M[- F]6K&5AC#%'43"FSJFT,*9J:!<[_9TT*_I.C[:$G>=OZLM'ADVI8&B2
MJ>\F&3:KPH%0K=Y=@GG5ZU0MJTH-J!8U5Y74Q%9WY?-B>B*;/&6CO5:D;OZ4
MY0X;_4C.<#_%)E0.IK)_#W4JFS!@F$/AC-IO],*)GONC?*
M&C7ZF4L#)K41=52K)S/-"$KID1+[7=>\^KIP!G\.=@FV]^0!T?1Q[P3C;*D"
M?S#P![-Q /Y@X \>(G\P\.%VRR9P?(^Z[$FG6I>L3%>5DNB%8F+):8"AB!QZ
M(5BPJ$IB=L)G(=RYME@I6VG=\)L!V^ZX\HZ?8AJQF)D&S/7906^ 7,/>5#)BRA\-)Q=NMQT/&L]3
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MHW.\B_:!9V6_@\K(88TJXZ>DP]A-A\:LQJ\!/LU=#^_J?:_'DYX'C^C
M*YJYCGRFS0*01S!E9_XH/0+@FF3@F_'T4K\3)?+%CCX!O\^@F*[CR50'Q1Q>
MQ9H_?2&@X?_:,5:/XCU$OHPC\@5B1P1>?, 'Z"((UY9OHV0ROOAN7!GM4U=:
MQ;J=8\4Y=(DRENQX1)H(?_;,:"5V'8C',28>Y_;/+?Y2[GT\W=MD;--XA<+G
ME>5G.N3$<=STY,JWJKI-394T9B%_1E_0.]KG$AB),%E#O5]YRQ7.K'DIVZV]
M(W_2O$^A/"4)SUV[Z'
M\%Z+ZH'K.R?F[DBU0]=BRQ*2TJR9HK.[S1%Q+N*?7P=^8N=O+8]<*TH/X>Y$
M1K-FJ4R/V?L$G'1O,K;Z'2.B\@UJ=LZN=T>2%P+9"I"M -D*D*T V0J0K: 1
MDI"M -D*NH:A=7N5+F7"NK&V37V[0JUCO)\)/[OZ:!5$/RPB4T.G]/26'&+L
MASN7IWZUD?!]&SJ;%9%;S=C 84+UF-#SBWL91.##IRE5BN 2Z$IUWWC1^_,52+/KN1[
MGL$YO$T_@%D2VPI>.OV3367(F8^I)]7Y0'MODL0I49-CW1_7E&I>
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M3R3ZI#0:KLQ]_N;T_D*?QB^&X;"EMKV%=U+J\>*HJ&=-!
M#RX=D?2K"WKY?D^Q+T^44PS_ JQA';3XZ9<+_,NEVD(U]?* UQR@W)+R
M;^W&JUD"-DD)S%,+W_BW+^L,G8KCO^JS[6]!:>5-36]-[C"DTPT*D[XC\*N.
MQZ\JQ]N0K1VR39'E]!!$-#]#54GP!(-_%?RKX%\%_RKX5\&_"OY5\*\.%T+P
MKX)_%?RKX%\%_RKX5X<$(*]_M=+3 3Y6\+$R?*PSR[E^#Y8ZYGB_F!6 >\K>%_!^PK>5_"^@O=5M:8+WE?PO@X7
M0O"^@O<5O*_@?07O*WA?AP0@K_>5[7D -RRX81ENV!N$N[7==,9\9[(F:^^O
M[/N3YX5M00-*%Y!BU[)JF$+@"7YD_?S(X(,%'ZQJ/R;X8,$'"SY8$]5<\,&"
M#W:X$((/%GRPX(,%'RSX8,$'.R0 >7VP3"\5N&#!!&I:_2ZG4AO1NE+I]:I]5Y0:7R,KVWY4(JCYSZW:;26#=<80$'
M&4TS8>II\CB60](M#=/,CC=K!_SJ]%U6#= M0;<$W1)T2Q'=
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MUQ<SVV"_
M C44U%!00^EJZ*T5^JZ_C&8H?%I9BA-73H6I4?:HQ56.W+V)%"(02'F5(A;;_Z@&(-B#(IQ9XJQ.F^M6>HQ*(4"E"ZYE^0Q
M\*^M:/44XZ58G*\L5(OIRFW5E%H/-I9UAR*\(%-_HQV[.PRPH..:JQ')\Y7O
M).6O"W\_KDU$(>A_\=V8^+V2EXY]&^4_G'RW0H=KN/WUJW8E5 \LD7RZ29D.
MFJV.Q@WK@D>V.2=35Q3[J^5M4XV$9..G/VN,38M.P#P&\QC,8S"/)=T7-3\(
M1F,ASZ2X.YB71QE$DRMTXFKL992BVN@^S\A$D\-<%8-\=8!U/S]("K
M^>S'Z(\0-(-X-I_1V-F@-H+:V(W::!9=D5G*XT/@+Q_!'P6>ZY#;B;JY:=R->[WD8QGJ.PX=)L
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M:6-L&UL4$L! A0#%     @ ;'^D2%]^3"

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings